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ABSTRACT
Obesity, a recognized health problem, is associated with cardiovascular disease, 
diabetes and hypertension. Removal o f adrenal steroids by adrenalectomy (ADX) slows 
the development of obesity. Leptin decreases food intake through effects initiated by 
activation o f the JAK-STAT pathway. Defects in leptin signaling lead to obesity, which 
is associated with hyperleptinemia and leptin resistance. In chapter 4, leptin induces 
phosphoewo/pyruvate carboxykinase (PEPCK) mRNA expression and increases glucose 
production in hepatocytes from lean but not obese Zucker rats. This suggests that 
hyperleptinemia in obesity causes hyperglycemia. In chapter 5, ADX decreased the levels 
o f PEPCK mRNA, and increased leptin receptor mRNA expression o f  obese Zucker rats. 
The decrease in PEPCK mRNA is presumed to correct the hyperglycemia in these rats. 
ADX decreases leptin levels and increases leptin receptor (OBR) mRNA in obese Zucker 
rats, suggesting that leptin downregulates OBR. ADX was reported to increase sensitivity 
to leptin treatment. I hypothesized that high glucocorticoids in obesity impaired OBR 
signaling, and removal thereof will activate this pathway. In chapter 6, ADX increased 
the expression o f leptin receptor mRNA in Sprague Dawley rats. ADX increased STAT-3 
mRNA and protein levels, and induced constitutive STAT-3 phosphorylation and DNA 
binding activity. ADX also reduced SOCS-3 mRNA and protein levels. ADX and leptin 
treatment increased STAT-3 phosphorylation, but with no concomitant increase in DNA 
binding activity. We speculate that PIAS-3, a protein inhibitor o f activated STAT-3, 
inhibited DNA binding o f the activated STAT-3 as a protective measure of cytokine 
hypersensitivity in the absence of SOCS-3. Leptin and ADX decreased NPY mRNA 
expression, but their combination did not further decrease NPY mRNA. In conclusion,
xvi
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ADX mimicked leptin in activating STAT-3, and ADX decreased SOCS-3 inhibitory 
system. Leptin sensitivity could also result from the release o f anorexigenic and 
orexigenic neuropeptides, but more research is warranted. In chapter 7, high-fat diet 
induced leptin resistance could be due to downregulation o f the leptin receptor proteins in 
the hypothalamus. Further research is required to define the leptin resistance in OM rats 
induced by high fat diet, such as changes in leptin receptor signaling and SOCS-3 
expression.
xvii
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CHAPTER OINE 
INTRODUCTION
Obesity, the prevalence of which has been progressively increasing, has reached 
epidemic proportions in the developed countries. This phenomenon is usually ascribed, 
through epidemiological studies, to the combination o f excess consumption o f  processed 
foods and decreased physical activity (Ravussin & Tataranni, 1997). The pathogenesis of 
obesity remains largely unknown, but obesity is  closely associated with increased 
morbidity and mortality caused by several o f the most common diseases in the western 
world, including type 2 diabetes, hypertension, dyslipidemia, atherosclerosis, 
cardiovascular disease and cancer (Bjomtorp, 19'98). The increasing rates o f obesity 
cannot be explained exclusively by the high availability of energy- and fat-dense foods 
and increased food intake, or decreased energy expenditure due to the increasingly 
sedentary lifestyle. The study of factors such as genetics and lifestyle implicated in 
obesity is crucial for predictions of the impact o f the  obesity epidemic, and provides an 
opportunity for the implementation of preventive measures (Grundy, 1998).
Variations in obesity-related phenotypes has been shown to be heritable 
(Commuzzie and Allison, 1998), and environmemtal factors are becoming important 
determinants in the development of obesity (Bray, 1998). A gene x environment effect 
arises when the response of a phenotype to environmental changes depends on the 
genotype of the individual. It is well known that tfiere are individual differences in the 
response to changes in energy balance. Therefore, gene x environment interactions are 
shown to be ubiquitous, as monozygotic twins responded similarly to variations in energy 
balance (Bouchard & Tremblay, 1997). The epidemic o f obesity is therefore attributed
1
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largely to environmental factors, namely, the abundance o f high energy foods and a 
sedentary lifestyle. It is possible that, in the nearest future, candidate genes predisposing 
individuals with susceptibility or resistance to the development of obesity in response to 
changes in environmental factors will be identified. Since obesity rates are high, the 
continuous efforts by scientists in genetic and molecular research are warranted in order 
to identify the genes responsible for the susceptibility to obesity and to delineate further 
the cause of obesity, which involves neuroendocrine, genetic and dietary factors, in 
addition to lifestyle (York, 1992b; York, 1996; Weinsier, et al., 1998; Williamson, 1996; 
Bray and Bouchard, 1997). The role of a genetic predisposition to obesity has long been 
recognized (Bray and Bouchard, 1997), with evidence from human single gene mutations 
(e.g. leptin, proopiomelanocortin, peroxisome proliferator-activated receptor-y, 
melanocortin-4 receptor), mendelian syndromes (e.g. Cushing’s, Prader-Willi), animal 
models (genetically obese rodents, transgenic animals) and linkage and association 
studies (twins and adoption, nuclear families).
In animals, obesity phenotypes have been categorized into dietary, 
neuroendocrine and genetic, depending on the origin o f the obesity (York, 1992; York, 
1996). Dietary obesity is produced by a variety o f dietary manipulations, which include 
increasing the dietary fat or sugar and increasing palatability of foods (Sclafani, 1992). 
Little is known of the factors that predispose individual humans to become obese, 
because obesity is a complex syndrome which appears to be polygenic rather than 
monogenic, and may be affected by environmental influences. The myriad o f  central 
neurotransmitters and peptide systems involved in the regulation of body weight in 
humans remain to be assessed, because these may regulate or be regulated by susceptible
2
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genes which in turn may alter appetite or food preference and fiiel metabolism. Animal 
models have become useful alternates for such studies. Single gene mutations producing 
obesity in rodents provide insights into the genetically modulated development of 
obesity. On the other hand, models o f dietary-induced obesity provide important insights 
into defects that might predispose rats to become obese, and these models can be 
identified prospectively before they express their respective phenotypes. These models 
also allow manipulations of the environment so as to alter metabolic and neural functions 
of rodents o f  a known phenotype or genotype. These studies will therefore help decipher 
whether diet-induced obesity in humans is an inherited polygenic trait or not.
Studies o f the interactions between heredity and physical activity have shown that 
the genetic background may modify the effect of physical activity on weight change 
(Heitman, et al., 1997; Samaras, et al., 1999), and that lifestyle may have an obesity- 
promoting effect, depending on a genetic predisposition (Hill, 1998; Hill and Peters, 
1998). Genotype-environment interactions, which arise when a phenotype responds to 
environmental changes based on the genotype o f an individual, may affect body weight 
and energy expenditure induced by overeating or by high fat diet consumption. 
Therefore, the examination of factors such as genetics and lifestyle, implicated in weight 
gain and obesity, is crucial in our understanding o f obesity development. This will impact 
on the integrated approach for the effectiveness o f prevention and management strategies 
for obesity. The main challenge for the future is, therefore, to precisely define the 
genotype-environment interactions that are fundamental to the development of obesity, 
and to show that this leads to the obesity phenotype observed due to changes in 
susceptibility genes that remained silent until the conducive environment was attained.
3
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This dissertation describes studies on l)the effects o f leptin and glucocorticoids 
on the liver phosphoewo/pyruvate carboxykinase, 2) the effects of glucocorticoids on the 
leptin receptor gene expression in lean and obese Zucker rats, and 3) the increased 
sensitivity to leptin treatment in adrenalectomized rats. These experiments tested the 
hypotheses that PEPCK gene expression contributes to hyperglycemia observed in obese 
Zucker rats, and that glucocorticoids also regulate the leptin receptor signaling system by 
playing a part in the leptin resistance observed in obesity.
In the following chapters, each of the various effects of leptin and glucocorticoids 
are described in detail. There are a total of eight chapters. Chapter two gives a detailed 
review o f the literature. Chapter three presents the general methods and techniques used 
in studies in this dissertation. Chapter four discusses the effects of leptin on liver gene 
expression and metabolism. Chapter five investigates the effects o f glucocorticoids on 
PEPCK and leptin receptor gene expression in lean and obese Zucker rats. Chapter six 
describes the effects o f adrenalectomy on the leptin receptor signaling system. Chapter 
seven describes the modulation of leptin receptor signaling system by high fat and low fat 
diets in Osbome-Mendei and S5B/P1 rats. Chapter eight offers the author’s summary and 
future research directions.
Final conclusions that can be drawn from the presented dissertation research are 
1) that glucocorticoids cause significant changes in the leptin receptor signaling system in 
the hypothalamus during obesity, and that these changes may account to some extent for 
the establishment o f leptin resistance in obesity, and 2) that high fat diet induces leptin 
resistance by downregulating the leptin receptors in the hypothalamus o f  obesity- 
susceptible Osbome-Mendei rats.
4
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CHAPTER TWO 
REVIEW OF THE LITERATURE
2.1 OBESITY
Obesity is the major nutritional problem affecting industrialized societies. The 
- specific syndromes of obesity both in animai models and in humans are associated with 
identified dietary, endocrine and/or genetic causes (York, 1996). However, the 
pathogenesis o f obesity in humans is still unknown, apart from unexplained chronic 
excess in caloric intake relative to energy needs. Therefore, an understanding o f obesity 
and its consequences requires the investigation of the many factors that control energy 
intake and energy expenditure. Such factors may be genetic, environmental, 
physiological, psychological, social or cultural, all of which are known to influence the 
presence of obesity in modem societies.
2.2 ANIMAL MODELS OF OBESITY
Using animal models, obesities have been categorized into dietary, 
neuroendocrine and genetic, depending on the origin o f  obesity (York, 1992b; York, 
1996). Dietary obesity can be produced in laboratory animals by a variety o f dietary 
manipulations, which include increasing the dietary fat or sugar and increasing 
palatability o f foods (Sclafani, 1992). Although the role o f dietary factors in human 
obesity has not been precisely identified, this research with laboratory animals clearly 
shows that certain diets promote hyperphagia and obesity in animals. Epidemiological 
studies show that obesity is more prevalent in humans consuming high fat diets, a 
characteristic o f westernized diets, accompanied by decreased physical activity (Ravussin 
& Tataranni, 1997).
5
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The ventromedial hypothalamic (VMH) region is responsible for integrating 
information about energy stores, and hypothalamic bilateral lesions o f the ventromedial 
nuclei (VMN) produce obesity in laboratory animals (Bray, et al., 1990). The VMH 
obesity was produced by lesions o f the VMN in rats by passing an electric current 
through an electrode, whereas in mice the lesions were produced by intraperitoneal (ip) 
injection o f gold thioglucose (GTG) (Brecher & Waxier, 1949). Obesity can also be 
produced by destroying the paraventricular hypothalamic nuclei (PVN) (Leibowitz, et al., 
1981) or by damaging the arcuate nucleus (ARC) bilaterally using monosodium 
glutamate (MSG) (Olney, 1969).
Apart from induction o f obesity by diet and hypothalamic lesions, a large number 
o f  genetically inherited forms o f obesity have been described (Trayhum, 1984; York, 
1996). Genetically obese animals have been divided according to their mode of 
inheritance into the single-gene dominant or single-gene recessive strains, and the 
polygenic inbred or hybrid strains due to a number of mutations in various genes (see 
Table 2.1). While great interest has justifiably been focused on the single gene mutations 
which result in obesity in rodents, and recently humans (Licinio, et al. 1998), it is likely 
that most instances o f human or animal obesity reflect the interaction o f a number of 
genes with a permissive environment. Recently, gene linkage analysis o f  animal models 
o f  obesity has identified over 80 linkages of chromosomal locations with obesity and/or 
body fat distribution in polygenic forms o f obesity (Chagnon, et al., 1999).
Classical parabiosis studies by Coleman (1978), in which blood circulation of 
obese (ob/ob) mice was joined to that o f obese (db/db) mice, showed that the ob/ob mice 
reduced food intake and lost weight, whereas db/db mice became more obese.
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Table 2.1 Animal models of genetically inherited obesity
Animal model Chromosome Gene defect Gene product Mechanism
Recessive inheritance




Leptin signal from fat to 
brain and peripheral organs
db/db 4 splicing defect Leptin receptor
(505 amino acids)
Impaired leptin receptor
M a 5 Gin to Pro mutation Leptin receptor Impaired leptin receptor
Fat 8 Insert Carboxypeptidase E Pro-peptides not cleaved
tub 7 Insert Phosphatase Phosphate not cleaved
Dominant inheritance




Competes with MSH 
for receptors
Polygenic inheritance
NZO mouse 7 ? ? 7
KK mouse ? 7 7 7
When ob/ob mice were joined to lean mice, the ob/ob mice lost weight and the lean mice 
remained normal. Upon joining the db/db mice to normal lean mice, the db/db mice 
became more obese and the lean rats had decreased glucose and insulinemia. This 
suggested either an absence o f a circulating factor or an inability to respond to a 
circulating factor was fundamental to the development o f obesity in these animal models 
(ob/ob, db/db and fa/fa). This factor was recently discovered to be leptin in ob/ob mice, 
while mutations in the leptin receptor in db/db mice and fa /fa  rats (Zhang, et al., 1994; 
Tartaglia, et al., 1995; Chua, et al., 1996; Lee, et al., 1996; Iida, et al., 1996) explained 
their inability to respond to leptin.
dfc !db normal dbitfo ed/tsfr abiats rwffiwi
Lean I insulinemia 
i blood glucose 
Diabetes t  body weight 
fWAT mass
Obese i  body weight 
I WAT mass 
1 insulinemia 
|  blood glucose 
Diabetes t  body weight 
tW AT mass
Lean No change 
Obese i  food intake 
j. insulinemia 
I blood glucose
Figure 2.1. Model o f  the parabiosis experiment o f Coleman (1978). When obese (ob/ob) 
mice were joined to obese (db/db) mice, the ob/ob mice reduced food intake and lost 
weight. These experiments led Coleman to hypothesize that ob/ob mice fail to produce a 
circulating factor (OB protein from their fat cells), but their brain remains sensitive to it, 
while db/db mice produced the circulating factor (functional OB proteins), but their brain 
was unresponsive. Adapted from Coleman (1978).
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2.3 EFFECTS OF GLUCOCORTICOIDS ON OBESITY
Adrenal hormone secretion plays a major role in the control o f substrate supply to 
tissues and in the partitioning o f dietary energy between storage compartments. In 
general, glucocorticoids are catabolic toward protein, increasing muscle protein 
breakdown and enhancing gluconeogenesis in stress and starvation to maintain the 
glucose supply for the brain. They are also catabolic toward fat at high doses (Woodward 
& Emery, 1989), but anabolic in fat metabolism at low doses (Diamant & Shafrir, 1975). 
Glucocorticoids enhance the induction o f lipogenic enzymes by insulin, an effect 
illustrated by the submaximal induction of linogenic enzymes on refeeding o f  
adrenalectomized rats (Wurdeman, et al., 1978).
Adrenalectomy (ADX) prevents all forms of obesity (Bray, et al., 1990a; Bray, et 
al., 1990b). The reduction in body weight in response to ADX is small in lean rats but 
pronounced in obese rats (Bray, et al., 1990a; Bray, et al., 1990b; King, et al., 1983; Saito 
& Bray, 1984; Tokuyama & Himms-Hagen, 1989). On the contrary, glucocorticoid 
replacement of adrenalectomized animals restores fat deposition irrespective of any 
increase in food intake (Saito & Bray, 1984; Bruce, et al., 1982; Freedman, et al., 1985; 
Freedman, et al., 1986). Glucocorticoid replacement in adrenalectomized obese rats 
restores obesity, whereas no induction of obesity is observed in lean animals upon 
replacement (Freedman, et al., 1985; Freedman, et al., 1986).
Glucocorticoids regulate the autonomic nervous system by suppressing the 
sympathetic drive to brown adipose tissue (BAT) and enhancing the parasympathetic 
drive to the pancreatic islets and thus promoting insulin secretion (Holt & York, 1989; 
Stubbs & York, 1991). The effects are exaggerated in obese rats and mice compared to
9
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lean animals (Bray, et al., 1990a; Bray, et al., 1990b). The low thermogenic response of 
BAT to diet contributes to the increased energy efficiency associated with obesity 
(Marchington, et al., 1983; York, 1989). Adrenalectomy enhances BAT thermogenesis to 
diet stimuli elevating the sympathetic drive to the tissue (Marchington, et al., 1983; York, 
1989; York, et al., 1985). Conversely, corticosterone suppresses BAT activity in lean rats, 
which is associated with the impairment in sympathetic drive to the tissue (York, 1989; 
York, et al., 1985). This impairment is specific to diet-related BAT thermogenesis in fa /fa  
rats and does not affect cold-responsive nonshivering thermogenesis (Bray, et al., 1990a; 
Bray, et al., 1990b; Holt, et al., 1983), showing that the glucocorticoid site o f action is 
prior to the efferent sympathetic pathway. Glucocorticoids also interfere with the central 
responses to glucose metabolism through suppression of both the feeding and 
sympathetic responses to 2-deoxyglucose (York, et al., 1985; Allars & York, 1986).
ADX reduces body weight gain in Zucker fa /fa  rats concomitant with reduction in 
food intake and marked attenuation o f fat accumulation (Yukimura, et al., 1978; Bray, et 
al., 1992). In the obese (ob/ob) mouse, ADX increases energy expenditure (Vander Tuig, 
et al., 1984), restores norepinephrine turnover to normal in BAT and heart (Vander Tuig, 
et al., 1984), abolishes insulin resistance in muscle (Oshima, et al., 1984), lowers 
circulating levels o f insulin and glucose (Yukimura & Bray, 1978a) and normalizes 
glucose tolerance (Solomon, et al., 1977; Bailey, et al., 1986). Similar changes have been 
reported for the diabetes (db/db) mouse (Bray, 1982) and the fatty rat (Marchington, et 
al., 1983). It is, therefore, likely that changes in the hormonal milieu, which include the 
effects o f glucocorticoids and insulin, contribute to the altered food intake, energy 
expenditure and obesity.
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2.4 GLUCOCORTICOID RECEPTOR
Glucocorticoids are steroid hormones synthesized and released by the adrenal 
cortex that influence a variety of physiological and developmental processes including 
intermediary metabolism, differentiation, response to stress and immunity. 
Glucocorticoids, like all steroid hormones, exert their effects on responsive cells by 
interacting with a specific cytosolic glucocorticoid receptors (GR), which in turn regulate 
glucocorticoid-responsive genes through interactions with hormone-response elements on 
the gene (Yamamoto, 1985). Moreover, studies using the GR antagonist, RU486, which 
inhibits obesity, showed that the development o f obesity is due to the overactivity of the 
GR receptor (Langley & York, 1990; Okada, et al., 1990).
2.4.1 GLUCOCORTICOID RECEPTOR STRUCTURE
GR shares a similar structure to nuclear receptors, for retinoic acid, vitamin D, 
estrogen, androgen, progesterone and thyroid hormone. This group collectively forms a 
superfamily referred to as ligand-activated transcription factors (Evans, 1988). Members 
o f this superfamily share a common domain structure composed o f three distinct regions, 
each required for a specific function (Figure 2.2). The amino terminal end o f the 
receptor, the transactivation domain, is responsible for its ability to activate transcription. 
The precise function of this domain is not known, but it appears to be involved in 
interactions with other transcription factors. The deoxyribonucleic acid (DNA) binding 
domain is located in the center of the receptor protein and comprises 70 amino acids. This 
sequence is required for interaction with the glucocorticoid response element (GRE), a 
short 15 base-pair regulatory DNA sequence located near the promoter, to which the 
receptor binds to modulate transcription. This domain also contains sequences involved
11
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in nuclear translocation o f  GR and for dimerization of the receptor. The carboxy terminal 
region of the GR comprises the hormone-binding domain. This region also contains 
residues important for transcription activation, nuclear translocation and dimerization 
(Gehring, 1993).
2.4.2 GLUCOCORTICOID RECEPTOR FUNCTION
The effect o f steroid hormone results from the hormone passing through the cell 
membrane by passive diffusion and binding to the receptor. Unbound GR is found 
predominantly in the cytosol. Unlike other hormones, eg. insulin, which transduce the 
hormonal signal as second messengers into the cell, glucocorticoids activate GR directly 
and influence transcription o f glucocorticoid-responsive cells. The mechanism o f action 
o f GR involves ligand binding to the receptor, which then results in dimerization and 
activation of GR (Figure 2.2). In the absence of ligand, the GR is composed o f multiple 
proteins in an aggregate with various components. The aggregates are formed by 
noncovalent interactions o f a monomeric GR with a heat shock protein 90K (Hsp90) 
dimer (Pratt, et al., 1992). In this state, the GR is unable to bind to DNA. Following 
ligand binding to GR, the Hsp90 dissociates from the ligand-GR complex, the Iigand-GR 
complex dimerizes and then translocates to the nucleus, where the GR binds to the GRE. 
The consensus sequence for the GRE is 5’-GGTACAnnnTGTTCT-3’, where n is any 
nucleotide (Beto, 1989).
2.4.3 GLUCOCORTICOID RECEPTOR REGULATION
Cellular responsiveness to glucocorticoids depends upon GR levels. Therefore, 
mechanisms that modulate the concentration of functional GR can be pivotal controllers
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Figure 2.2. A model for the mechanism of glucocorticoid receptor action. GR is folded 
into three domains: hormone-binding domain at the C-terminus, DNA binding domain in 
the middle, and the gene transcription activation domain at the N-terminus. See text for 
description of the mechanism. Adapted from Boumpas, et al. (1991).
o f  glucocorticoid action. All steroid hormone receptors are regulated by their specific
hormone, leading to autoregulation (Haddock and Malbon, 1991). This process involves
hormone-mediated transcriptional (mRNA synthesis), post-transcriptional (mRNA
stability) and post-translational (protein turnover) mechanisms. Sequence analysis studies
o f human GR, by Burnstein and colleagues (1993), showed that the gene contains
sufficient sequence information to confer glucocorticoid-inducible GR down regulation,
which could involve either the rate o f transcription or the stability o f the GR mRNA.
Most steroid hormone receptors are phosphoproteins (Orti, et al., 1992). The GR 
is phosphorylated predominantly in the amino terminal transactivation domain. All the
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phosphorylated amino acids are serines except for one threonine (Bodwell, et al., 1991). 
So far, the function o f this phosphorylation of GR is unknown. It is hypothesized that 
phosphorylation-dephosphorylation mechanisms could be involved in the regulation of 
transcription.
2.4.4 GLUCOCORTICOIDS AND THE HYPOTHALAMIC-PITUITARY- 
ADRENAL AXIS
Cortisol, the major glucocorticoid secreted by the human adrenal cortex, 
(corticosterone in the rat) mediates a number o f metabolic functions essential for life. The 
secretion o f cortisol is narrowly regulated because both deficient and excess plasma 
concentration o f cortisol are associated with disease and mortality. Hypothalamic 
corticotropic releasing hormone (CRH) stimulates the pituitary to secrete 
adrenocorticotropic hormone (ACTH) which in turn stimulates the secretion o f cortisol 
from the adrenal cortex into the systemic circulation. Circulating cortisol exerts negative 
feedback on the hypothalamus and pituitary by inhibiting the secretion of CRH and 
ACTH. These functionally linked units, composed of the hypothalamus, pituitary and 
adrenal cortex, form a regulatory system for plasma cortisol, termed the hypothalamic- 
pituitary-adrenal (HPA) axis (Bjomtorp, 1995; Chalew, et al., 1995).
Glucocorticoids impair insulin action and increase circulating glucose levels. 
They inhibit glucose uptake by peripheral tissues (Bowes, et al., 1991; Nosadini, et al.,
1993) and augment the effect of glucagon and epinephrine to enhance gluconeogenesis in 
the liver (DeFeo, et al., 1990). Therefore, the effects of cortisol work to render insulin 
action ineffective. Furthermore, glucocorticoids promote the differentiation o f human 
adipocyte precursor cells into fat cells (Hauner, et al., 1987) and is associated with 
increased adipocyte lipoprotein lipase activity and hyperlipidemia (Taskinen, et al.,
14
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1983). The pathological role of cortisol in the development o f glucose intolerance and 
other complications o f obesity makes it imperative to study the HPA axis and its role in 
obesity.
2.5 THE ob GENE AND LEPTIN
The ob (obese) gene was recently identified (Zhang, et al., 1994) and initially found to be 
expressed and the protein secreted primarily in the adipose tissue, where it encodes a 4.0-
4.5 kb mRNA with a 167-amino acid open-reading frame without any similarities to other 
proteins. The search of a 3-dimensional structure database, to determine whether the ob 
protein might adopt a fold similar to any known structure, revealed that the ob sequence 
is comparable with structures from the family o f helical cytokines that includes 
interleukin-2 and growth hormone (Madej, et al., 1995; Zhang, et al., 1994; Murakami & 
Shima, 1995). Whether the gene is also expressed in the brown adipose tissue is 
controversial (Frederich, et al., 1995; Moinat, et al., 1995; Deng, et al., 1997). The ob 
mRNA encodes an 18 kDa protein which is secreted, after cleavage o f the  signal peptide, 
from the adipocytes as a 16 kDa glycoprotein named leptin, from the Greek leptos, 
meaning thin or small (Halaas, et al., 1995). Leptin is single-stranded with a disulfide 
bridge at the C-terminus, which is pivotal for stability and bioactivity (Rock, et al., 1996).
Leptin mRNA and protein levels increase with adipose stores (Maffei, et al., 
1995a; Frederich, et al., 1995) and therefore, leptin is considered to signal the size o f the 
white adipose tissue (WAT) depots. This provides a molecular basis for the lipostat 
theory o f energy regulation (Kennedy, 1953), proposing that there is a feedback loop. The 
existence of such a chemical feedback signal was supported by the classical parabiosis 
experiments o f Coleman (Coleman, 1973; Coleman, 1978). Leptin may w ork as a satiety
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factor because administration of the recombinant leptin to ob/ob mice decreased food 
intake and body weight (Halaas, et al., 1995; Pelleymounter, et al., 1995; Campfield, et 







Figure 2.3. Model o f the feedback loop proposed by Kennedy (1953). The hypothalamus 
is depicted as the central controller of food intake, and leptin, which increases due to 
increased white adipose tissue mass, sends a satiety signal to the hypothalamus, thus 
causing the decrease in food intake.
There are site-specific variations in the expression o f the ob gene (Trayhum, et 
al., 1995; Maffei, et al., 1995a; Masuzaki, et al., 1995; Frederich, et al., 1995), and the 
highest level o f expression is evident in the epididymal and perirenal adipose tissue 
(Trayhum, et al., 1995; Maffei, et al., 1995a; Masuzaki, et al., 1995). Leptin has also 
been shown to be expressed in the stomach (Bado, et al., 1998), and placenta (Masuzaki, 
et al., 1997; Hoggard, et al., 1997b). Increased levels o f  ob mRNA have been reported for 
ob/ob mouse, db/db mouse and the Zucker fa /fa  rat (Zhang, et al., 1994; Trayhum, et al., 
1995; Maffei, et al., 1995; Frederich, et al., 1995; Funahashi, et al., 1995). Therefore,
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obesity seems to be associated with increased expression of the ob gene. Classic 
parabiotic experiments between ob/ob and wild-type mice indicated that a factor 
circulating in the bloodstream of lean (ob/ob littermates) or db/db mice reverses the 
effects o f the ob mutation (Coleman, 1973; Coleman, 1978). Thus, the elevated levels o f 
ob mRNA may reflect the strength of the feedback signals to adipose tissue resulting 
from the fact that a truncated, non-functional leptin is synthesized in this mutant (Zhang, 
et al., 1994). This is true for the db/db mouse and the fa /fa  rat because the mutants 
produce defective receptor systems for leptin. Treatment o f ob/ob mice with leptin 
reversed the obesity phenotype (Weigle, et al., 1995; Halaas, et al., 1995; Pelleymounter, 
et al., 1995).
2.6 REGULATION OF LEPTIN PRODUCTION
Leptin biosynthesis and release is governed by a complex array o f 
neuroendocrine, endocrine and paracrine signals that impinge on the adipocyte. Fasting 
decreases the level o f ob mRNA expression, which is rapidly reversed on refeeding 
(Trayhurn, et al., 1995; Frederich, et al., 1995; Hardie, et al., 1996; MacDougald, et al., 
1995; Saladin, et al., 1995). In contrast with normal rats and mice, fasting does not induce 
the decrease in the ob mRNA in ob/ob mice (Trayhurn, et al., 1995; Frederich, et al.,
1995). The decrease in leptin appears to be central to the neuroendocrine adaptation to 
starvation (Ahima, et al., 1996). Insulin increases the ob mRNA expression (Wabitsch, et 
al., 1996) and circulating protein levels (Malmstrom, et al., 1996), and the idea that 
insulin may be a controlling factor over leptin expression has been suggested. During 
starvation, the decrease in insulin may be a key regulatory signal for the suppression of 
leptin expression (Boden, et al., 1996).
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Leptin is also regulated positively by glucocorticoids at high doses (De Vos, et al., 
1995; Slieker, et al., 1996; Wabitsch, et al., 1996; Considine et al., 1997) and cytokines 
(Grunfeld, et al., 1996; Sarraf, et al., 1997), and negatively by B2- and 133-adrenergic 
receptor agonists and cAMP (Slieker, et al., 1996; Mantzoros, et al., 1996; Trayhum, 
1996b). Thyroid hormones also suppress leptin production from the adipose tissue (Fain, 
et al., 1997; Escobar-Morreale, et al., 1997; Valvaci, et al., 1997; Yoshida, et al., 1997) 
The ob gene promoter is positively regulated through a functional binding site for 
CAAT/enhancer binding protein (C/EBP-a) (He, et al., 1995; Miller, et al. 1996; Hwang, 
et al., 1996), whereas thiazolidinedione agonists for peroxisome proliferation activated 
receptor (PPAR-y) transcription factor suppress leptin expression in rodents (Forman, et 
al., 1995; De Vos, et al., 1996; Nolan, et al., 1996; Zhang, et al., 1996; Kallen & Lazar,
1996). This may involve a functional antagonism between C/EBPa and PPARy on the 
leptin promoter (Hollenberg, et al., 1997). In summary, nutritional status, stress and 
immune activation influence leptin expression and production.
2.7 LEPTIN RECEPTOR
The receptor for the leptin protein was recently identified by an expression 
cloning strategy (Tartaglia, et al., 1995; Devos, et al., 1996). A cDNA library was 
constructed from mouse choroid plexus to clone this leptin binding activity. From this 
screen, cDNAs that encoded a cell surface leptin receptor (OB-R) were identified 
(Tartaglia, et al., 1995). The majority o f the transcripts are those encoding the short forms 
of the receptor (Ghilardi, et al., 1996). The transcript that encodes the long form is less 
abundant even though it was detected in nearly all tissues in mice and humans by 
ribonuclease protection analysis (RPA) and polymerase chain reaction (PCR) (Ghilardi,
18
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et al., 1996). Nevertheless, the long form is expressed mainly in the hypothalamus. This 
long form transcript is found in regions that are thought to control body weight, namely, 
the ARC, VMN and PVN (Mercer, et al., 1996a).
The murine cDNA clones identified above revealed a single membrane-spanning 
receptor that is similar to the class I cytokine receptor family (Tartaglia, et al., 1995). The 
closest relatives of OB-R were shown to be gpl30 (Taga, et al., 1989; Hirano, et al.,
1994), the granulocyte colony stimulating factor (G-CSF) receptor (Larsen, et al., 1990), 
and leukemia inhibitory factor receptor (LIF-R) (Gearing, et al., 1991).
O B-R s O B-R l
100% 816 aa
transmembrane domain





Figure 2.4. Short form (OB-Rs) and long form (OB-Rl) leptin receptors. The similarities 
and differences between the extracellular, transmembrane, and intracellular domains of 
OB-Rs and OB-Rl are shown schematically, aa; amino acids, 100% is similarity between 
extracellular domains. 23 aa represents the transmembrane domain o f  the OB-Rs and OB- 
R l. OB-Rs has 34 aa and OB-RL has 303 aa in the intracellular domain. Adapted from 
Tartaglia (1997).
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The extracellular domain o f OB-R is about 816 amino acids and the intracellular 
domain o f the short form is composed o f 34 amino acids. The long form has an 
intracellular domain made of approximately 303 amino acids (Tartaglia, et al., 1995; 
Chen, et al., 1996; Lee, et al., 1996). The extracellular domains o f the short and long 
forms are identical throughout their entire length, except in the fa /fa  rat where a mutation 
has been described (Chua, et al., 1996; Iida, et al., 1996a; Iida, et al., 1996b). Differences 
only arise from the alternative RNA splicing at the carboxy-terminal coding exon, which 
results in the leptin receptor intracellular domains with differing length and sequence 
composition (Chen, et al., 1996; Lee, et al., 1996; Tartaglia, 1997). Additional short 
forms have been identified, all of which terminate shortly after the point o f divergence at 
Lys889, i.e., after amino acid 29 of the intracellular domain (Chen, et al., 1996; Chua, et 
al., 1996). A transcript that potentially encodes a soluble form of the receptor was also 
described (Lee, et al., 1996). This protein lacks the transmembrane domain found in the 
other OB-R proteins. Genetic mapping of the gene encoding OB-R localized its position 
to mouse chromosome 4 (Tartaglia, et al., 1995). The position is within the genetic 
interval to which the db locus has been mapped (Chen, et al., 1996).
2.8 LEPTIN RECEPTOR MUTATIONS
The gene encoding the leptin receptor was sequenced from the wild type and 
db/db mice and revealed a mutation in db/db mice (Chen, et al., 1996; Lee, et al., 1996). 
The mutation is a single nucleotide substitution, G—>T, within the exon containing the 
carboxy terminus and 3’-UTR of the short form o f OB-R. The mutation consequently 
resulted in the generation of a new splice donor site, creating an exon that is 
inappropriately spliced into the transcript encoding the long form o f OB-R. This new
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exon is made up o f the last six codons and the first 88-bp of the 3’-UTR o f the primary 
short form and is inserted where the long form and short form domains diverge. As a 
result of this insertion, the long form transcript in db/db mice encodes a protein in which 
the majority of the intracellular domain is truncated and thus identical to the major short 
form. The defect in db/db mice is in the OB-R gene providing evidence for the 
importance o f this receptor in body weight control (Chen, et al., 1996).
In the fa /fa  Zucker rat, the genetic mutation is a single nucleotide substitution, 
A —»C that leads to a single amino acid substitution, from Gin to Pro , in the 
extracellular domain. This mutation causes the obesity phenotype as it affects cell surface 
expression and binding affinity of leptin at the cell surface (Chua, et al., 1996a; Chua, et 
al., 1996b; Philips, et al., 1996, Iida, et al., 1996a; Iida, et al., 1996b). The expression 
levels of the OB-R mRNA in the brain of Zucker fa /fa  rat was higher than for lean 
littermates (Iida, et al., 1996). The fa  mutation was mapped to rat chromosome 5, a region 
syntenic with the db region on mouse chromosome 4 (Truett, et al., 1991).
Another mutation o f the leptin receptor was found in the inbred genetic model of 
non-insulin-dependent diabetes mellitus (NEDDM), an NIH-corpulent rat (cp/cp), 
(Koletsky, 1973; Lee, et al., 1997). This mutation is a fa  allele (fa^/fa09) since crosses of 
rats carrying the fa  mutation with rats carrying the cp mutation yielded obese progeny 
(Yen, et al., 1977). The mutation is a single base change o f T2289 to A2289 in the obese 
corpulent rats resulting in the conversion of Tyr763 to a stop codon (Lee, et al., 1997). 
This nonsense mutation results in the termination of translation at the amino terminal end 
o f the transmembrane domain. As a result, none of the leptin receptor isoforms in cp/cp 
rats are predicted to encode a transmembrane domain, nor any o f the motifs necessary for
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signal transduction. The mutation in the corpulent rat and the ffameshift mutation in 129 
db3J/db3J mice confirm that defects in the leptin receptor lead to abnormalities in the 
leptin-leptin receptor pathway and an obese phenotype.
2.9 LEPTIN RECEPTOR FUNCTIONS
The functions o f the long and short intracellular domains o f  the leptin receptor are 
currently being defined. The high expression levels o f  the short form have been 
speculated to play a role in transporting leptin from the blood to the cerebrospinal fluid 
(CSF), where leptin can then move by diffusion to the ARC, PVN or VMN to regulate 
body weight. This is supported by the observation that leptin enters the brain by a specific 
and saturable transport mechanism (Banks, et al., 1996). However, the role of the leptin 
receptors in this transport system has not been described. The short form of OB-R may 
also play a role in clearance due to their distinct tissue distribution (Cumin, et al., 1996).
The long form o f the receptor shows sequence homology to members o f the class 
I cytokine receptor superfamily (Tartaglia, et al., 1995; Bazan, 1990). This provides 
important information as to possible intracellular mediators o f leptin receptor activation 
(Figure 2.5). The cytoplasmic domains o f the class I cytokine receptors lack enzymatic 
activity and instead they associate with the cytoplasmic tyrosine kinase of the Janus 
kinase (JAK) family (Ihle, 1995). Ligand binding leads to activation of receptor-bound 
JAK kinases, which phosphorylate tyrosines in the cytoplasmic domain o f the receptor as 
well as other cytoplasmic target proteins, including the signal transducers and activators 
of transcription (ST AT), ras/mitogen activated protein (MAP) kinase, and 
phosphoinositide-3-kinase pathways (Ihle, 1996; Darnell, et al., 1994). The activated 
ST AT proteins then translocate to the nucleus and stimulate gene transcription.
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Figure 2.5. Schematic diagram of the leptin receptor and its molecular signaling 
pathways. Homodimerization of the OBR complex by leptin binding to leptin binding 
domain (LBD) activates JAK kinase activity, which phosphorylates OBR on tyrosine 
residues in the cytoplasmic domain. Phosphorylated tyrosine residues provide specific 
docking sites for the SH2 domains of STAT-3 proteins, causing receptor association and 
subsequent phosphorylation of STAT-3. After activation, STAT3 translocates to the 
nucleus to modulate transcription. Negative regulators o f JAK/STAT signaling, e.g., 
SOCS and PIAS, interfere at specific sites in the signaling cascade, with SOCS-3 
inhibiting JAK association with the OBR and inhibit OBR activation and STAT-3 
phosphorylation, and PIAS-3 inhibiting the DNA binding o f activated STAT-3. In 
addition to activating the JAK/STAT cascade, leptin also stimulates the MAP kinase 
pathway. This pattern o f JAK/STAT protein activation by leptin is predominantly in the 
hypothalamus. Adapted from Auernhammer and Melmed (2000).
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Thus, the long form OB-R is likely to be the active signaling receptor because it has 
features similar to that of the class I cytokine receptors that are essential for signaling. 
Furthermore, it is preferentially expressed in the hypothalamus, the primary site o f leptin 
action.
Co-transfection studies have shown that the long form of OB-R is capable o f 
activating the STAT proteins in response to ligand binding (Baumann, et al., 1996; 
Ghilardi, et al., 1996). This effect is not observed in the presence o f the short form 
receptor. The short form of the receptor was unable to bind to or activate JAK kinase 
(Ghilardi & Skoda, 1997) which is consistent with the inability to activate STAT 
proteins. In contrast to the inability o f the short form leptin receptor to bind and activate 
JAK/STAT proteins, the short form does induces gene transcription o f c-fos and c-jun 
(Murakami, et al., 1997; Yamashita, et al., 1997). This is similar to transcription induced 
by the truncated G-CSF receptor, which contains a short cytoplasmic domain (Baumann, 
et al., 1996). This suggests, therefore, that the leptin-induced mRNA expression in CHO 
cells transformed with the short form OB-R was signaled through the short cytoplasmic 
domain (Murakami, et al., 1997). The Zucker rat leptin receptor not only exhibits a 
slightly reduced leptin binding affinity, it was also shown to perform reduced signal 
transduction by stimulating the transcription o f c-fos, c-jun and jun-B  (Yamashita, et al.,
1997).
2.10 PERIPHERAL METABOLIC ACTIONS OF LEPTIN
The presence of receptors for leptin not only in the hypothalamus, but also in the 
peripheral tissues, including adipose tissue, liver, skeletal muscle and islet cells, suggests 
that leptin has peripheral as well as central actions (Tartaglia, et al., 1995; Tartaglia,
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1997; Wang, et al., 1997a; Berti, et al., 1997; Muller, et al., 1997). Such peripheral 
actions were confirmed by studies which showed that leptin can impair insulin signaling, 
both in skeletal muscle and adipocytes. For example, leptin impairs insulin-mediated 
glucose uptake in adipocytes (Muller, et al., 1997). Furthermore, in both HepG2 cells and 
skeletal muscle myotubules, leptin was found to inhibit phosphorylation of insulin 
receptor substrate-1 (IRS-1) (Berti, et al., 1997; Muller, et al., 1997).
In addition to its effect on insulin-mediated glucose uptake, leptin inhibits insulin- 
mediated lipogenesis, and stimulates lipolysis and protein kinase A (PKA) (Wang, et al., 
1997a). These studies suggest a role for leptin in peripheral metabolic regulation, and 
have raised the possibility that the impaired insulin signaling in obese subjects might 
result, in part, from increased circulating leptin levels.
2.11 LEPTIN AND THE HP A AXIS
Conflicting results have been obtained in studies looking at the relationship 
between plasma leptin and cortisol levels (Licinio, et al., 1997; Haffner, et al., 1997; 
Vettor, et al., 1997). The diurnal variation of leptin and cortisol is reciprocal, leptin levels 
peak during the nadir of cortisol secretion. In cultured adrenocortical cells, leptin was 
found to dose-dependently inhibit ACTH-stimulated cortisol production and P450 17a- 
hydroxylase mRNA expression (Bomstein, et al., 1997). In contrast, leptin increases 
CRH expression in the PVN (Schwartz, et al., 1996). Despite the observation that 
dexamethasone can stimulate leptin production in culture adipocytes, peripheral CRH 
administration in humans does not influence leptin levels (Cizza, et al., 1997). It is 
therefore apparent that leptin and HPA axis may be reciprocally related, but with 
interactions at several levels.
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An intact HPA axis has been suggested to be necessary for the normal actions of 
leptin on energy balance. Leptin feeds back to the HPA axis to inhibit release o f CRH. 
Stress is the classic stimulus to the HPA axis (Dallman, M.F. 1993). Starvation and 
immobilization stress markedly stimulate this endocrine axis (Chowers, et al., 1969; 
Akana, et al., 1992). Administration o f leptin to fasting mice or to restraint-stressed rats 
attenuates stimulation of the HPA axis and both ACTH and corticosterone levels are 
normalized to that o f the fed state (Ahima et al., 1996). Heiman and colleagues showed 
that such inhibition may be exerted at the hypothalamic level, because leptin directly 
inhibited CRH release in response to hypoglycemia, and because it did not directly 
change the secretion o f ACTH, which is a counterregulatory response to prevent 
hypoglycemia (Aizawa, et al., 1981; Widmaier, et al., 1988; Heiman, et al., 1997).
Injection o f leptin centrally to ADX rats showed that the hypophagic and weight- 
reducing effects o f leptin were significantly amplified, and this effect was abolished by 
treatment with dexamethasone (Zakrzewska, et al., 1997). These observations suggested 
that glucocorticoids exert a counter-regulatory effect on leptin action, and that the activity 
o f the HPA axis may set the level o f sensitivity to leptin. In humans, however, little is 
known about the possible effects of leptin on the HPA axis in human obesity. Vettor et al. 
(1997) showed that no relationship exists between the activity o f the HPA axis and serum 
leptin concentrations in women with different obesity phenotypes.
2.12 LEPTIN AND REPRODUCTION
Studies in rodents have shown that male and female homozygous ob/ob mice are 
obese and infertile (Hoggard, et al., 1998) and these mice do not produce functional 
leptin (Chehab, et al., 1996). Whereas male ob/ob mice can reproduce if maintained on a
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restricted diet, female ob/ob mice are always sterile (Lane and Dickie, 1964). Early 
sexual development is normal in ob/ob females; however, ovulation never occurs and the 
mice remain prepubertal indefinitely, with no occurrence o f  estrus cycle. Reproductive 
hormones are reduced in ob/ob female mice, showing a functional defect from the 
hypothalamic-pituitary axis (Chehab, et al., 1996). When injected with leptin, female 
ob/ob mice show an increase in serum luteinizing hormone (LH) levels and ovarian 
weight, and they become fertile (Chehab, et al., 1996; Barash, et al., 1996). The leptin- 
induced elevation in LH in ob/ob mice suggested that the primary regulatory effect of 
leptin was on the reproductive neuroendocrine system, with the ovarian effects being 
secondary to stimulation by LH. The detection of leptin receptor mRNA in human ovary 
has suggested a direct action o f leptin in the ovary (Cioffi, et al., 1996). Zachow and 
Magoffin (1997) showed that leptin can act directly on the ovarian granulosa cells to 
selectively decrease estradiol (E2 ) but not progesterone (P4 ) production. Interestingly, 
follicle-stimulating hormone (FSH)-dependent E2 production was not reduced by leptin, 
whereas leptin impaired the sensitizing effect of insulin-like growth factor-l (IGF-1) on 
FSH-dependent E2 synthesis by granulosa cells.
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CHAPTER THREE 
GENERAL METHODS AND TECHNIQUES
3.1 PREPARATION OF HEPATOCYTES
Perfusion and preparation o f hepatocytes was carried out as illustrated in Figure
3.1 using the in situ  collagenase perfusion method as described previously (Berry and 
Friend, 1969; Seglen, 1976) with modifications o f Pertoft & Smedsrod (1987). Rats were 
anesthetized by intraperitoneal injection o f ketamine (0.125 ml/100 g body weight) and 
decontaminated with a 70% ethanol solution. The first cannula was placed in the hepatic
Hver
inflow  c a n n u la  
(insK ja p o r ta l vam )
o
Figure 3.1. Diagrammatic representation o f liver perfusion.
portal vein, and a second was placed in the inferior vena cava. The liver was perfused, at 
a rate o f 30 ml/min, with calcium-free perfusion buffer [Hank’s Balanced Salt Solution 
(HBSS), pH 7.5; 10 mM glucose] that had been equilibrated at 37°C with 95% oxygen 
and 5% CO2 . This initial perfusate was allowed to drain to waste. The liver was then
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enzymatically digested for 10 min by recirculating 50 ml o f collagenase buffer [HBSS; 2 
mM CaCI2; 0.05% (w/v) type 1 collagenase (Worthington Biochemical Corp., Lakewood, 
NJ)]. The liver was carefully removed, placed in a beaker containing collagenase buffer 
and minced. The liver lysate was further incubated at 37°C for 15 min with shaking to 
release hepatocytes, and then placed on ice for 5 min. An equal volume of ice-cold wash 
buffer [HBSS; 2 mM CaCl2] was added to the cell suspension, which was then filtered 
through a 250 pm nylon filter into a sterile centrifuge tube. The cell suspension was 
centrifuged at 300 rpm for 2 min at 4°C. Cells were washed three times in the wash 
buffer. The final pellet was resuspended in 20 ml o f wash buffer. For cell counting and 
viability determination, cells were diluted 1:10 with William’s E (WE) medium (Sigma 
Chemical Co., St Louis, MO) and counted on a hemacytometer using the inverted 
microscope. Cell viability was determined by using the trypan blue dye exclusion 
method. Hepatocytes (4 x 106/5ml) were plated onto collagen-coated 60 mm2 cell culture 
dishes (Coming Glass Works, Coming, NY) in WE medium containing I nM insulin, 1 
nM dexamethasone (DEX) and 5% (v/v) fetal bovine serum (FBS). The cultures were 
incubated at 37°C in a humidified 5% C 02/95% air incubator for 4 hr to allow the cells to 
attach to the substratum. After 4 hr, unattached cells were removed by aspiration of 
medium, and cells were incubated overnight in serum-free medium containing 1 nM 
insulin and 1 nM DEX. The spent medium was replaced with either fresh WE medium or 
fresh glucose-, L-glutamine and sodium pyruvate-free Dulbecco’s minimal essential 
medium (DMEM) (Life Technologies, GIBCO BRL, Grand Island, NY) containing 
different hormones as described in the respective experimental setups.
29
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3.2 TOTAL RNA EXTRACTION FROM HEPATOCYTES
Isolation of total RNA was carried out by the standard procedure of Chomczynski 
and Sacchi (1987, 1992) with modifications. After treatment with various hormones, the 
culture medium was aspirated and cells were quickly washed with 2 ml o f ice-cold 
phosphate-buffered saline (PBS, pH 7.2) and lysed in 1 ml o f ice-cold solution D (4 M 
guanidinium isothiocyanate; 25 mM sodium citrate; 0.5 % Sarcosyl; 0.72% P- 
mercaptoethanol). The cell lysate was scraped to one end of the plate using a sterile 
disposable cell scraper (Fisher Scientific, Pittsburg, PA), passed up-and-down four times 
through a 1-ml micropipette and transferred into heavy gel phase lock tubes (5 Prime —> 
3 Prime, Inc., Boulder, CO, USA). The following solutions were sequentially added to 
the lysate with mixing: 0.1 ml o f 2 M sodium acetate (pH 4.0), 1 ml water-saturated 
phenol and 0.5 ml chloroform. The suspension was incubated on ice for 15 min, and then 
centrifuged at 3,300 rpm for 15 min at 4°C. The aqueous phase was transferred into a 
fresh polypropylene tube and total RNA was precipitated with an equal volume of 
isopropanol at -20°C for 1 hr. Total RNA was pelleted by centrifugation at 10,000 rpm 
for 10 min at 4°. The pellet was resuspended in 0.3 ml solution D and transferred into an
1.5 ml Eppendorf tube. The RNA was re-precipitated overnight at -20°C with an equal 
volume of isopropanol. The precipitate was centrifuged at 14,000 rpm at 4°C in a 
Eppendorf microcentrifuge. The pellet was washed with 75% ethanol, air-dried and 
completely dissolved in 0.1 ml RNAse-free water at 60°C for 10 min. Total RNA was 
quantified spectrophotometrically at 260 and 280 nm (1 A260 unit = 40 pg/mL RNA) and 
the purity was determined by the 260/280 ratio. The quality of the total RNA was further 
analyzed by 1% agarose-2.2 M formaldehyde gel electrophoresis at 100 V for 2-3 hr.
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3.3 ISOLATION OF TOTAL RNA FROM TISSUES USING TRIZOL REAGENT
Isolation of total RNA was carried out using the TRIzoI reagent protocol as 
described by the manufacturer (GD3CO BRL, Grand Island, NY, USA) and modified 
recently (Nakajima, et al., 1998). This protocol follows the original method o f RNA 
isolation described by Chomczynski and Sacchi (1987, 1992). Frozen liver tissue (0.1 g) 
was homogenized in 1 ml TRIzol reagent using the Polytron (model MR3000, 
Kinematica AG, Switzerland) at maximum speed for 15 sec. The homogenate was 
transferred into a heavy gel phase lock tube (5 Prime —> 3 Prime, Inc., Boulder, CO, 
USA) and incubated at room temperature for 5 min. After 5 min, 0.2 ml chloroform was 
added per 1 ml of TRIzol. The suspension was mixed vigorously for 15 sec, incubated at 
room temperature for 3 min, and then centrifuged at 3,300 rpm for 5 min at 4°C. After 
centrifugation, the aqueous phase containing total RNA was transferred into a fresh 
polypropylene tube. Total RNA was precipitated with 0.5 ml isopropanol per 1 ml of 
TRIzol at -20°C for 1 hr, and centrifuged at 10,000 rpm for 15 min at 4°C. The pellet was 
resuspended in 0.3 ml Solution D [4 M guanidinium isothiocyanate; 25 mM sodium 
citrate; 0.5 % sarcosyl; 0.72% P-mercaptoethanol], and transferred into an Eppendorf 
tube. The RNA was precipitated with an equal volume of isopropanol overnight at -20°C. 
Total RNA was recovered by centrifugation at 14,000 rpm at 4°C in a microcentrifuge 
(Eppendorf centrifuge model 5402, Hamburg, Germany). The pellet was washed with 
75% ethanol, air-dried and completely dissolved in 1 ml o f RNAse-free water at 60°C for 
10 min. RNA was quantified and quality checked as described above.
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3.4 NORTHERN BLOT ANALYSIS
Agarose gel electrophoresis and Northern blotting were performed according to 
standard procedure (Sambrook, et al., 1989). Total RNA (20 or 40 pg/lane) obtained from 
tissues or hepatocytes was mixed (1:2 v/v) with RNA sample buffer [62.5% formamide; 
9.25% formaldehyde; 1.25X formaldehyde gel running buffer; 50 fig/ml bromophenol 
blue; 50 gg/ml xylene cyanole FF; 50 pg/ml ethidium bromide (5 Prime —> 3 Prime, Inc., 
Boulder, CO, USA)], denatured at 65°C for 10 min, and immediately chilled on ice for 5 
min. Samples were loaded and size-fractionated in a 1% agarose-2.2 M formaldehyde gel 
at 100 V for 2-3 hr. The quality of the RNA was determined by visualization under UV 
light using either a UV transilluminator (Spectronics Corp., Westbury, NY) or 
Chemilmager (Alpha Innotech Corp., San Leandro, CA). The gel was photographed 
using Polaroid DS34 instant camera (Polaroid Corp., Cambridge, MA), placed in 10 mM 
NaOH solution for 10 min and the RNA was transferred overnight onto a Hybond N+ 
nylon membrane (Amersham, Buckinghamshire, UK) by using the standard upward 
transfer method with 10X SSC as transfer buffer (20X SSC = 3 M sodium chloride, 0.3 
M sodium citrate, pH 7.0). The efficiency of transfer was determined by checking the gel 
under UV light after transfer. The 18S and 28S ribosomal RNA positions were marked by 
nicking the membrane. The membrane was briefly rinsed with 2X SSC, dab-dried and 
baked in a vacuum-oven at 80°C for 30 min. The membrane was prehybridized for 3 hr 
or overnight at 42°C (for cDNA probes) or 50°C (for oligonucleotide probes) in a 
prehybridization solution [50% formamide; 0.12 M Na2HPC>4; 0.25 M NaCl, 7% (w/v) 
SDS], After prehybridization, the membrane was hybridized for 18 hr with radiolabeled 
probe in prehybridization buffer. The membrane was then stringently washed three times
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as follows: 2X SSC/0.1% SDS for 15 min at room temperature, 0.5X SSC/0.1%SDS for 
20 min at room temperature, 0.1X SSC/0.1% SDS for 15 min at 60°C, placed in a sealed 
plastic bag and exposed to phosphoscreen overnight. The signal was quantified using the 
Phosphoimager and the ImageQuant software (Molecular Dynamics, Sunnyvale, C A).
♦ Labeling o f cDNA probes by random priming
cDNA inserts, obtained from various plasmids used in this study, were labeled by 
random primer labeling method using the DECAprime II kit (Ambion Inc., Austin, TX). 
Briefly, 25ng template DNA was mixed with 1 pL o f 10X decamers to a final volume of 
11 pL and heated for 5 min at 95°C. The solution was snap-frozen in liquid nitrogen 
before placing on ice. Then, 14 pL of labeling master mix [IX  dCTP-minus buffer, [a- 
32P]dCTP, Klenow large fragment E. coli polymerase] was added and incubated at 37°C 
for 30 min. The reaction was stopped by adding 1 pi o f 0.5 M EDTA and the 
unincorporated label was removed by centrifugation through a Micro Bio-Spin™-30 
chromatography column (Bio-Rad Laboratories, Hercules, CA). The specific activity of 
the probe was determined by counting 1 pi in 10 ml o f EcoLite scintillation liquid in the 
Beckman LS6000 scintillation counter (Beckman Instruments Inc., Fullerton, CA). 
Before use, the radiolabeled probe (1-5 x 106 cpm/ml hybridization buffer) was linearized 
by heating at 95°C for 5 min, chilled on ice, and added to prehybridization buffer.
3.5 CLONING THE LEPTIN RECEPTOR FRAGMENT
♦ cDNA synthesis
Total RNA was isolated from the hypothalamus o f a lean Zucker rat using the 
TRIzol reagent method as described in section 3.3. Reverse transcription polymerase- 
chain reaction (RT-PCR) was carried out according to the manufacturer’s instructions
33
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(Promega Corp., Madison, WI) and as described by Ghilardi and colleagues (1996). Five 
pg of hypothalamic RNA or yeast control RNA was mixed with oligo(dT)i2-i8 primers 
(Life Technologies, GIBCO BRL, Grand Island, NY, USA) in a sterile 0.5 ml PCR tube 
and incubated at 70°C for 10 min to denature RNA secondary structure. A 12 pi reverse 
transcriptase master mix [IX  reverse transcriptase buffer, 2.5 mM MgCh, 0.5 mM 
deoxyribonucleotides (dNTPs), 10 mM dithiothreitol (DTT), 1 pL Moloney-Murine 
leukemia virus reverse transcriptase (M-MLV)] was prepared. After denaturation, the 
tubes were chilled on ice for 1 min and the master mix was added. To ensure that the 
primers did not prime o ff o f the contaminating genomic DNA, a negative control omitted 
the reverse transcriptase. The tubes were incubated at 42°C for 55 min for synthesis, and 
the enzyme was inactivated by heating at 70°C for 15 min. The tubes were chilled at 0°C 
for 1 min. One pi o f RNAse H was added to each tube and further incubated at 37°C for 
30 min. The reaction was thereafter chilled on ice or stored at —20°C until required for 
PCR.
♦ Polymerase-chain reaction (PCR) amplification
The leptin receptor cDNA was amplified using the PCR amplification reagents 
obtained from Promega (Madison, WI. USA). The following primers were used to 
amplify the leptin receptor cDNA: forward, 5’-TTCCTATCGAGAAATATCAG-3’, 
reverse, 5’-GGTACCATCTCATCTTTATT-3’, (named leptin I and H, respectively), 
selected to amplify sequences corresponding to nucleotides from +2473 to +2875 o f  the 
rat leptin receptor cDNA (GenBank U52966) as described by Ghilardi, et al. (1996). Two 
pL of the cDNA synthesis reactions were mixed with 48 pi of the PCR master mix [IX  
PCR buffer, 1.5 mM MgCl, 0.4 mM dNTP mix, 0.5 pi Taq polymerase, 200 nM each o f
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leptin I and II primers or control primers for yeast RNA] and amplified for 40 cycles 
[PCR conditions: initial denaturation at 94°C for 90 sec; followed by 94°C for 45 sec; 
45°C for 45 sec; 72°C for 2 min; final extension at 72°C for 10 min, and held at 4°C, 
using the Programmable Thermal Controller (PTC-100™, MJ Research Inc., USA). PCR 
products were electrophoresed on a 1% agarose gel in 0.5X TBE at 100 V for I hr. The 
amplified products were visualized under UV light and photographed. Figure 3.2 shows 
the PCR amplified leptin receptor cDNA, named ObR403 based on its expected size.
1 2 3 4  5 6  7  8 9 M
ObR403
Figure 3.2. RT-PCR product of the hypothalamic leptin receptor. Leptin receptor was 
amplified from the cDNA obtained from total hypothalamus RNA. Reverse transcription 
was performed using hexamers [lanes 2-5] and oligo(dT)i2-i8 primers [lanes 6-9]. Lane I 
is a control without reverse transcriptase. M = 100 base-pair DNA ladder. PCR products 
were fractionated in a 1.5% agarose gel for 1.5 hr.
♦ Cloning of ObR403 cDNA
The amplified ObR403 cDNA was cloned by T-A cloning method using pGEM^-T Easy 
vector systems according to the manufacturer’s instructions (Promega Corp., Madison, 
WI). Briefly, the ObR403 cDNA was mixed with 50 ng pGEM®-T Easy vector (3:1 and 
1:3 ratios) in a ligation reaction containing IX T4 DNA ligase buffer and 0.3 Weiss 
units/pl T4 DNA ligase. The reaction was carried out overnight at 10°C, and placed on
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ice. Escherichia coli (E. coli) JM 109 strain was transformed with 50 ng DNA according 
to supplier’s instructions (Promega Corp., Madison, WI). Briefly, bacterial cells were 
thawed on ice. Cells were mixed with the ligated DNA and incubated on ice for 30 min. 
The cells were heat-shocked for 50 sec in a 42°C water bath and placed back on ice for 2 
min. Sterile SOC medium, pH 7.0 [2% tryptone, 0.5% yeast extract, 0.05% NaCl, 2.5 
mM KC1] at room temperature was added and the cells were allowed to recover for 1.5 hr 
at 37°C with shaking at 225 rpm. Cells were diluted 1:10, spread-plated on Luria-Bertani 
(LB) agar plates containing 50 pg/ml ampicilin and incubated at 37°C for 16 hours. 
Individual isolated colonies were picked and cultured overnight in 5 ml LB medium 
containing 100 pg/ml ampicilin. DNA minipreps were performed, as described below, to 
identify the clones that were successfully transformed with the ObR403 cDNA.
3.6 PLASMID DNA EXTRACTION PROTOCOL
Plasmid DNA was extracted using the Wizard™ Plus DNA purification system 
(Promega Corp., Madison, WI). Cells were pelleted by centrifugation at 10,000 xg for 10 
min at 4°C using the Eppendorf microcentrifuge. The pellet was completely resuspended 
in 300 pi o f cell resuspension solution [10 mM Tris-HCl, pH 8.0, 0.5 mM NaCl, 1 mM 
EDTA, 10 pg/ml lysozyme]. To the suspension, 300 pL o f fresh lysis solution [0.2 N 
NaOH, 1% SDS] was added and the contents were mixed by inversion. Then, 300 pi o f 
the neutralization solution [1.32 M potassium acetate, pH 5.2] was added and mixed by 
inversion. The lysate was centrifuged at 10,000 xg for 5 min at 4°C in a microcentrifuge. 
The supernatant was carefully aspirated and mixed with 1 ml o f DNA purification resin. 
The DNA/resin mix was then transferred into the barrel o f a mini-column/syringe 
assembly and vacuum was applied to draw the solution through the mini-column. Then 2
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ml o f  column wash solution was added to the mini-column and vacuum was applied as 
above. The mini-column was dried under vacuum and transferred to an Eppendorf tube 
for further drying by centrifugation at 10,000 xg for 2 min. The plasmid DNA was eluted 
by adding 50 (il o f TE [10 mM Tris-HCl, pH 8.0; 1 mM EDTA] and centrifuged at 
10,000 xg for 20 sec. The plasmid DNA was subjected to restriction enzyme analyses and 
agarose gel electrophoresis, and aliquots were stored at -20°C until required for further 
analysis. Figure 3.3 shows the gel electrophoresis profile o f ObR403 cDNA cloned into 
pGEM-T Easy vector. The ObR403 DNA insert was then excised from the pGEM-T Easy 


















Figure 3.3. Restriction endonuclease digestion of purified pZObR403 plasmid. The 
amplified plasmid was undigested (lane 1), insert excised with EcoRl (lane 2) and 
BamHl-HindlH (lane 3), and plasmid linearized with BamHl (lane 4) and HindlH (lane 
5). Lanes M are 100-bp/l-kb DNA ladders. Fragments were fractionated on a 1% agarose 
gel containing ethidium bromide at 80V for 1.5 hr. Arrow indicates the position of the 
403 bp fragment after EcoRl digestion.
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3.7 SEQUENCING OF CDNA CLONES
The cloned and purified plasmid DNAs for pZObR403, pSOCS-3 and pSTAT-3 
were sequenced using T7 universal primers. The plasmid DNA inserts were PCR 
amplified using T7 primers with conditions as follows: denaturation at 95°C for 4 min, 
and 30 cycles of denaturation at 95°C for 30 sec, synthesis at 56°C for 1 min and 
extension at 70°C for 30 sec, and final extension at 70°C for 5 min. The inserts were 
sequenced by using the Big Dye Terminator Cycle Sequencing Ready Reaction kit 
(Perkin Elmer, Foster City, CA). Sequencing reaction products were purified using 
96-well gel filtration kit for Big Dye Terminator clean-up, and loaded in a 6% FS 
automated polyacrylamide sequencing gel in a 373 A automated DNA sequencer (Perkin 
Elmer, Applied Biosystems, Foster City, CA). Figure 3.4 shows an electrophoretogram 
of the ObR403 sequence.
3.8 GEL PURIFICATION OF cDNA INSERTS
Purified plasmid DNA was digested overnight with specific restriction enzymes 
as indicated by the restriction maps and on the legends to the figures. Restriction 
fragments were fractionated by 1% agarose gel electrophoresis in 0.5X TBE (Tris- 
Borate-EDTA) buffer at 100 V for 1.5 hr. The fragments were visualized under UV light 
and photographed. The band of interest was excised from the gel, minced in 200 pi TE 
buffer and transferred into the nebulizer and Microcon concentrating system (Amicon 
Inc., Beverly, MA). The unit was centrifuged at 10,000 xg for 5 min. The cDNA was 
recovered by centrifuging the Microcon in an inverted position as above for 30 s. The 
DNA was quantified by 1% agarose gel electrophoresis using the high or low DNA Mass 
ladder (GIBCO BRL, Grand Island, NY).
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Figure 3.4. An electrophoretogram of pZObR403 plasmid DNA sequence obtained by sequencing using the ABI PRISM® 
BigDye1M terminator cycle sequencing ready reaction kit after purification of the PCR products. Samples were loaded onto 
a 36 cm gel containing 5% LongRanger gel, and run on an ABI PRISM® 373 automated DNA sequencer. A BLAST 
search (v. u w .m. In nlmmli uh ./Moni) identified nucleotides 4-69 as pBluescript II vector sequence and nucleotides 72.-330 
as rat longform leptin receptor gene sequence.
3.9 IN  VITRO  TRANSCRIPTION REACTION FOR PREPARATION OF 
RIBOPROBES
♦ Preparation of Template
Template DNA (50 pg) was linearized by complete restriction enzyme digestion 
with an enzyme that cleaves distally from the selected promoter site. An aliquot o f  the 
linearized product (0.5 pg) was analyzed by I% agarose gel electrophoresis in 0.5X TBE 
at 100 V for 2 hr to determine complete digestion by restriction enzymes. The linearized 
template DNA was then incubated with 100 pg/ml Proteinase K in 10 mM Tris-HCl (pH 
8.0), 0.5% SDS and 2 mM CaCl2 at 50°C for 30 min. The mixture was extracted once 
with phenol/chloroform (1:1) to remove any contaminating proteins. The aqueous phase 
was carefully transferred to a new tube and the linearized DNA was precipitated with 0.1 
volume of 5M ammonium acetate and 2 volumes o f ethanol at -20°C for 1 hr. The 
template DNA was recovered by centrifugation at 14,000 rpm for 15 min at 4°C. The 
pellet was washed with 70% ethanol, air-dried and resuspended in nuclease-free water to 
0.5 pg/pl. The quality o f  template DNA was assessed by 1% agarose gel electrophoresis 
and the concentration was estimated by comparison to the DNA mass ladder.
♦ Assembly of the Transcription Reaction
The transcription reaction was carried out according to the manufacturer’s instructions 
using the RPA III kit (Ambion Inc., Austin, TX). Reagents were added at room 
temperature. One pg of the linearized DNA template, transcription buffer, 
ribonucleotides (NTPs), [a-32P]UTP and RNA polymerase (T3 or T7) were mixed in a 
final volume o f 10 pi and incubated at 37°C for 1 hr. The template DNA was removed by 
digestion with 0.5 pi o f RNase-free DNase I (2U/pL) at 37°C for 15 min. The reaction
40
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
was terminated by adding 0.5 pL of 0.5 M EDTA. An equal volume o f gel loading buffer 
was added to the reaction, heated at 95°C for 5 min, and then chilled on ice for 5 min. 
One pi aliquot was removed and added to 10 ml o f EcoLite (Amersham, 
Buckinghamshire, UK) scintillation liquid and radioactivity was counted using the 
Beckman LS6000 scintillation counter (Beckman Instruments Inc., Fullerton, CA). The 
remaining aliquot was heated at 95°C for 3 min, loaded onto a 5% acrylamide/8M urea 
gel and electrophoresed at 300 V for 2.5 hr. After electrophoresis, the gel was exposed to 
X-ray film (Eastman Kodak Co., Rochester, NY) for 1-5 min in the dark. The film was 
developed using the Kodak X-OMAT automatic developer. The full-length labeled 
transcript was precisely localized and excised with a razor blade. The gel piece was 
transferred into an Eppendorf tube containing 350 pL o f Elution Buffer, vortexed and 
centrifuged briefly. The elution was allowed to proceed overnight at 37°C. One pL 
aliquot of the eluted probe was removed to count radioactivity as described above.
♦ Ribonuclease Protection Assay (RPA)
Ribonuclease protection assay (RPA) was carried out essentially as described by the 
manufacturer (Ambion Inc., Austin, TX). Routinely, 20 or 40 pg total RNA was mixed 
with antisense radiolabeled riboprobe (300,000 cpm), and the mixture was precipitated 
with 0.1 volumes of ammonium acetate and 2.5 volumes o f absolute ethanol at —20°C for 
15 min. Tubes were centrifUged at 14,000 rpm for 15 min at 4°C, and the supernatant was 
completely aspirated. The pellet was dissolved in hybridization solution and the tubes 
were heated at 95°C for 4 min and vortexed vigorously. The tubes were incubated in a 
45°C water bath for 18 hours to allow hybridization o f probe and complementary mRNA. 
After hybridization, a diluted mixture of RNase A+Tl solution was added and the tubes
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were incubated at 37°C for 30 min to digest the unprotected single-stranded RNA. 
RNases were inactivated by adding the RNAse inactivating solution, and the protected 
RNA was precipitated at -20°C for 15 min. The tubes were centrifuged as before and the 
supernatant was discarded. The pellets were resuspended in gel loading buffer and heated 
at 95°C for 4 min to solubilize and denature the RNA. The protected fragments were 
resolved on a 5% denaturing polyacrylamide gel at 250 V for 3 hr in IX TBE. The gels 
were carefully transferred onto a Whatman 3M filter paper and dried at 80°C under 
vacuum. The dried gels were exposed to a phosphoscreen overnight. Signals were 
quantified using the Phosphoimager and the ImageQuant software (Molecular Dynamics, 
Sunnyvale, CA). Figure 3.5 shows a typical RPA gel showing the hypothalamic and liver 
leptin receptor protected fragments. The long form ObR, represented by the 403-bp 
protected fragment, was evident only in the hypothalamus and none was seen in the liver. 
The short isoform, 270-bp, of ObR was present in both tissues.
3.10 PREPARATION OF TOTAL PROTEIN LYSATES
Total protein lysates were prepared according to O’Donnell, et al., (1995). 
Briefly, frozen hypothalamic tissue was placed directly into a 2 ml Eppendorf tube 
containing 5 volumes of ice-cold TEGMD buffer [TEGMD = 20 mM Tris-HCl, pH 7.4, 1 
mM EDTA, 10% Glycerol, 10 mM Sodium Molybdate, 1 mM Dithiothreitol], and 
homogenized on ice using a sonicator (Ultrasonic Homogenizer, 4710 series, Cole- 
Parmer) at output 6 for 2 sec to disrupt the tissue and cells. The sonication was repeated 5 
more times on ice. The resulting homogenate was centrifuged at 105, 000 xg for 45 min 
at 4°C in a Beckman L8-80 ultracentrifuge. The supernatant, containing the total protein 
fraction, was collected and aliquoted into 1.5 ml Eppendorf tubes.
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Figure 3.5. Leptin receptor ribonuclease protection assay o f total RNA from the 
hypothalamus and liver. Increasing concentration o f total RNA from the hypothalamus 
and liver were hybridized overnight with 32P-labeIed antisense ObR403 and P-actin RNA 
riboprobes. Samples were processed as detailed in the preceding section and fractionated 
on a 5% sequencing gel. M is the century RNA molecular marker. The protected 
fragments, 403 and 270 bp, represent the long and short isoforms o f the leptin receptor. 
The other bands could represent other ObR transcripts that we did not study very closely. 
The P-actin protected fragment was used as an internal standard to ensure linearity.
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Protein concentration was determined by using the BCA assay (Pierce Chemical 
Co., Rockford, IL). The tubes were snap-frozen in liquid nitrogen and stored at -80°C 
until needed for analysis.
3.11 PREPARATION OF HYPOTHALAMIC NUCLEAR EXTRACTS
Nuclear extracts from hypothalami were prepared according to the method of 
Vaisse, et al. (1996) with modifications. The hypothalami were cleanly dissected and 
frozen in liquid nitrogen. Frozen hypothalami were homogenized in 0.5 mL o f  buffer A 
[10 mM Hepes, pH 7.9; 10 mM KC1; 1.5 mM MgCU; I mM DTT; ImM Na3VC)4; I mM 
EDTA; 1 mM EGTA; 10% glycerol; 0.5 mM PMSF; 10 mM NaF; 1 mM Benzamidine; 1 
mM sodium pyrophosphate; 1 pg/ml each of leupeptin, aprotinin, pepstatin], five strokes 
each, in a loose-fit and a tight-fit Dounce homogenizer, respectively. Homogenates were 
centrifuged at 2,000 xg for 10 min at 4°C, and the supernatant (containing the cytosolic 
extract) was carefully removed into a new tube. The pellet was resuspended in 4 volumes 
o f buffer A and homogenized in a tight-fit Dounce homogenizer. The homogenate was 
centrifuged as above and the supernatant was combined with the one obtained above. The 
pellet, which contained nuclei, was resuspended in 2 volumes of buffer B [20 mM Hepes, 
pH 7.9; 420 mM NaCl; 10 mM KC1; 20% glycerol; 1 mM DTT; 1 mM Na3V 0 4; 1 mM 
EDTA; 1 mM EGTA; 0.5 mM PMSF; 10 mM NaF; 1 mM Benzamidine; 1 mM sodium 
pyrophosphate; 1 pg/ml each of leupeptin, aprotinin, pepstatin], and the nuclear proteins 
were extracted for 30 min on ice, with shaking. The tubes were centrifuged at 16,000 xg 
for 10 min at 4°C and the supernatant (containing the nuclear proteins) was carefully 
removed into a new tube and the pellet was discarded. The supernatant was diluted 1:1 
with buffer C [20 mM Hepes, pH 7.9; 10 mM KC1; 20% glycerol; 1 mM DTT; I mM
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Na3V 04; 1 mM EDTA; 1 mM EGTA; 0.5 mM PMSF; 10 mMNaF; 1 mM Benzamidine; 
1 mM sodium pyrophosphate; 1 pg/ml each of leupeptin, aprotinin, pepstatin], aliquoted 
and snap-frozen in liquid nitrogen and then stored at —80°C. Protein concentrations were 
determined by using the BCA reagent (Pierce Chemical Co., Rockford, IL). The nuclear 
extract was used to analyze proteins by Western blotting and gel shift assays.
3.12 ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA)
Electrophoretic Mobility Shift Assay (EMSA) or gel shift assays were performed 
according to the method o f Vaisse, et al. (1996), with modifications of Levy et al. (1989) 
and Gronowski et al. (1995). The Stat-3 high affinity c-fos .S7.s--inducible element (m67- 
SDE) probe was used to determine the binding capacity o f  nuclear proteins in this study. 
The pair of m67-SIE oligonucleotide sequences used were m67-SIE sense, 5’- 
CGCTCCATTTCCCGTAAATCAT-3’, and m67-SIE antisense, 5’- 
CGCTC ATGATTT ACGGGAAATG-3 ’.
The double-stranded DNA was generated by annealing equimolar concentrations 
o f the oligonucleotides in annealing buffer [10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 
mM EDTA]. The mixture was heated to 95°C for 5 min and allowed to cool slowly at 
room temperature for 2 hr. The annealed m67-SIE was diluted to 6 and 20 ng/pL with 
nuclease-free water. For use in EMSA studies, 20 ng of m67-SIE DNA was end-labeled 
using 10 pCi [y-32P]ATP and T4 polynucleotide kinase at 37°C for 30 min. The reaction 
was stopped by addition of sterile water and the probe was purified by using the Bio-Gel 
30 spin-columns at 1,000 xg for 4 min. Radioactivity was counted and the probe was 
diluted to 35,000 cpm/pL, which represents a final probe concentration of 0.06 ng/pL. 
For competition assays in EMSA, a 100-fold excess o f cold m-67 (6 ng) was added in the
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reaction. All EMSA incubations were carried out at room temperature. One to 5 pg 
hypothalamic nuclear extract was incubated with 2 pL of I pg/pL poly(dI-dC)-poly(dI- 
dC) (Pharmacia Biotech Inc., Piscataway, NJ), in EMSA buffer [20 mM Hepes, pH 7.9, 
40 mM KC1, 10 mM MgCh, 10 mM NaCl, 0.2 mM EDTA, 0.1 mM EGTA, 0.5 mM 
DTT, 1 pL of 20 mg/ml BSA, and 4% Ficoll] in a final volume of 24 pL. For nonspecific 
binding, 2 pL of unrelated sheared E. coli B DNA was added to one tube, and for 
antibody supershift, 3 pL o f Stat-3 was added. The mixture was incubated for 10 min and 
the 32P-labeled m67-SIE (3 x 104 cpm) was added. The mixture was further incubated for 
15 min, and thereafter 3 pL of 10X gel retardation loading buffer [IX  = Tris-HCl, pH 
7.5; 0.4% glycerol; 0.002% bromophenol blue]. The samples were resolved on a pre-run 
(100 V, 30 min) 4% native PAGE at 250 V for 1-2 hours in 0.5X TBE. The gel was fixed 
in 10% acetic acid solution for 15 min and vacuum dried at 80°C for 1 hr. The dry gel 
was exposed to the phosphoscreen overnight and the bands were analyzed using the 
Phospholmager and quantified using the ImageQuant software (Molecular Dynamics 
Inc., Sunnyvale, CA).
3.13 IMMUNOPRECIPITATION OF CYTOSOLIC AND NUCLEAR PROTEINS
Generally, 100 to 300 pg of hypothalamic nuclear or cytosol extracts were used 
for immunoprecipitation. Proteins were mixed with immunoprecipitation buffer [150 mM 
NaCl, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% 
NP-40, fresh 0.2 mM NasVCU, fresh 0.2 mM PMSF] and 10 pL o f monoclonal or 
polyclonal antibody (as indicated in the respective legends to figures on protein assays) 
was added and incubated for 2 hr at 4°C with shaking at 120 rpm. Thereafter, 20 pL of 
50% slurry Protein-A agarose (Pierce Chemical Co., Rockford, IL) was added and further
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incubated for 2 hr at 4°C, with agitation. The mixture was centrifuged at 16,000 xg for 4 
min at 4°C. The beads were washed three times with immunoprecipitation buffer. The 
beads were resuspended in an equal volume of 2X Laemmli sample buffer and proteins 
were eluted by boiling for 5 min. The tubes were centrifuge at 16,000 xg for 4 min and 
the eluates were analyzed on 8 or 10% SDS-PAGE. After electrophoresis, the proteins 
were transferred overnight with cold transfer buffer [25 mM Tris base, 192 mM Glycine, 
15% methanol] onto PVDF nylon membranes (Boehringer-Mannheim, GmbH, Germany) 
using the Bio-Rad Trans-blot apparatus (Bio-Rad Laboratories, Hercules, CA). Western 
blotting was carried out using the Renaissance® chemiluminescence reagent plus method 
(NEN Inc., Boston, MA). Briefly, membranes were blocked for I hr with 5% nonfat dry 
milk in TBS-T [Tris-buffered saline with 0.05% Tween-20]. After blocking, the 
membrane was washed with TBS-T three times for 10 min each wash. After washing, the 
membrane was incubated for 1 hr with diluted primary antibody in 1% nonfat dry milk in 
TBS-T. The membrane was washed as above and incubated for 1 hr with an appropriate 
HRP-conjugated secondary antibody diluted 1:2000 in 1% nonfat dry milk in TBS-T. The 
membrane was washed as above. Depending on the membrane size, equal volumes of 
reagents A and B were mixed together and incubated for exactly 1 min with the 
membrane. After 1 min, the reagent was discarded. The membrane was placed in a bag 
and exposed to X ray film. After processing, the membrane was stripped using the 
stripping buffer [62.5 mM Tris-HCl, 2% SDS, 100 mM P-mercaptoethanol], washed and 
reprobed with other antibodies.
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3.14 RT-PCR FOR SOCS-3 AND STAT-3 mRNA EXPRESSION
Five [xg o f total RNA from individual hypothalami was reverse-transcribed by oligo(dT) 
priming and Moloney murine leukemia virus (M-MLV) reverse transcriptase (Promega) 
using oligo(dT)i5-i8 . mRNA expression was determined by PCR using the following 
primer sequences: 5’-ACCAGCGCCACTTCTTCACA-3’ and 5’-
GTGGAGCATCATACTGGTCC-3’ to amplify a 450-bp DNA fragment o f SOCS-3 
(GenBank AF075383, Bjorbaek et al. (1999)), 5’-AAGGACATCAGTGGCAAG-3’ and 
5 ’-AC AGGCGGAC AGAAC AT AG-3 ’ to amplify a 715-bp DNA fragment o f STAT-3 
(GenBank X91810) and 5’-GACAAAGTTCCAAAGACAGCAGAAAAC-3 ’ and 5’- 
ACTTCAGTGAGAGCAGAGATTACAGGG-3’ were used to amplify a 528-bp DNA 
fragment of cyclophilin (GenBank M19533). PCR products were then cloned directly 
into pCR2.1 T-A cloning system (Invitrogen, Carlsbad, CA), amplified and restriction 
mapped as shown in Figures 3.6 and 3.8 for SOCS-3 and STAT-3, respectively. The 
identity o f each cloned product was confirmed by sequencing using the ABI PRISM 373 
Big Dye terminator sequencing kit, as shown in Figure 3.7 and 3.9 for SOCS-3 and 
STAT-3, respectively. Quantitation of mRNA expression was performed by quantitative 
RT-PCR and ethidium bromide staining as described by Emilsson et al. (1999). The 
intensities o f the bands were quantified using the Chemilmager™ 4000 (Alpha Innotech 
Corp., San Leandro, CA). The bands were quantified relative to cyclophilin as an internal 
standard.
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Figure 3.6. Restriction endonuclease digestion o f purified pSOCS-3 plasmid. The 
amplified plasmid was undigested (lane 6), 250-bp insert excised with Kpnl (lane 1), 
~460-bp SOCS-3 insert excised with EcoRl (lane 2), Hindlll-Xhol cut plasmid (lane 3), 
HindEH-linearized plasmid (lane 4) and Xhol-linearized plasmid (lane 5). Lanes M are 
100-bp/l-kb DNA ladders. Fragments were fractionated on a 1% agarose gel containing 
ethidium bromide at 80 V for 1.5 hr. Arrow indicates the position of the SOCS-3 fragment 
after EcoRl digestion.
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Figure 3.7. An electrophoretogram of pSOCS-3 plasmid DNA sequence obtained by sequencing using the ABI PRISM® 
BigDye1M terminator cycle sequencing ready reaction kit after purification of the PCR products. Samples were loaded onto a 
36 cm gel containing 5% LongRanger gel, and run on an ABI PRISM® 373 automated DNA sequencer. A BLAST search 























Figure 3.8. Restriction endonuclease digestion of purified pSTAT-3 plasmid. The 
amplified plasmid was undigested (lanes 3), digested with EcoRl (lanes 1, 4, 5) and Aval 
(lane 2). The arrow indicates the 730-bp STAT-3 insert. Lane M is the 100-bp/l-kb DNA 
ladder. Fragments were fractionated on a 1% agarose gel containing ethidium bromide at 
80 V for 1.5 hr. Lanes 4 and 5 show EcoRl-digested STAT-3 fragment from large-scale 
preparations.
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Figure 3.9. An electrophoretogram of pSTAT-3 plasmid DNA sequence obtained by sequencing using the ABI PRISM® 
BigDye1M terminator cycle sequencing ready reaction kit after purification of the PCR products. Samples were loaded onto a 
36 cm gel containing 5% LongRanger gel, and run on an ABI PRISM® 373 automated DNA sequencer. A BLAST search 
(u v. 'a 11* .hi.i) 1111.n111. -  hia-.i) identified nucleotides 60-120 as pCR2.1/TOPO vector sequence and nucleotides 121-390 as rat 
Stat3 gene sequence.
CHAPTER FOUR 
LEPTIN EFFECTS ON LIVER GENE EXPRESSION AND METABOLISM
4.1 INTRODUCTION
The liver is one o f the most complex organs in the body, carrying out a multitaide 
of different processes. Metabolism of glucose, fatty acids and protein occur in the liver. 
The liver synthesizes and breaks down glucose by the processes of gluconeogenesis and 
glycolysis, respectively. Glycogen is also synthesized and broken down in the liver by 
processes of glycogenesis and glycogenolysis. Hepatic protein synthesis is involved in 
enzyme regulation and in the production of other circulating factors. Among all thiese 
functions, a change in liver glucoregulatory function is a characteristic response to 
feeding, fasting, and to glucocorticoids. Liver glucose regulatory responses are mediated 
by the balance o f glucose uptake into the liver and the endogenous glucose release from 
the liver into circulation. Glucose uptake into the liver is an insulin independent process 
carried out by glucose transporters, Glut-1 and Glut-2 (Zierler, 1999). The balance 
between glycolysis and gluconeogenesis and the ratio o f glycogenesis and glycogenolysis 
determines the rate o f endogenous production of glucose from the liver.
Gluconeogenesis is an energy-dependent process whereby lactate, pyruvate, 
glycerol, and some amino acids are converted to glucose. The most important functiora of 
gluconeogenesis is the maintenance of blood glucose levels during times o f low food 
supply and/or low glycogen stores. Hepatic gluconeogenesis and glycogenolysis are  
alternative sources of the glucose produced by the liver. Hepatic gluconeogenesis is 
affected by many modulators, the most important o f which include insulin, glucagon, 
glucocorticoids and catecholamines (Chu, et al., 1997). Insulin suppresses endogenous
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glucose output by inhibiting glucagon release from the pancreas (McCall, et al., 1998; 
Sindelar, et al., 1997), and also directly inhibits gluconeogenesis and glycogenolysis 
(Giacca, et al., 1997; Sindelar, et al., 1998).
Regulatory mechanisms o f enzymes involved in hepatic gluconeogenesis have 
been extensively studied (Pilkis and Granner, 1992). Both transcriptional and post- 
transcriptional regulatory mechanisms are involved. A number o f hormones regulating 
the expression o f genes that encode regulatory enzymes have been studied. Insulin 
induces mRNAs that encode glycolytic enzymes and represses mRNAs that encode 
gluconeogenic enzymes, whereas cAMP has opposite effects. Glucose also regulates the 
expression o f these hepatic enzymes (Kahn, 1997; Rencurel and Girard, 1998). One of 
the extensively studied regulatory liver enzymes is phosphoewo/pyruvate carboxykinase 
(PEPCK). PEPCK is the rate-limiting enzyme in gluconeogenesis and its activity is solely 
determined by gene regulation, and not by allosteric effectors. PEPCK gene is regulated 
by a variety of dietary and hormonal signals, which result in an alteration o f the synthesis 
o f the enzyme, both by transcription and by translation. Major factors that increase 
PEPCK gene expression include cAMP, glucocorticoids, and thyroid hormone, whereas 
insulin inhibits this process (Pilkis & Granner, 1992). Rose and Heath (1986) reported 
that corticosterone or sympathetic activation stimulate PEPCK synthesis by increasing 
glucagon and hepatic cAMP, despite the increase in portal insulin levels. Regulatory 
elements that control PEPCK gene transcription in liver, kidney and adipose tissue have 
been delineated, and many o f the transcription factors that bind to these elements have 
been identified (Hanson & Reshef, 1997).
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Genetic studies in rodents have revealed leptin and its receptor as important 
factors in the regulation of both appetite suppression and energy expenditure. Obesity had 
been largely related to insulin resistance, and the discovery o f leptin has shed new insight 
on the regulation o f  body weight and energy metabolism. Evidence that leptin exerts 
adipose-reducing effects in rodents was obtained from pair-feeding and Zucker rats 
studies (Levin, et al., 1996; Unger, 1997). This suggested a significant metabolic 
regulatory role for leptin, in addition to appetite suppression. Moreover, the expression of 
the leptin receptors in peripheral tissues, such as liver, muscle and adipose tissue 
(Ghilardi, et al., 1996; Luoh, et al., 1997; Cohen, et al., 1996), further supported this 
metabolic role of leptin. Based on these findings, it is possible that leptin interferes with 
glucose metabolism by acting directly on the liver. In fact, leptin was reported to exert a 
direct effect on glucose metabolism in skeletal muscle (Ceddia, et al., 1999) and isolated 
adipocytes (Ceddia, etal., 1998).
In vitro studies with a human hepatic cell line, HepG2 cells, and the rat hepatoma 
cell line, H4-Q-E, indicated that leptin causes attenuation o f  several insulin-induced 
effects (Cohen, et al., 1996). In contrast, Wang, et al. (1997), showed that in rat (H-35) 
and human (HepG2) hepatoma cell lines expressing the long form o f the leptin receptor, 
leptin did not cause any significant alteration in insulin effects. They therefore argued 
that, in this instance, leptin will not contribute to the diabetic symptoms associated with 
obesity.
In vivo studies by Rossetti and colleagues (1997) demonstrated that an acute 
increase in plasma leptin enhances the inhibitory effect of insulin on hepatic glucose 
production, induces redistribution o f glucose fluxes within the liver and induces changes
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in the expression o f  genes encoding hepatic enzymes that closely resemble those of 
fasting. It is evident that these studies focused on the effects of leptin on insulin actions 
and hepatic glucose production, and generated conflicting results regarding the role of 
leptin in liver glucose metabolism. Recently, Nemecz, et al. (1999) reported that in the 
presence o f leptin, adrenaline-stimulated hepatic glucose release was suppressed in 
perfused livers. These studies performed in isolated perfused rat liver indicated that leptin 
directly and acutely modulated hepatic glucose flux.
In the present study, I investigated whether leptin modulates expression of the 
PEPCK gene in rat hepatocytes. Using Northern blotting, the time course of expression of 
PEPCK mRNA in untreated hepatocytes, and in those treated with either leptin, 
dexamethasone, or insulin was determined.
4.2 EXPERIMENTAL PROTOCOLS 
Animals
Adult, eight-week-old male lean and obese Zucker rats and 10-week-old Sprague- 
Dawley rats were used in this study. They were housed individually in hanging wire- 
mesh cages attached to an automated watering system in a room with a 12 hour light/dark 
(7:00 AM to 7:00 PM) cycle at a temperature of 22-23°C. All rats consumed nonpurified 
chow diet (Rodent chow 5001, Purina Mills, St. Louis, MO, USA). All protocols used 
were approved by the Pennington Biomedical Research Center Institutional Animal Care 
and Use Committee (IACUC). Hepatocytes were prepared by the in situ collagenase 
perfusion method as described in Chapter three.
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Experiment 4.1 Time course of PEPCK mRNA expression in hepatocytes from
Sprague Dawley rats
This experiment investigated the effects o f leptin, dexamethasone and insulin on 
the expression o f PEPCK in hepatocytes obtained from Sprague Dawley rats. Two adult, 
10 week old male Sprague Dawley rats were used per experiment. The rats were ad  
libitum  fed before use. Hepatocytes were prepared in the morning and plated before 12:00 
noon. Cells were allowed to attach to the substratum for 4 hr, and thereafter incubated in 
WE medium containing 5% fetal calf serum. The spent medium was changed the next 
day and cells were incubated in serum-free medium supplemented with 10 mM glutamine 
containing either 100 ng/ml leptin, 100 nM dexamethasone or 100 nM insulin. Cells were 
treated for the times indicated in the figure legends. Total RNA was isolated as described 
in Chapter three.
Experiment 4.2 The time course of PEPCK mRNA expression in hepatocytes from 
lean and obese Zucker rats
This experiment investigated the effects o f leptin, dexamethasone and insulin on 
the expression o f  PEPCK in hepatocytes obtained from lean and obese Zucker rats. Two 
lean and two obese 8-week-old Zucker rats were used per experiment. The rats were 
either fed ad libitum  or were food deprived a day before use. Hepatocytes were prepared 
in the morning and plated before noon. Cells were allowed to attach to the substratum and 
thereafter incubated in WE medium containing 5% fetal calf serum. The spent medium 
was changed the next day and cells were incubated in serum-free medium supplemented 
with 10 mM glutamine containing either 100 ng/ml leptin, 100 nM dexamethasone or 100
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nM insulin. Cells were treated for the times indicated in the figure legends. Total RNA 
was isolated as described in Chapter three.
Experiment 4.3 Hormone concentration effect on PEPCK mRNA expression in
hepatocytes from lean and obese Zucker rats
This experiment determined the effects of increasing concentrations o f leptin, 
dexamethasone and insulin on the expression o f PEPCK mRNA in hepatocytes obtained 
from lean and obese Zucker rats. Hepatocyte cells were handled as described above and 
were incubated with increasing concentrations of the hormones for 3 hr in serum-free 
medium. After 3 hr treatment, spent medium was aspirated and cells were harvested by 
lysis in solution D and RNA was extracted as described in Chapter three.
Experiment 4.4 The time course of glucose production from hepatocytes from
lean Zucker rats
This experiment determined the time course o f glucose production induced by 
leptin, dexamethasone and insulin from hepatocytes isolated from either lean Zucker or 
Sprague Dawley rats. Hepatocytes were isolated from lean Zucker rats and plated as 
above. After adherence to the plate, cells were incubated in serum-free WE medium 
containing 1 ng/ml dexamethasone and 1 ng/ml insulin. After overnight incubation, spent 
medium was aspirated and cells were treated with either leptin, dexamethasone or insulin 
in 2 ml o f serum-free and glucose-, L-glutamine-, and sodium pyruvate-free DMEM. At 
each time point, the medium was aspirated and frozen for use in glucose analysis studies. 
Cells were harvested by washing with ice-cold PBS and total RNA was extracted as 
described in Chapter three.
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4. 3 RESULTS
Experiment 4.1
This experiment was designed to investigate whether leptin affects the expression 
o f PEPCK mRNA in hepatocytes. As shown in Figure 4.1, leptin induced the PEPCK 
gene expression in Sprague Dawley rat hepatocytes after 3 hr incubation. Compared with 
serum-free medium control, leptin at concentrations greater than 3 ng/ml increased the 
levels o f PEPCK mRNA expression. Incubation of hepatocytes with fetal bovine serum 
(FBS) also increased the expression o f PEPCK mRNA compared to control. This data 
showed that FBS may contain factors that can induce the expression of PEPCK mRNA, 
with leptin being one of those factors.
Figure 4.2 shows the effects o f leptin, dexamethasone, or both on PEPCK mRNA 
expression. Leptin at 30 and 100 ng/ml induced the expression of PEPCK mRNA 
compared to serum-free control hepatocytes. Dexamethasone at 100 nM increased 
PEPCK mRNA expression compared to control. A higher concentration of 
dexamethasone (1 pM) was cytotoxic to cells and induced PEPCK mRNA levels lower 
than at the 100 nM dose. The induction of PEPCK mRNA was, however, still greater 
than that of the untreated control. Treatment of hepatocytes with a combination o f 30 
ng/ml leptin and 100 nM dexamethasone showed a slight, but statistically not significant, 
increase in PEPCK mRNA expression, which was reduced when the leptin concentration 
was increased to 100 ng/ml. The cytotoxicity observed in 1 pM dexamethasone-treated 
hepatocytes was reduced by co-treatment with leptin. This was accompanied by a 
significant increase in PEPCK mRNA expression compared to untreated control and 1 
pM dexamethasone-treated cells.
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Figure 4.1 Effects o f leptin concentrations on PEPCK gene expression in hepatocytes 
treated with media alone, FBS or various concentrations of leptin. Hepatocytes from ad  
libitum fed Sprague Dawley rats were incubated for 3 hr with different concentrations of 
leptin. Total RNA was extracted and analyzed by Northern blot. (A) Northern blot 
analyses o f PEPCK and P-actin mRNA. (B) Histogram showing the quantification of 
PEPCK mRNA using ImageQuant software. * p < 0.05 from zero leptun group (2 
observations in triplicate per group).
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Figure 4.2 Effects o f leptin and dexamethasone on PEPCK mRNA expression in 
hepatocyte from Sprague Dawley rats. Hepatocytes from ad libitum  fed Sprague Dawley 
rats were incubated for 3 hr with either leptin (30 and 100 ng/ml) or dexamethasone (0.1 
and 1.0 pM) or the combinations of leptin and dexamethasone. Total RNA was extracted 
and analyzed by Northern blot. Relative expression o f PEPCK mRNA was determined by 
Northern blot analysis and bands were quantified using the Phosphorlmager ImageQuant 
software. Data expressed as mean ± SEM for samples in triplicates. * p < 0.05 compared 
to control group and NS indicates not statistically significant.
61
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Experiment 4.2
This experiment was designed to determine the time course o f PEPCK gene 
expression in hepatocytes from lean (Figure 4.3) and obese (Figure 4.4) Zucker rats 
treated with leptin, dexamethasone and insulin. As shown in Figure 4.3, leptin treatment 
o f hepatocytes from lean rats caused an increase in PEPCK mRNA expression at the 3 hr 
time point and this was followed by a decline in mRNA expression. Dexamethasone did 
not increase PEPCK gene expression until after 12 hours o f incubation, which is 
consistent with the literature. Insulin, had no effect on the expression o f PEPCK mRNA.
The results of the time course o f PEPCK mRNA expression in hepatocytes from 
obese Zucker rats are shown in Figure 4.4. In these cells, untreated obese Zucker rat 
hepatocytes showed a rapid decrease in PEPCK mRNA expression. This decrease was 
also evident in all other treatments, with leptin, dexamethasone and insulin. These 
hepatocytes showed no response to treatment with any of the hormones.
The effect of leptin and dexamethasone on the production o f glucose from the 
gluconeogenic substrates, pyruvate and glutamine, was also determined, as shown in 
Figure 4.5. Hepatocytes from lean Zucker rats were incubated in serum-, glucose-, L- 
glutamine-, and sodium pyruvate-free DMEM medium supplemented with 10 mM 
pyruvate and 10 mM glutamine. As shown in this figure, control cells produced on 
average 10 mg/dL glucose in the medium, except after 24 hr where the levels o f glucose 
in the medium rose to over 120 mg/dL. Leptin, on the other hand, progressively increased 
the production o f glucose from 10 mg/dL to about 150 mg/dL after 24 hr in culture. 
Dexamethasone only effected changes in gluconeogenic glucose after 24 hr in culture.
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Figure 4.3 Time course of PEPCK gene expression in hepatocytes from lean Zucker rats 
treated with leptin, dexamethasone and insulin. Hepatocytes were cultured for the 
indicated times in serum-free medium containing either 100 ng/ml leptin, 100 nM insulin 
or 100 nM dexamethasone (DEX). Relative expression of PEPCK mRNA was 
determined by Northern blot analysis and bands were quantified using the 
Phosphorlmager ImageQuant software. 0-actin mRNA shown is that of the leptin treated 
samples. Data expressed as mean % of control at 0 hr ± SEM for samples in triplicates. * 
p < 0.05 compared to control time value (n = 3 observations per group).
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Figure 4.4 Time course o f PEPCK gene expression in hepatocytes from obese Zucker 
rats treated with leptin, dexamethasone and insulin. Hepatocytes were cultured for the 
indicated times in serum-free medium containing either 100 ng/ml leptin, 100 nM insulin 
or 100 nM dexamethasone (DEX). Relative expression o f PEPCK mRNA was 
determined by Northern blot analysis (A) and bands were quantified using the 
Phosphorlmager ImageQuant software (B). Three different blots for leptin 
dexamethasone and insulin treatment, and P-actin shown is for insulin treatment. Data is 
expressed as mean % o f control ± SEM for samples in triplicate.
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Figure 4.5 Effects of leptin (100 ng/ml) and dexamethasone (100 nM) on glucose 
production o f hepatocytes from lean Zucker rats. Hepatocytes were cultured for the 
indicated times in serum-free DMEM medium supplemented with 10 mM glutamine and 
10 mM pyruvate and treated with either 100 ng/ml leptin or 100 nM dexamethasone 
(DEX). Glucose produced in the medium was assayed using the glucose kit from Sigma. 
Data expressed as mean ± SEM for samples in triplicates. * p < 0.05 compared to control 
values at the same time.
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Experiment 4.3
This experiment was undertaken to determine the effects o f leptin and 
dexamethasone on the expression o f PEPCK mRNA in lean and obese Zucker rats after 3 
hr in culture. In this study, as shown in Figure 4.6, PEPCK mRNA expression was ten­
fold higher in hepatocytes from obese Zucker rats compared to those from the lean rats. 
Treatment with 0.1 pM dexamethasone increased PEPCK gene expression. Again, 
treatment with 1 pM dexamethasone decreased the expression o f  PEPCK mRNA 
compared to 0.1 pM dexamethasone treatment. Surprisingly, no effect o f PEPCK mRNA 
expression was observed with leptin treatment of hepatocytes from lean Zucker rats. In 
hepatocytes from obese Zucker rats, dexamethasone and leptin treatment did not affect 
the expression o f PEPCK mRNA.
4.4 DISCUSSION
The objective o f experiments described here was to investigate the direct effects 
o f leptin, dexamethasone and insulin on the gene expression of the liver cytosolic form of 
PEPCK and to determine whether changes in gene expression would account for the 
changes in sensitivity to these hormones in both lean and obese Zucker rats. It has been 
proposed that leptin may play a role in carbohydrate metabolism and insulin action (Flier, 
1997; Cohen, et al., 1996; Kolaczynski, et al., 1996). Conversely, leptin treatment of 
ob/ob mice decreased both plasma insulin and glucose concentrations, suggesting that 
leptin may directly or indirectly improve in vivo insulin action (Pelleymounter, et al., 
1995; Weigle, et al., 1995; Schwartz, et al., 1996; Halaas, et al., 1995). Recent work in 
cultured hepatocytes and human hepatoma cells indicated that leptin may regulate gene 
expression of a key gluconeogenic enzyme, phosphoewo/pyruvate carboxykinase and also
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Figure 4.6 Effects of leptin and dexamethasone on PEPCK mRNA expression in 
hepatocyte from lean (A) and obese (B) Zucker rats. Hepatocytes from ad libitum  fed 
lean and obese Zucker rats were incubated for 3 hr with either leptin (10 and 100 ng/ml) 
or dexamethasone (0.1 and 1.0 pM). Total RNA was extracted and analyzed by Northern 
blot. Relative expression o f PEPCK mRNA was determined by Northern blot analysis 
and bands were quantified using the Phosphorlmager ImageQuant software. D ata 
expressed as mean ± SEM for samples in triplicates.
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antagonize insulin action (Cohen et al., 1996). In the studies described in this dissertation, 
leptin was shown to increase the expression of PEPCK mRNA in hepatocytes from 
Sprague Dawley and lean Zucker rats, but not obese Zucker rats. The effect of leptin was 
neither synergistic nor additive when combined with dexamethasone, although leptin 
seemed to have a protective effect against cytotoxicity induced by high dexamethasone 
concentrations.
Leptin increased the expression of PEPCK mRNA after 3 hr in culture o f 
hepatocytes from lean Zucker rats, and this was accompanied by a steady increase in 
glucose production from gluconeogenic substrates. In contrast, no effect o f either leptin, 
dexamethasone or insulin was observed in the expression o f  PEPCK mRNA from 
hepatocytes isolated from obese Zucker rats. The amount o f glucose produced was 
insignificant and below detection limits in hepatocytes from obese Zucker rats. This 
could, of course, be due to either the quick utilization of glucose by these cells for 
glycolytic purposes to supply energy to the cell or that no glucose was produced in the 
presence of gluconeogenic substrates, pyruvate and glutamine. The latter could be due to 
the observed decrease in PEPCK mRNA levels, resulting in the shut off o f 
gluconeogenesis. Alternatively, the high intracellular levels o f glucose in these cells may 
repress the PEPCK mRNA and consequently inhibit gluconeogenesis. These observations 
are consistent with the literature, where studies have shown that insulin resistance in 
genetically obese Zucker rats affects peripheral tissues, such as liver, muscle and adipose 
tissue (Czech, et al., 1978; Kemmer, et al., 1979; Terrettaz, et al., 1986). The 
responsiveness to insulin o f  basal gluconeogenesis from lactate was shown to be reduced 
in hepatocytes from obese Zucker rats compared to their lean littermates (Sanchez-
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Gutierrez, et al., 1994; Sanchez-Gutierrez, et al., 1997). This data was consistent with the 
reduction o f  gluconeogenesis observed in studies reported herein.
Recent in vivo euglycemic hyperinsulinemic clamp studies have reported that 
leptin, when administered intravenously for 6 hr, enhanced the inhibition of hepatic 
glucose production in response to insulin. Also, leptin induced redistribution of 
intrahepatic glucose fluxes with a decrease in hepatic glucose production by inhibiting 
glycogenolysis (Rossetti, et al., 1997). In another study, leptin by itself was not capable 
of changing glucose production by the liver, but it markedly reduced the rate of 
glucagon-stimulated hepatic glucose production (Ceddia, et al., 1999). These two studies, 
in vivo and in vitro, respectively, showed that leptin is associated with a decrease in 
hepatic glycogenolysis. In the presence o f gluconeogenic precursors, such as glycerol, L- 
lactate, L-alanine and L-glutamine, leptin reduced glucose production by isolated 
hepatocytes. This, however, was contradictory to the effect o f leptin on PEPCK mRNA 
gene expression, where leptin was shown to increase PEPCK gene expression (Cohen, et 
al., 1996; Rossetti, et al., 1997). These studies showed an increase in PEPCK mRNA 
expression after intravenous leptin infusion in rats or after incubation o f human hepatoma 
cells with leptin.
In our experiments, we used isolated rat hepatocytes and exposed them to 
increasing leptin concentrations (0, 3, 10, 30 and 100 ng/ml) for 3 hr. Within this 
incubation period, temporal changes in gene expression o f PEPCK were observed. 
Initially, we used hepatocytes isolated from ad libitum fed rats, and could not observe any 
gluconeogenic responses to leptin, dexamethasone and insulin. It was reported that 
hepatocytes from ad libitum fed rats have increased glycolysis and glycogenolysis due to
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the increase in adenosine monophosphate (AMP) levels (Lopez, et al., 1988). AMP is a 
known allosteric activator of phosphofructokinase and glycogen phosphorylase. In the 
presence o f increased AMP concentrations, activation of PEPCK and amino acid (L- 
glutamine)-induced gluconeogenesis could not be observed due to intensive glycolysis. 
This situation, therefore, altered the capability o f hepatocytes to respond to 
gluconeogenic precursors and to leptin dexamethasone and insulin.
When we made the switch to using overnight fasted rats, the effects o f these 
hormones became evident. In the presence of L-glutamine, the average glucose 
production o f  hepatocytes increased with time of incubation with leptin. Dexamethasone 
treatment only increased glucose production after 12 hr in culture, indicating the 
dependence o f this mechanism on PEPCK gene expression. It has been reported that 
PEPCK gene expression in hepatocytes treated with dexamethasone does not occur until 
12 hours in culture. Our studies are, therefore, consistent with the late expression of 
PEPCK by dexamethasone and shows that leptin induces the expression much earlier. 
From these studies, leptin was capable of altering the metabolic flux in hepatocytes from 
overnight fasted rats by increasing not only the PEPCK gene expression, but also by 
increasing glucose production from these cells.
Recently, it has been reported that 5 ng/ml leptin administered directly to perfused 
livers o f ob/ob mice in vitro, caused an increase in glycogen synthesis, which was 
accompanied by an increase in hepatic glycogen synthase activity (Cohen, et al., 1998). 
This short term leptin treatment is consistent with leptin modulating pathways that 
control hepatic glycogen synthesis in an insulin independent manner. In our studies under 
fasting conditions, we assumed that glycogen stores had been depleted and that glycogen
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synthesis and breakdown was at a minimum. Therefore, addition of L-glutamine to the 
medium could be used by hepatocytes as a source of energy for the maintenance of 
hepatocyte metabolism. Also assuming limited glycogenolysis due to low levels of 
glycogen in fasted rats, leptin caused a direct effect on gluconeogenesis in isolated 
hepatocytes by increasing PEPCK gene expression. The direct mechanism by which 
leptin promotes gluconeogenesis in the liver remains to be determined.
Various peripheral tissues or organs have detectable levels o f mRNA encoding 
the long (ObR-L) and short (ObR-S) leptin receptor isoforms. The abundance o f  the long 
isoform in peripheral tissues is minimal (Ghilardi, et al., 1996; Luoh, et al., 1997). It 
remains to be investigated how leptin receptors are involved in the modulation o f leptin 
effects in isolated hepatocytes, especially considering the known fact that the majority of 
the transcripts in the liver encode the short isoforms o f  the leptin receptor. In the current 
studies, we could not identify any of the long isoform of the leptin receptor in the 
hepatocytes. Only the short isoform of the leptin receptor was present. This observation is 
consistent with the literature (Hoggard, et al., 1997; Ghilardi, et al., 1996). Zhao and 
colleagues (2000), recently showed the presence o f various short isoforms o f  ObR in 
hepatocyte extracts and only the hypothalamic extracts contained both the long and short 
ObR isoforms (Zhao, et al., 2000).
In vitro studies o f Cohen and colleagues (1996), using HepG2 and H4II hepatoma 
cells, reported that leptin attenuated insulin-induced activities by altering the insulin 
signaling pathway. For example, leptin treatment reduced the tyrosine phosphorylation of 
insulin receptor substrate (IRS)-I and decreased the association of Grb2 with IRS-I. 
Recently, Nemecz et al. (1999) showed that leptin or insulin inhibited hepatic glucose
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release using in vitro perfused livers. A combination of the two hormones had no further 
inhibition. They speculated that leptin could exert its inhibitory effects via the same 
signaling pathway as that o f insulin. Also, Walder et al. (1997) have demonstrated that 
leptin inhibits insulin binding to its receptor in isolated adipocytes.
Recent studies have also shown that in cells expressing short forms of ObR, JAK2 
and IRS-1, leptin can induce tyrosine phosphorylation o f ERS-1 through the short form o f 
the leptin receptor (Bjorbaek, et al., 1997). Also, leptin has been shown to activate PI3- 
kinase in primary hepatocytes, myotubes (C2C 12) and pancreatic P-cells (Berti, et al., 
1997; Kellerer, et al., 1997).
In non-obese humans, plasma leptin values lie between 1 and 20 ng/ml, while 
values up to 100 ng/ml exist in obese humans (Unger, et al., 1997). The leptin 
concentrations (3-100 ng/ml) used in the studies reported here were within the 
physiological range, inclusive o f obese and non-obese ranges. It can be concluded from 
our data and results from short term in vivo leptin administration (Rossetti, et al., 1997) 
that leptin regulates liver glucose production through PEPCK, by antagonizing the effect 
o f insulin on PEPCK mRNA expression and thus activating the gluconeogenic pathway. 
Also, our experience and data obtained with hepatocytes isolated from obese Zucker rats 
show that these rats have an intrinsically defective response to short term leptin, 
dexamethasone and insulin treatment under gluconeogenic conditions. This may arise 
from the in vivo impairment o f the insulin-mediated reduction o f cAMP in these 
hyperinsulinemic obese animals.
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CHAPTER FIVE 
EFFECTS OF GLUCOCORTICOIDS ON GENE EXPRESSION IN LEAN AND 
OBESE ZUCKER RATS
5.1 INTRODUCTION
The homozygous recessive trait found in Zucker fatty (fa/fa) rats is associated 
with massive obesity, increased total body fat, increase in fat cell size and number, 
increased levels of serum insulin leading to gradual development of insulin resistance, 
and an increase in lipoprotein lipase activity in adipose tissue (Bray & York, 1979). 
Compared to lean Iittermates, the obese Zucker rats have hyperinsulinemia, 
hyperlipidemia, mild hyperglycemia and abnormal glucose tolerance. In vitro and in vivo 
studies have demonstrated that insulin resistance in obese Zucker rats affects peripheral 
tissues, such as liver, muscle and adipose tissue (Czech, et al., 1978; Crettaz, et al., 1980; 
Terrettaz & Jeanrenaud, 1983; Terrettaz, et al., 1986). In the liver glucose output was not 
blocked by the basal hyperinsulinemia, indicating insulin resistance (Terrettaz & 
Jeanrenaud, 1983). In contrast, hepatic glycolysis in obese Zucker rats does not show 
insulin resistance, as this metabolic pathway is continuously overstimulated by the 
hyperinsulinemia present in these animals (Jeanrenaud, 1988).
Genetically obese rodents and women with abdominal obesity have slightly 
elevated basal corticosterone/cortisol secretion during the diurnal trough (Walker, et al., 
1992; Pasquali, et al., 1993). Altered circadian rhythms have been described in the 
Zucker rat (Prins, et al., 1986; Fukagawa, et al., 1992; Martin, et al., 1979; Murakami, et 
al., 1995). These altered phases o f daily rhythms may also characterize obesity in humans 
(Belisle, et al., 1988; Fricker, et al., 1990). The contribution o f the circadian rhythm to 
the development and maintenance of excessive weight gain and obesity is unknown.
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In general, glucocorticoids increase muscle protein breakdown and 
gluconeogenesis in stress and starvation to maintain the glucose supply for the brain 
(Steele, 1975). The clinical syndrome o f  glucocorticoid excess (Cushing's syndrome) is 
associated with glucose intolerance, obesity and hypertension (Andrews & Walker, 
1999). By opposing the actions o f insulin, glucocorticoids could contribute to insulin 
resistance and obesity.
Adrenalectomy (ADX) was shown to slow the weight gain in both obese Zucker 
rats and in their lean littermates, with the greater effect of ADX in the obese rats (Bray, et 
al., 1992). ADX also produces a number o f profound effects on other animals with 
recessive inherited obesity. In the ob/ob mouse, ADX reduced food intake (Saito & Bray,
1984), slowed down body weight gain (Bray, 1982; Yukimura & Bray, 1978b), increased 
energy expenditure (Vander Tuig, et al., 1984), restored norepinephrine turnover to 
normal in BAT and heart (Vander Tuig, et al., 1984), abolished insulin resistance in 
muscle (Oshima, et al., 1984), lowers circulating insulin levels (Yukimura & Bray, 
1978a) and normalized glucose tolerance (Bailey, et al., 1986; Solomon, et al., 1977). 
Similar changes have been shown for the db/db mouse upon ADX (Bray, 1982). In the 
obese Zucker (fa/fa) rat, ADX also produced decrease in weight gain, decreased food 
intake and increased energy expenditure due to enhanced thermogenesis in BAT 
(Yukimura, et al., 1978b; Marchington, et al., 1983). ADX also changed the 
characteristics o f the adipose tissue. The fat pad weights o f epididymal, inguinal and 
retroperitoneal WAT were decreased by ADX. This decrease was associated with a 
decrease in fat cell size in the epididymal and retroperitoneal fat pads, and a decrease in 
the LPL activity o f WAT of obese Zucker rats and not the lean (Bray, et al., 1992). These
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studies suggested that ADX normalizes anomalies associated with genetic obesity, but 
does not completely reverse the genetic defect o f the fatty Zucker rat (Bray, et al., 1989).
Increased ob mRNA expression has been reported for all forms o f obesity, namely 
genetic, hypothalamic and dietary (Zhang, et al., 1994; Trayhurn, et al., 1995a; Maffei, et 
al., 1995; Frederich, et al., 1995a; Funahashi, et al., 1995). This suggested that obesity 
may be associated with increased expression o f the ob gene. However, ob/ob mice do not 
produce normal leptin. Synthesis and release o f leptin is regulated by neuroendocrine, 
endocrine and paracrine signals that impinge on the adipocyte. Fasting, 02- and B3- 
adrenergic receptor agonists, cAMP and thyroid hormones decrease the level of ob 
mRNA expression and leptin production (Trayhurn, et al., 1995a; Frederich, et al., 1995; 
Hardie, et al., 1996; Ahima, et al., 1996; MacDougald, et al., 1995; Saladin, et al., 1995; 
Fain, et al., 1997; Escobar-Morreale, et al., 1997; Valvaci, et al., 1997; Yoshida, et al., 
1997; Slieker, et al., 1996; Mantzoros, et al., 1996; Trayhurn, 1996). Glucocorticoids, 
cytokines and insulin increase the ob mRNA expression (De Vos, et al., 1995; Slieker, et 
al., 1996; Wabitsch, et al., 1996; Considine et al., 1997; Wabitsch, et al., 1996; Grunfeld, 
et al., 1996; Sarraf, et al., 1997) and circulating protein levels (Malmstrom, et al., 1996).
Leptin signaling is mediated by the leptin receptor (OBR) (Tartaglia, et al., 1995; 
Lee, et al., 1996; Chen, et al., 1996). In humans and rodents, two major isoforms o f OBR, 
long and short, are detected, which differ in the intracellular domains that represent 
products of alternative splicing. Despite normal ligand binding activity, OBR-S has been 
described as being incapable of signaling (Ghilardi, et al., 1996; Baumann, et al., 1996). 
It has, however, been recently shown that the short forms of OBR carry out limited 
signaling function in peripheral tissues (Bjorbaek, et al., 1997; Murakami, et al., 1997;
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Yamashita, et al., 1998). For example, in human HepG2 cells and lean rat hepatocytes, it 
has been shown that leptin enhances PEPCK mRNA levels (Cohen, et al., 1996; Chapter 
3 of this dissertation). These effects o f leptin were attributed to the action o f leptin on 
OBR-S because OBR-L could not be detected in either study. In contrast, the OBR-L 
isoform, which is primarily expressed in the hypothalamus, is considered to be the 
signaling-competent receptor (Vaisse, et al., 1996; Ghilardi, et al., 1996; Baumann, et al., 
1996). The obese Zucker i f  a/fa) rats carry a mutation (Gln269Pro) of the OBR in the 
extracellular domain, whereas the db/db mouse has a mutation in the intracellular domain 
due to splicing defect (Chua, et al., 1996a; Chua, et al., 1996b; Truett, et al., 1991). The 
mutation in the Zucker rat has been shown to reduce leptin receptor affinity and 
decreased signaling capacity of the OBR (Crouse, et al., 1998, Yamashita, et al., 1998), 
and the splicing defect in the db/db mouse produces receptors that are signaling 
incompetent (Chua, et al., 1996b).
To gain insight into the effects of glucocorticoids on gene expression in the liver 
and hypothalamus of lean and obese Zucker rats, I studied 1) the effect o f adrenalectomy 
on the liver PEPCK mRNA expression, 2) the effect of adrenalectomy on the leptin 
receptor mRNA expression in the hypothalamus and liver, and 3) the effect of 
physiological changes of corticosterone and leptin on the leptin receptor mRNA 
expression, in lean and obese Zucker rats. I assessed changes in serum hormone levels 
and modulations o f the mRNA expressions, in an attempt to test the hypotheses that 
glucocorticoid excess in obesity 1 ) causes hyperglycemia due to dysregulation of 
PEPCK, and 2) leads to hyperleptinemia, which down-regulates the leptin receptor 
mRNA expression, and leads to a reduced response to endogenous leptin.
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5.2 MATERIALS AND METHODS 
Animals
Age-matched, eight to ten-week-old male or female lean and obese Zucker rats, 
were used in these studies. All protocols used were approved by the Pennington 
Biomedical Research Center Institutional Animal Care and Use Committee (LACUC). 
The animals were housed individually in shoe-box cages in a temperature-controlled 
room with a 12-hour light/dark cycle. All rats consumed nonpurified chow diet (Rodent 
Chow 5001, Purina Mills, St. Louis, MO, USA) ad libitum  throughout the experiment, 
and water or saline (where indicated) was provided in water bottles.
Experiment 5.1 Effects of adrenalectomy on liver PEPCK mRNA expression in 
lean and obese Zucker rats
Age-matched lean and obese Zucker rats were bilaterally adrenalectomized via a 
dorsal approach under isoflurane anesthesia. One group o f adrenalectomized rats were 
subcutaneous implanted with 3 week-slow release 50 mg corticosterone pellets 
(Innovative Research of America, Sarasota, FL). Adrenalectomized rats were provided 
with 0.9% saline drinking water and allowed to recover for a week. Body weights were 
monitored daily after adrenalectomy. After recovery, rats were killed by decapitation to 
allow collection o f trunk blood and preparation of serum. Liver, epididymal adipose 
tissues, hypothalamic and hippocampal tissues were dissected, weighed and snap-frozen 
in liquid nitrogen and stored at -80°C until used for RNA extractions. Serum samples 
were stored at -80°C before being used for hormone assays. Serum insulin and leptin 
were measured using commercially available RIA kits (Linco, St. Charles, MO, USA) 
based on rat standards according to the supplier’s instructions. Serum corticosterone was
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assayed using a commercial corticosterone RIA kit (ICN Pharmaceuticals, Costa Mesa, 
CA). Total RNA was extracted from liver by the modified acid-phenol guanidinium- 
isothiocyanate and Northern analyses (PEPCK, P-actin) were performed as described in 
general methods. The intensities o f the signals were analyzed relative to P-actin using the 
Phospholmager (Molecular Dynamics, Sunnyvale, CA, USA) and quantified using 
ImageQuant software.
Experiment 5.2 The effect of adrenalectomy on liver leptin receptor (OBR) 
mRNA expression in lean and obese Zucker rats
Liver total RNA was obtained from Experiment 4.1. Semi-quantitative RT-PCR 
and ribonuclease protection assays for OBR-S and P-actin were carried out as described 
in the General Methods section. The intensities of the signals were analyzed relative to 3- 
actin using the Phospholmager (Molecular Dynamics, Sunnyvale, CA, USA) and 
quantified using ImageQuant software.
Experiment 5.3 The effect of adrenalectomy on hypothalamic OBR, NPY-Y1,
NPY-Y5 and CRH mRNA expression in lean and obese Zucker rats
This experiment investigated the effects o f adrenalectomy on the mRNA 
expressions o f OBR and genes associated with regulation o f food intake, namely NPY- 
Y l and Y5 receptors, and CRH, in lean and obese Zucker rats. Total RNA was extracted 
from hypothalami of lean and obese Zucker rats by the TRIzol method as described in the 
general methods. RPAs for OBR, CRH, NPY-Yl, NPY-Y5 and P-actin were carried out 
as described in general methods. The intensities of the signals were analyzed relative to 
P-actin using the Phospholmager (Molecular Dynamics, Sunnyvale, CA) and quantified 
using ImageQuant software.
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Experiment 5.4 The effect of corticosterone diurnal rhythm on liver and 
hypothalamic OBR mRNA expressions in lean and obese Zucker rats
This experiment investigated the relationship of diurnal changes in corticosterone 
and leptin to the diurnal variation in the expression of OBR in lean and obese Zucker rats.
Eight-week-old, weight-matched lean and obese Zucker rats were used in this 
experiment. Rats were adapted to their living environment with a 12 hr light/dark cycle 
(6:00 am-6:00 pm), and food and water was provided ad libitum. After adaptation, the 
first group o f  rats was sacrificed at 4:00 p.m., the second at 9:00 pm and the last group at 
8:00 a.m. the next day. Trunk blood was collected for serum preparation. Liver, 
epididymal adipose tissues, hypothalamic and hippocampal tissues were dissected, 
weighed and snap-frozen in liquid nitrogen and stored at —80°C until used for RNA 
extractions. Serum samples were stored at -80°C before being used for hormone assays. 
Serum corticosterone, insulin and leptin were measured as described above. Total RNA 
was extracted from liver by the TRIzol method as detailed in the general methods. RPAs 
for OBR and P-actin were carried out as described in general methods, and OBR signal 
intensities were analyzed relative to 3-actin using the Phospholmager (Molecular 
Dynamics, Sunnyvale, CA, USA) and quantified using ImageQuant software.
Statistics
Analyses o f plasma corticosterone, leptin and insulin data as well as body and 
tissue weights were performed using a two-way analysis o f variance (ANOVA). Analysis 
of gene expression was done by Student’s t test.
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5.3 RESULTS
Experiment 5.1 Effects of adrenalectomy on liver PEPCK mRNA expression in lean 
and obese Zucker rats
In all experiments, age-matched obese rats were significantly heavier than lean 
rats. Changes in body and tissue weights and serum hormones caused by adrenalectomy 
are summarized in Table 5.1. At the end o f the experiments, obese sham-operated rats 
had significantly higher body weights compared to lean rats. The increase in body weight 
was associated with an increase in mass of epididymal white adipose tissue and the liver. 
Adrenalectomy attenuated the increase in body weight in obese rats, and this decline was 
associated with decreased epididymal fat and liver weights compared with the sham- 
operated rats. Corticosterone replacement restored the obesity syndrome in 
adrenalectomized rats, increasing the body weights parallel to those of sham-operated 
rats. Sham-operated obese Zucker rats had higher serum corticosterone, insulin and leptin 
levels than the lean Zucker rats (Table 5.1). Adrenalectomy reduced the levels of 
corticosterone to low levels in both the lean and obese rats, and also decreased the levels 
of circulating leptin and insulin in lean and obese. Corticosterone replacement in lean rats 
increased the levels o f circulating corticosterone, leptin and insulin to the levels 
approaching or comparable to those found in sham-operated rats, whereas in obese rats 
the hormone levels remained below those of the sham-operated rats.
The results for the PEPCK mRNA expression in lean and obese Zucker rats of 
various corticosterone status are shown in Figure 5.1. Sham-operated obese Zucker rats 
had significantly higher levels of PEPCK mRNA expressed compared to sham-operated 
lean rats. Adrenalectomy significantly reduced the PEPCK mRNA levels of obese Zucker
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Table 5.1. Body and epididymal WAT weights, and serum hormones o f adrenalectomized, adrenalectomized and steroid replaced, and 
sham-operated lean (Fa/?) and obese (fa/fa) Zucker rats
LEAN ZUCKER RAT________   OBESE ZUCKER RAT
ADX ADX+R SHAM ADX ADX+R SHAM
Initial Body weight (g) 196.7 ±11,7 203.2 ± 13,7 187.6 ±9.5 245,9 ±17,2 271,3 ± 14.0 229.7 ±15.6
Final body weight (g) 206,9 ± 12.7 215.5 ± 15.9 218.2 ±12.1 258,0 ±17,6 297,2 ±17.4 282.1 ±16.9
Body weight gain (g) 10.2 + 3.6° 12.3 + 4.3° 30.7 ± 4.3b 12,1 ±2.6° 25.9 ± 7.0b° 52.4 ± 6,9a
Epididymal WAT (g) 1.15 ± 0.13° 1.83 ±0.23° 1,88 ±0.19° 4.48 ± 0.35b 6.88 ±0.26“ 7.61 ±0,43“
Corticosterone (ng/ml) 6,1 ±2 .09d 103,3 ± 8,76b 61.9 ±9.5° 6,9 ± 2,85d 108,2 ±8,38b 210.5 ± 18,59*
Insulin (ng/ml) 1.3 + 0.19° 3.56 + 0.59° 3,11 ±0.45° 5.61 ±0.71° 17.43 ±2.99b 26.15 ±2.34“
Leptin (ng/ml) 0,96 ± 0,14d 2.2 ± 0.3d 2.95 ± 0,55d 17.2 ± 1,95° 29.5 ± 3,6b 39.3 ± 2.64*
Values are means ± SEM. There were significant differences in body weight gain (F5i67 = 9.78, P < 0.0001), epididymal WAT (Fs,46 = 
93.05, P < 0.0001), serum corticosterone (F5>g6= 65,79, P < 0,0001), serum insulin (F5ig6= 34,71, P < 0,0001), and serum leptin (Fs.se = 
57.01, P < 0,0001) levels between lean and obese Zucker rats. Significant difference between groups is indicated by the differences in 
letter symbols, with P < 0,05,
rats compared with sham-operated obese rats. In contrast, adrenalectomy had no 
significant effect on the PEPCK mRNA levels o f lean rats compared with the sham- 
operated lean rats. Corticosterone replacement o f obese adrenalectomized rats did not 
return the PEPCK mRNA levels to that of sham-operated rats. Corticosterone 
replacement did not have any effect on PEPCK mRNA expression in adrenalectomized 
and steroid replaced lean rats.
Experiment 5.2 The effect of adrenalectomy on liver leptin receptor (OBR) mRNA 
expression in lean and obese Zucker rats
In this experiment we determined the effects o f adrenalectomy on the expression 
of liver OBR mRNA in lean and obese Zucker rats. The expression o f liver OBR mRNA 
was examined by semi-quantitative RT-PCR and by RPA. The OBR-S mRNA expression 
and quantification by RT-PCR are shown in Figure 5.2. Adrenalectomy significantly 
increased OBR-S mRNA level in livers o f obese Zucker rats compared with sham- 
operated obese rats. Corticosterone treatment of obese adrenalectomized rats decreased 
the levels of OBR-S mRNA to that comparable to sham-operated obese rats. In contrast, 
adrenalectomy and corticosterone replacement had no significant effects on the OBR-S 
mRNA expression in livers of lean Zucker rats. Similar observations were obtained in a 
separate experiment using RPA to measure OBR-S (Figure 5.3). Again, a statistically 
significant increase in OBR-S mRNA expression was obtained in adrenalectomized obese 
Zucker rats compared to sham-operated obese rats. Adrenalectomy did not have any 
effect on the OBR-S mRNA expression from lean Zucker rats. However, corticosterone 
replacement did not show any effect on OBR-S mRNA expression in either the lean or 
obese rats in this experiment.
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Experiment 5.3
This experiment was designed to determine the effects of ADX on the expression 
o f OBR-L mRNAs in the hypothalamus o f  lean and obese Zucker rats. The OBR mRNA 
expression was examined by semi-quantitative RT-PCR and RPA. Figure 5.4 shows the 
effect o f ADX on OBR-L mRNA expression in lean and obese Zucker rats. ADX caused 
a significant increase in OBR-L mRNA expression in obese Zucker rats compared to 
sham-operated rats. ADX did not have any effect on the OBR-L mRNA expression in 
lean rats compared to sham-operated rats. The effect of corticosterone replacement was 
not evaluated in this study.
Figure 5.5 shows the effects o f ADX on OBR mRNA expression in the 
hypothalamus o f lean and obese Zucker rats as determined by RPA. Unexpectedly, ADX 
did not have any significant effect on the expression o f either the long and short isoforms 
o f OBR in lean and obese Zucker rats. We also determined the effect of ADX on the 
expression of NPY receptors and CRH mRNA levels. Figure 5.6 shows the RPA 
autoradiograms for NPY-Y1, NPY-Y5, CRH and P-actin for lean (A) and obese Zucker 
rats. In all experimental groups, the NPY-Y1, NPY-Y5 receptors and CRH were 
significantly higher in lean Zucker rats compared to obese Zucker rats. ADX did not have 
any effects on the mRNA levels of NPY-Y1, NPY-Y5 receptors and CRH.
Experiment 5.4
This experiment was designed to determine the effects o f basal physiological 
changes in corticosterone during the diurnal rhythm, on the expression o f hypothalamic 
OBR-S and OBR-L mRNAs in lean and obese Zucker rats. Figure 5.7 shows the changes 
in basal levels of corticosterone and leptin in lean and obese Zucker rats. In lean rats,
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Figure 5.1. Effects of adrenalectomy on liver PEPCK mRNA expression in lean and 
obese Zucker rats. (A) A representative Northern blot of PEPCK and 3-actin mRNA. (B) 
Histogram showing the quantification of PEPCK mRNA relative to 3-actin. Total liver 
RNA (40 pg/lane) was analyzed by Northern blotting. Relative expression of PEPCK 
mRNA was determined by hybridization with 32P-Iabeled PEPCK and 3-actin cDNAs. 
Lanes 1,3,13,15 = lean-ADX, lanes 2,4,14,16 = obese-ADX, lanes 5,7,17,19 = lean- 
ADX+R, lanes 6,8,18,20 = obese-ADX+R, lanes 9,11,21,23 = lean-sham, and lanes 
10,1222,24 = obese-sham. Bands were quantified using the ImageQuant software. Data 
are expressed as means ± SEM. This figure represents typical data obtained from 5 
separate experiments. * p < 0.05 compared to lean sham-operated rats, ** p < 0.005 
compared to sham-operated obese rats.
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L-ADX L-ADX-R L-SHAM O-ADX O-ADX-R O-SHAM
Figure 5.2. Effects o f adrenalectomy on liver OBR-S mRNA expression in lean and 
obese Zucker rats. (A) A representative semi-quantitative RT-PCR for OBR-S and 3" 
actin mRNA. Lanes 1, 5, 9 = lean-sham, lanes 2, 6 , 10 = Iean-ADX, lanes 3, 7, 1 1  = 
obese-sham and lanes 4, 8 , 12 = obese-ADX. (B) Histogram showing the quantification 
o f  OBR-S mRNA relative to 3-actin. Total RNA was extracted and analyzed by RT-PCR. 
10 pg of total RNA was reverse transcribed and amplified by PCR in the presence of [a- 
3 2 P]dCTP (10 pCi was used for whole experiment). cDNA (5 pL) was mixed with 
sequencing stop solution and fractionated on a sequencing gel. The gel was dried and 
exposed to phosphoscreen. Expression of OBR-S mRNA was determined relative to 3" 
actin. Bands were quantified using the ImageQuant software. Data is expressed as means 
± SEM for 3 rats in each group. * p < 0.05 compared to obese sham-operated rats.
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Figure 5.3. Ribonuclease protection assay to determine the effect o f ADX on liver leptin 
receptor mRNA expression. Total RNA was extracted from livers o f ADX, ADX+R and 
sham-operated lean (A) and obese (B) Zucker rats. RNA was hybridized with 32P-labeled 
antisense probes for OBR, GR and (3-actin and processed as described in the general 
methods. Representative RPA autoradiograms for short leptin receptor isoforms, and 
histograms showing the quantification of the OBR-S mRNAs. The arrow shows the 270- 
bp protected fragment for OBR-S, and the * arrow shows GR protected fragment. P is 
undigested probe for OBR (top band) and GR (bottom band). Data are presented as 
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Figure 5.4. Effects o f adrenalectomy on hypothalamic OBR-L mRNA expression in lean 
and obese Zucker rats. (A) A representative semi-quantitative RT-PCR for OBR and 3- 
actin mRNA. Lanes 1, 5, 9 = lean-sham, lanes 2, 6, 10 = lean-ADX, lanes 3, 7, 11 = 
obese-sham and lanes 4, 8, 12 = obese-ADX. (B) Histogram showing the quantification 
of OBR-L mRNA relative to 3-actin. Total RNA was extracted and analyzed by RT- 
PCR. 10 pg o f total RNA was reverse transcribed and amplified by PCR in the presence 
of [<x-32P]dCTP (10 pCi was used for whole experiment). cDNA (5 pL) was mixed with 
sequencing stop solution and fractionated on a sequencing gel. The gel was dried and 
exposed to phosphoscreen. Expression of OBR-L mRNA was determined relative to 3- 
actin. Bands were quantified using the ImageQuant software. Data is expressed as means 
± SEM for samples in triplicate. * p < 0.05 compared to obese sham-operated rats.
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corticosterone were high 2 hr before lights off and slightly, but significantly (p < 0.05), 
decreased after feeding. The levels o f corticosterone further decreased significantly (p < 
0.005) the following morning [Figure 5.7 (A)]. The levels o f  corticosterone was also 
elevated in obese rats before dark-onset. After feeding, the corticosterone levels 
decreased significantly (p < 0.05). The levels o f corticosterone in the obese rats did not 
decrease any further in the morning compared to the lean rats. Serum leptin levels in lean 
rats showed some rhythm [Figure 5.7 (B)]. Leptin levels in these rats were lower before 
dark-onset and significantly (p < 0.005) increased after feeding. In the morning, leptin 
levels were significantly (p < 0.005) reduced compared to those observed after feeding.
In contrast, no leptin rhythm was observed in obese rats, even though there was a change 
in corticosterone levels in these rats. Figures 5.8 and 5.9 indicates the effect o f  leptin and 
corticosterone rhythms on the liver and hypothalamic OBR-S and hypothalamic OBR-L 
mRNA expressions in lean and obese Zucker rats. There were no significant effects of 
leptin or corticosterone rhythms on OBR mRNA expression.
5.4 DISCUSSION
This study was undertaken to investigate the role o f glucocorticoids on the 
regulation o f gene expression of PEPCK and OBR mRNAs in lean and obese Zucker rats. 
Data presented in this dissertation provide evidence for a role of glucocorticoids in 
modulating PEPCK and OBR mRNA, particularly in obese animals. Adrenalectomy 
reduced circulating serum corticosterone, insulin and leptin levels in both lean and obese 
rats. The decrease in serum hormones was accompanied by an increase in the 
hypothalamic OBR-L and OBR-S mRNA, and liver OBR-S mRNA in obese Zucker rats.
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Figure 5.5. Ribonuclease protection assay to determine the effect o f ADX on leptin 
receptor mRNA expression. Total RNA was extracted from individual hypothalami of 
ADX, ADX+R and sham-operated lean and obese Zucker rats. RNA was hybridized with 
P-labeled antisense probes for OBR and 3-actin and processed as described in the 
general methods. A) A representative RPA autoradiogram for leptin receptor isoforms, 
and B) histograms showing the quantification of the OBR-L and OBR-S mRNAs, where 
the open-bars are lean and dark-bars are obese samples. Data are presented as means ± 
SEM. There were no statistically significant differences between all groups.
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Figure 5.6. Ribonuclease protection assay to determine the effects of adrenalectomy on 
NPY receptors mRNA expression in the hypothalamus of lean and obese Zucker rats. 
Total RNA was extracted from individual hypothalami of ADX, ADX+R and sham- 
operated lean and obese Zucker rats. RNA was hybridized with 32P-Iabeled antisense 
probes for NPY-Y1, NPY-Y5, CRH and P-actin and processed as described in the 
general methods. Representative RPA autoradiograms for NPY-Y1, NPY-Y5, CRH, and 
P-actin in lean (A) and obese (B) Zucker rats.
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Figure 5.6. (cont.). Histograms showing the quantification of the NPY-Y1, NPY-Y5 and 
CRH mRNA relative to P-actin, where the open-bars are lean and dark-bars are obese 
samples. Data are presented as means ± SEM. There were no statistically significant 
differences caused by ADX between all groups.
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The increase in the mRNA expressions was concomitant with the correction o f  the 
hyperleptinemia by adrenalectomy in obese Zucker rats.
An increase in hepatic gluconeogenesis is believed to be an important factor 
responsible for the fasting hyperglycemia detected in patients with NIDDM (Valera, et 
al., 1994). The presence o f mild hyperglycemia has been reported in obese Zucker rats 
compared to lean rats, and this was more pronounced in males than in females (Triscari, 
et al., 1979; observation in this study). This hyperglycemia was associated with elevated 
liver and kidney PEPCK activity and kidney glucose production in obese compared to 
lean rats. Furthermore, total liver glycogen levels and rates of glycogen synthesis were 
increased significantly in obese compared to lean rats. The authors concluded that the 
mild hyperglycemia present in obese Zucker rats was not associated with delayed 
disappearance o f  intravenously administered glucose, but could be due to the increased 
production o f glucose by whole kidney and liver (Triscari, et al., 1979).
Recently, Friedman and colleagues (1997), using transgenic mice expressing the 
intact PEPCK(460)-C-reactive protein transgene, showed that these mice were obese, 
hyperinsulinemic, and developed fasting hyperglycemia with age. Levels o f  CRP reporter 
gene expression were increased 2-fold despite severe hyperinsulinemia compared with 
non-diabetic non-obese transgenic mice, and treatment o f obese diabetic db/db transgenic 
mice with the glucocorticoid receptor blocker RU 486 decreased plasma glucose by 50% 
and reduced PEPCK, GLUT2, gIucose-6-phosphatase, tyrosine aminotransferase and 
CRP reporter gene expression to levels similar to those o f  non-obese normoglycemic 
transgenic mice. These results showed that -460 bp o f 5'-flanking sequence is sufficient 
to mediate the induction of PEPCK gene transcription in genetically obese db/db mice
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Figure 5.7. Serum corticosterone and leptin rhythms in lean and obese Zucker rats. 
Serum was obtained from lean and obese Zucker rats killed by decapitation at 4:00 pm 
(open bars), 9:00 pm (slashed bars) and 8:00 am (black bars). Corticosterone (A) and 
leptin (B) were measured by RIA kits. The insert is an enlargement of the serum leptin 
levels in lean Zucker rats to indicate the rhythm in leptin. Data is expressed as mean ± 
SEM.
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Figure 5.8. The effect of leptin and corticosterone rhythms on liver OBR-S mRNA 
expression. Livers were dissected from lean and obese Zucker rats killed by decapitation. 
Histogram showing the quantification of OBR-S mRNA relative to P-actin. Total RNA 
was extracted and analyzed by RPA. 40 gg o f total RNA was hybridized to 32P-labelled 
antisense ObR403 probe. Expression of OBR-S mRNA was determined relative to P- 
actin. Bands were quantified using the ImageQuant software. Data is expressed as means 
± SEM for samples in triplicate.
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Figure 5.9. The effect of leptin and corticosterone rhythms on hypothalamic OBR-S and 
OBR-L mRNA expression. Hypothalami were dissected from lean and obese Zucker rats 
killed by decapitation. Histograms showing the quantification of OBR-S and OBR-L 
mRNA relative to 3-actin. Total RNA was extracted and analyzed by RPA. 40 pig o f  total
RNA was hybridized to 32P-labelled antisense ObR403 probe. Expressions o f OBR-S and 
OBR-L mRNA were determined relative to P-actin. Bands were quantified using the 
ImageQuant software. Data is expressed as means ± SEM for samples in triplicate.
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during the development of hyperglycemia, demonstrating that the mechanism underlying 
increased expression of gluconeogenic enzymes in the db/db mouse requires the action o f 
glucocorticoids (Friedman, et al., 1997). Sharma and Patnaik (1983, 1984) have shown 
that the activity o f PEPCK is highest in livers o f adult rats and that adrenalectomy 
decreases significantly the activity o f  PEPCK of livers of rats o f  all the ages. 
Administration o f hydrocortisone to adrenalectomized rats increased the activity o f 
PEPCK in the liver o f young and adult rats but not in the old rats. Our studies indicate a 
significant induction o f liver PEPCK mRNA in obese Zucker rats, and that this increase 
can be reduced by adrenalectomy. PEPCK mRNA transcription is negatively regulated by 
insulin. The obese Zucker rat is hyperinsulinemic, but this high endogenous insulin 
concentration cannot inhibit PEPCK gene transcription. Rosella and colleagues (1995) 
recently described an overexpressed, non-insulin-responsive gluconeogenic PEPCK. This 
leads us to speculate that obese Zucker rats express this type of PEPCK mRNA, which is 
mainly under regulation by glucocorticoids. Data presented in this study is consistent 
with previous reports which showed an increased ob gene expression and leptin levels in 
adipose tissue from obese Zucker rats compared to lean littermates (Murakami & Shima, 
1995). Maffei and colleagues (1995) reported a 50-fold increase in circulating leptin in 
obese Zucker rats, which was quantitatively comparable to our results. They also showed 
that an increased expression of the ob gene is common to other animal genetic obesity 
models and diet-induced obesity (Maffei, et al., 1995).
The beneficial effects of adrenalectomy, such as decreases in food intake, body 
weight gain, plasma insulin, triglycerides, fat cell size and LPL activity, have been shown 
to be reversed by the replacement of corticosterone (Castonguay, et al., 1986; Freedman,
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et al., 1986; Bray & York, 1979). However, the mechanisms by which the loss of 
glucocorticoids prevents the phenotypic expression o f obesity in the obese Zucker rat are 
still unknown. This study provides data consistent with the possibility that expression of 
the leptin receptor is regulated by glucocorticoids, whereby glucocorticoids increase 
leptin gene expression and protein levels which then causes downregulation o f OBR-L 
and OBR-S. This suggests that corticosterone, directly or indirectly, is an important 
factor in the expression o f obesity in fa /fa  rats. It is possible that glucocorticoid hormones 
have a direct effect to regulate transcription o f the OBR gene. Indirectly, corticosterone 
increases ob gene expression and secretion, and this increase in leptin may lead to 
downregulation o f the leptin receptor isoforms. Alternatively, it is also possible that 
glucocorticoids modulate other genes, the products o f which regulate leptin receptor or 
leptin gene expression. Obese (fa/fa) Zucker rats carry a mutation (Gln269Pro) on the 
cytokine-binding domain o f the leptin receptor (Chua, et al., 1996), and this mutation has 
been shown to reduce leptin receptor signaling (Chen, et al., 1996). As adrenalectomy 
prevented further weight gain in fa /fa  rats, it suggests that the effects o f adrenal steroids 
are independent o f the changes observed in the levels of the mutated receptor. The 
increase in leptin expression in fa /fa  rats could result from a number of mechanisms. It 
could reflect the absence o f an appropriate leptin feedback onto the mutated leptin 
receptor. Alternatively, it is possible that increased hyperinsulinemia may stimulate 
increased synthesis and secretion of leptin in obese Zucker rats. This was recently 
supported by the observation that ob gene expression was not increased in preweaning 
obese rats, whereas it increased with increase in insulin after weaning and in adult 
animals (Cusin, et al., 1995). In contrast, basal leptin was not further increased by
97
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
hyperleptinemia in obese rats despite the higher plasma insulin concentration reached in 
obese animals (Pagano, et al., 1997). This could indicate a possible alternative 
mechanism whereby the ob gene is not under the control of insulin in obese fci/fa rats, but 
under the control o f glucocorticoids. Our data supports the latter mechanism, which is 
further supported by the observation that fasting, which reduces plasma insulin and 
increases glucocorticoids both in lean and obese Zucker rats, inhibits ob gene expression 
only in lean rats (Cusin, et al., 1995). This indicates that increase in already high 
glucocorticoids in obese rats during fasting increased ob gene expression.
It is still unclear whether hyperleptinemia in obesity results from the increased 
size of the white adipose tissue, or if other hormonal, metabolic and neuroendocrine 
factors may also play a role. Our results suggest that glucocorticoids are important 
regulators of leptin and leptin receptor mRNA expression, because adrenalectomy was 
effective in decreasing the former and increasing the latter. This reciprocal modulation of 
the ligand and its receptor could suggest that the receptor is down-regulated in the 
presence of circulating high ligand, in this case with leptin down regulating the receptor 
in the presence of high glucocorticoids. This also indicates that, in the absence of 
glucocorticoids, leptin secretion by white adipose tissue is reduced. This could reflect a 
direct effect of the absence o f adrenal glucocorticoids on leptin gene expression or it 
could be due to decreased fat pad size induced by removal of adrenal glucocorticoids. 
However, the effect o f insulin on our system cannot be entirely discounted, even though a 
role of insulin in influencing leptin concentration in humans does not support this. The 
size of the white adipose tissue was shown to be a relevant determinant of circulating 
leptin (Considine, et al., 1996). Our results also indicate that glucocorticoids do influence
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leptin secretion by adipose tissue, since leptin secretion was increased by the replacement 
with corticosterone in adrenalectomized rats.
NPY is the most potent orexigenic agent known, and icv administration thereof 
causes hyperphagia, hyperinsulinemia and obesity. However, the mechanism by which 
NPY causes obesity development remains to be defined. Much research is now focused 
on which NPY receptor might mediate the potent NPY induced feeding response. Several 
pieces of evidence pointed to NPY-Y1 and NPY-Y5 receptor subtypes to be the 
candidates for this action. Glucocorticoids play an important role in energy balance, as 
excessive corticosterone promotes obesity and increase NPY synthesis and NPY-Y1 
receptor expression in the ARC. ADX reduces hyperphagia and body weight in obese 
Zucker rats, and prevents obesity induced by central icv NPY infusion. Larsen et al. 
(1994) reported that ADX does not alter NPY-Y1 mRNA expression in the ARC. Our 
data is consistent with this observation, because ADX did not influence the mRNA levels 
o f NPY-Y1 and NPY-Y5. In contrast, Wisialowski and colleagues (2000) recently 
showed that ADX decreases NPY-Y1 and NPY-Y5 receptor mRNA in the VMH. It is 
possible that significant localized changes in NPY receptor expression within nuclei 
occur, but overall there seems to be no changes in these receptor mRNAs in our studies 
o f  the whole hypothalamus. However, these observations could imply that NPY receptors 
are modulated by glucocorticoids. It is also possible that glucocorticoids act by regulating 
the levels of CRH, which has been shown to decrease food intake and inhibit NPY 
synthesis and release. The decrease in NPY expression in ADX rats was proposed to be a 
result of increased CRH activity as well as decreased corticosterone levels. In this study,
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however, no changes in CRH mRNA were observed, but we cannot rule out changes 
occurring within the PVN, the site of glucocorticoid effects on CRH.
Glucocorticoids, at physiological concentrations, stimulate leptin secretion by 
enhancing the pre-translational machinery in human visceral fat. This effect was more 
pronounced in obese subjects due to a greater responsiveness o f  the ob gene and could 
contribute to the metabolic abnormalities associated with central obesity by paracrine or 
endocrine actions o f hyperleptinemia on adipocytes and liver (Halleux, et al., 1998). 
Unlike dexamethasone, insulin had no direct stimulatory effect on ob gene expression 
and leptin secretion, and even prevented the positive response to dexamethasone by a 
cAMP-independent mechanism that remained functional despite insulin resistance 
(Halleux, et al., 1998). A similar argument can be presented in this study, where insulin, 
per se, may not have any effect on the expression and secretion of leptin, but that the 
observed effects were exclusively under the influence o f glucocorticoids.
The existence o f abnormal regulation of the HPA axis in genetically obese Zucker 
rats has been reported (Guillaume-Gentil, et al., 1990). Previous data have shown 
increased morning plasma corticosterone in obese animals (White, et al., 1988). Some 
results have described the absence of a circadian rhythm of the corticosterone in obese 
rats (Martin, et al., 1978; Gibson & Krieger, 1981). In the present study, basal 
measurement of corticosterone and leptin were determined. Morning serum 
corticosterone levels o f obese Zucker rats are significantly higher than those of their lean 
littermates. Afternoon corticosterone levels are significantly higher than the morning 
levels in lean rats, and this level is decreased 3 hr after meal time. In contrast, 
corticosterone levels in obese rats decreased after meal time, but did not decrease to
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lower levels in the moming. This data could be in keeping with the preservation of a 
“partial” circadian rhythm of corticosterone in the obese rats, even though the trough will 
not be as deep as it could be in the lean rats. This data supports that o f Yukimura and 
colleagues (1978). This data is also in keeping with the study that showed an increased 
daily urinary corticosterone output in obese Zucker rats in comparison to lean Iittermates 
(Cunningham, et al., 1986). Furthermore, our results may indicate that there is an 
increased activity of the HPA axis in the obese Zucker rats compared to the lean rats. In 
contrast to the partial diurnal rhythm o f corticosterone in obese Zucker rats, no leptin 
rhythm was observed in these rats. Lean Zucker rats showed a rhythm where leptin was 
reduced before dark-onset, increased 2 hr after a meal and decreased during the lights on. 
This rhythm could be a functional regulator o f the leptin receptor in lean rats, with the 
receptor decreasing during high leptin and increasing during the low levels. This, 
however, would be a lost function in obese Zucker rats that are hyperleptinemic and have 
no rhythm o f the circulating leptin. This effect could induce down-regulation o f the leptin 
receptor, which may in turn be responsible for potential leptin resistance. Even though we 
observed leptin rhythm in lean Zucker rats, no rhythm of OBR was seen in these rats. 
This could suggest that leptin does not regulate OBR or that the time o f sampling for 
OBR was inappropriate because we did not allow a lag time from leptin measurements.
The presence of glucocorticoids is necessary for the development and 
maintenance o f  obesity (Fletcher, 1986), and the administration o f corticosterone to 
normal rodents causes hyperinsulinemia (Diamant & Shafrir, 1975) and increased fat 
deposition and hyperphagia (Bray, et al., 1990), Furthermore, adrenalectomy of 
underweight rats blunted hyperphagic response associated with free access to food, and
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this defect was normalized by central administration of glucocorticoids (Green, et al., 
1992). These observations suggested that hypercorticosteronemia observed in the obese 
rat contributes to several aspects o f its metabolic abnormalities (Jeanrenaud, et al., 1985). 
This is validated by reports that administration o f cortisol to normal humans produced 
insulin resistance (Rizza, et al., 1982), a similar feature o f Zucker rats (Jeanrenaud, et al.,
1985). The increased HPA activity o f the obese Zucker rats has been shown to be 
associated with an abnormal (increased) regulation o f  CRF release (Bestetti, et al., 1990). 
Adrenalectomy may therefore, help restore the hypothalamic CRF content and normalize 
abnormalities o f  obesity via restoration of the autonomic nervous system (Rohner- 
Jeanrenaud, et al., 1989).
While we could demonstrate effects o f adrenalectomy on the levels o f OBR 
mRNA in obese rats, the lack of difference in OBR mRNA between lean and obese rats 
and the lack o f a diurnal variation in OBR mRNA suggest that corticosterone does not 
regulate OBR at physiological concentrations. However, the dramatic effect o f 
adrenalectomy might be interpreted to suggest that there is a permissive requirement for 
glucocorticoids for the downregulation of the leptin receptor.
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CHAPTER SIX
EFFECTS OF ADRENALECTOMY ON THE LEPTIN RECEPTOR
SIGNALING SYSTEM
6.1 INTRODUCTION
Adrenalectomy prevents the development of all forms o f rodent obesity, including 
those that have a defect in the leptin signaling pathway. The mechanism through which 
this response is mediated remains unclear, but is related primarily to the removal of 
adrenal glucocorticoids because glucocorticoid replacement of adrenalectomized animals 
restores fat deposition and obesity (Bray, et al., 1990a; Bray, et al., 1990b; Saito & Bray, 
1984; Bruce, et al., 1982; Freedman, et al., 1986). Also, blockage o f  type II GR with the 
antagonist RU486, inhibits development of obesity induced by the overactivity o f the GR 
receptor (Langley & York, 1990; Okada, et al., 1990). Leptin, a hormone secreted by the 
adipose tissue, plays an important role in the regulation of energy balance, providing a 
signal to the central nervous system on the levels o f triglyceride stores (Halaas, et al. 
1995; Friedman & Halaas, 1998; Friedman, 1999). Glucocorticoids and insulin stimulate 
leptin gene expression in the adipose tissue and leptin protein secretion into the 
circulation (De Vos, et al., 1995; Slieker, et al., 1996; Wabitsch, et al., 1996; Malmstrom, 
et al., 1996). Administration of glucocorticoids increases food intake in rodents, 
overriding the effect o f increased endogenous leptin expression and secretion. These 
contrasting effects o f glucocorticoids may suggest that glucocorticoids either reduce 
sensitivity to leptin or oppose leptin action through independent pathways. Indeed, an 
increase in response to leptin has been described in adrenalectomized rats by Zakrzewska 
and colleagues (1997). Corticotropin-releasing hormone (CRH), which suppresses food 
intake, is negatively regulated by glucocorticoids. However, CRH deficiency after ADX
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did not affect food intake and body weight, indicating that factors other than or in 
addition to CRH are important in mediating food intake responses after ADX (Jacobson, 
1999).
The effects of leptin are impaired when receptors o f neurotransmitters implicated 
in feeding, namely GLP-1, MC-4, and NPY, are either knocked out or blocked by 
specific antagonists (Marsh, et al., 1999; Hollopeter, et al., 1998b; Scrocchi, et al., 1997; 
Goldstone, et al., 1997). These observations led to the conclusion that leptin’s actions to 
inhibit food intake may not be direct, but mediated or modified by the action o f other 
neurotransmitters. Figure 6.1 shows some of the suggested possible pathways that leptin 
uses to regulate feeding. Evidence supporting an interaction between leptin and NPY 
came from studies showing that the NPY mRNA expression in the ARC is increased in 
animal models with leptin signaling abnormalities (Schwartz, et al., 1996a). Peripheral 
injection of leptin to fasted rats and ob/ob mice normalized the overexpression of NPY in 
these situations (Stephens, et al., 1995; Schwartz, et al., 1996a; Wang, et al., 1997; 
Schwartz, et al., 1996b). More evidence for the interaction between leptin and NPY was 
shown by the presence o f leptin receptors on NPY neurons (Hakansson, et al., 1996; 
Baskin, et al., 1999a; Baskin, et al., 1999b). NPY, which is modulated by leptin and 
glucocorticoids, is an important mediator of leptin’s action in the CNS (Rohner- 
Jeanrenaud, et al., 1996), since recombinant leptin inhibits, and glucocorticoids enhance, 
hypothalamic NPY gene expression and secretion (Stephens, et al., 1995; Schwartz, et al.,
1996).
Neurons of the ARC also synthesize POMC, which is enzymatically cleaved into 
melanocyte stimulating hormones (a, 3, and y) and P-endorphin. a-MSH has been shown
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to affect food intake by activating post-synaptic receptors, especially the melanocortin-4 
(MC-4) receptor subtype (Zemel & Shi H, 2000; York, 1999; Kask, et al., 1998). 
Targeted disruption o f this receptor subtype causes obesity (Huszar, et al. 1997). POMC 
neurons in the ARC express leptin receptor mRNA, suggesting that leptin may bind to 
neurons in this brain region to influence the production o f melanocortins (Cheung, et al.,
1997). Injection of leptin to fasted animals and ob/ob mice increased POMC mRNA 
expression, but this effect was not observed in db/db mice which lack the capacity for 


















Figure 6.1. Possible pathways downstream of leptin receptor to control feeding. 
Corticotropin releasing hormone (CRH), pro-opiomelanocortin (POMC) and cocaine- 
amphetamine related transcript (CART) decrease food intake, whereas neuropeptide Y 
(NPY), orexin, melanin-concentrating hormone (MCH) and agouti-related protein 
(AGRP) increase food intake. Agouti-related protein (AGRP) is increased by leptin and 
competes with a-MSH for the MC-4 receptor to decrease food intake.
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CRH is released in the median eminence, where it induces ACTH release from the 
anterior pituitary via the hypothalamic pituitary portal circulation. In addition to its 
ability to activate the HPA axis, CRH also regulates food intake and energy balance 
(Arase, et al., 1989). Loss of the negative feedback from glucocorticoids to the brain 
following ADX acts to increase CRH mRNA and content in the PVN (Jacobson, et al., 
1990).
The Ieptin receptor (OBR) is a single membrane-spanning receptor that is similar 
to the class I cytokine receptor family (Tartaglia, et al., 1995). The majority of the 
transcripts in most tissues are those encoding the short forms o f the receptor (Ghilardi, et 
al., 1996), and the transcript that encodes the long form is less abundant except in the 
hypothalamus. Within the hypothalamus, the long OBR isoform is expressed in regions 
that are thought to control food intake and body weight, namely, the arcuate nuclei 
(ARC), ventromedial nuclei (VMN) and paraventricular nuclei (PVN) (Mercer, et al., 
1996). The functions of the long and short intracellular domains of the leptin receptor are 
currently being defined. The short isoforms play a major role in transporting leptin from 
the blood into the brain or out of the brain into the cerebrospinal fluid (CSF) for clearance 
(Cumin, et al., 1996; Cumin, et al., 1997; Esler, et al., 1998). The long OB-R isoform 
provides intracellular signaling by acting through the JAK-STAT pathway as illustrated 
in Figure 2.5, particularly the STAT-3 protein in the hypothalamus (Vaisse, et al., 1996). 
The JAK proteins are associated with the receptor intracellular domain, where they 
phosphorylate tyrosine residues of the receptor upon ligand binding. The phosphorylated 
receptor then provides the docking site for ST AT proteins, which are also tyrosine 
phosphorylated upon binding the phosphorylated receptor. The activated ST AT proteins
106
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
then dimerize and translocate to the nucleus to stimulate gene transcription (Darnell, et 
al., 1994; Darnell, 1996; Darnell, 1997).
Recently, a family o f cytokine-induced cytokine signaling inhibitors has been 
described. It includes eight members, namely the cytokine-inducible SH2 proteins (CIS) 
and suppressor o f  cytokine signaling (SOCS) 1 to 7 (Hilton, et al., 1998). Structurally, the 
SOCS proteins are composed of an N-terminal region of variable length and amino acid 
composition, a central SH2 domain, and a previously unrecognized C-terminal motif 
called the SOCS box. By using the SOCS box amino acid sequence consensus, 16 other 
proteins that contain this motif were identified. These proteins fall into five classes based 
on the protein motifs found N-terminal o f the SOCS box. In addition to four new SOCS 
proteins (SOCS-4 to SOCS-7) containing an SH2 domain and a SOCS box, three new 
families o f proteins that contain either WD-40 repeats (WSB-1 and -2), SPRY domains 
(SSB-1 to -3) or ankyrin repeats (ASB-1 to -3) N-terminal o f  the SOCS box were 
identified (Hilton, et al., 1998).
The expression of SOCS proteins is induced by various cytokines, and once 
expressed, SOCS proteins down-regulate JAK/STAT pathways and hence modulate the 
biological response. Peripheral administration of leptin to ob/ob, but not db/db mice, 
rapidly induced SOCS-3 mRNA in hypothalamus (Bjorbaek, et al., 1998; Emilsson, et al., 
1999). This leptin-dependent increase o f SOCS-3 mRNA was seen in areas of the 
hypothalamus expressing high levels o f the long form OBR. Furthermore, SOCS-3 was 
shown to block leptin-induced signal transduction in mammalian cell lines. The 
expression o f SOCS-3 mRNA in the ARC and DMN is increased in agouti mice, an 
obesity model o f  leptin-resistance. This indicated that SOCS-3 is a leptin-inducible
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inhibitor o f leptin signaling, and suggested SOCS-3 to be a potential mediator o f leptin 
resistance in obesity (Bjorbaek, et al., 1998). Furthermore, Auemhammer and colleagues 
(1998), showed an inhibition of LIF-stimuIated STAT-3 phosphorylation in SOCS-3 
overexpressing AtT-20 cells, and concluded that SOCS-3 inhibits the JAK-STAT 
pathway.
Adrenalectomy has been shown to increase sensitivity to leptin (Zakrzewska, et 
al., 1997). We hypothesize that this leptin sensitivity upon adrenalectomy could be 
through several mechanisms, including direct action on expression of the leptin receptor, 
changes in activation o f the JAK/STAT pathway or expression of the suppressors of 
cytokine signaling or through direct effects on the neuropeptide genes that modulate the 
effects of leptin on energy balance. To determine if glucocorticoids impair the activity of 
the leptin receptor signaling pathway, we studied the effects of adrenalectomy and 
corticosterone replacement on components o f the leptin receptor signaling pathway, 
including the hypothalamic leptin receptors, SOCS-3, STAT-3 and NPY.
6.2 EXPERIMENTAL PROTOCOLS 
Animals
Ten-week-old male Sprague Dawley rats were purchased from Harlan Sprague 
Dawley, Inc. (Indianapolis, IN). They were housed individually in hanging wire-mesh 
cages attached to an automated watering system in a room with a 12 hour light/dark (7:00 
AM to 7:00 PM) cycle at a temperature of 22-23°C. All rats consumed nonpurified chow 
diet (Rodent chow 5001, Purina Mills, St. Louis, MO, USA). Food was available ad 
libitum  throughout the experiment. All protocols used in these studies were reviewed and 
approved by the Pennington Center’s Institutional Animal Care and Use Committee.
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Intracerebroventricular (icv) Cannulation
Rats weighing 270-300 g were anesthetized by intraperitoneal (ip) injection with 
0.125ml anesthesia per lOOg body weight [anesthesia = mixture of Ketamine (80mg/ml); 
Ace Promazine (1.6mg/ml) and Xylazine (5mg/ml)]. They were stereotaxically implanted 
with a stainless steel guide cannula (25 gauge, 14-mm long) into the third cerebral 
ventricle. The coordinates were: 2.8 mm posterior to bregma, 0.0 mm lateral to 
midsagittal, and 8.1 mm ventral to the dura according to the brain atlas of Paxinos and 
Watson (1982). Cannulas were secured in place with anchor screws and dental acrylic 
and occluded with 30-gauge wire stylet. The injector (31-gauge) was projected 0.5 mm 
longer beyond the tip o f the guide cannula. Body weights were monitored daily during 
the 7 days recovery period.
Ad renalecto my
Seven days after recovery from cannula placement surgery, rats were bilaterally 
adrenalectomized via a dorsal approach under isoflurane anesthesia. One group of 
adrenalectomized rats were subcutaneous implanted with 3 weeks-release 100 mg 
corticosterone pellets (Innovative Research of America, Sarasota, FL). Adrenalectomized 
rats were provided with 0.9% saline drinking water and allowed to recover for 7 days 
before leptin treatment. Body weights were monitored daily after adrenalectomy.
In vivo experiments
Intracerebroventricular microinfusions (2.0 pi leptin/rat) in unrestrained rats were 
at the rate o f lpl/min using an infusion pump (Harvard Apparatus, South Natick, MA). 
Each animal was infused between 3:00 and 3:30 pm (4 hours before dark onset). Rats 
received either vehicle (sterile physiological saline, 2 pl/rat) or 2.5 gg/rat recombinant
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leptin (R&D Systems, Inc., Minneapolis, MN) dissolved in 2 \xL saline vehicle. Twenty- 
four (24) h food intake and body weight were monitored. After 24 hours, rats were given 
second icv injections o f saline or 2.5 pg leptin. Two hours later, rats were killed by 
decapitation. Trunk blood was collected for the determination of plasma hormones. 
Hypothalami, epididymal fat pads and livers were dissected out, weighed and snap-frozen 
in liquid nitrogen and stored at -80°C until used for total RNA and protein analyses. The 
dose o f  leptin chosen for these studies was based on our lab’s previous studies that 
determined the concentration-dependence of leptin effects on food intake (Lin, et al., 
1999). The time selected for tissue sampling (2 h after icv administration and 2 h before 
dark onset) was also based on the food intake profiles exhibited by rats receiving leptin. 
RNA analysis
Total RNA was extracted from hypothalamus and liver tissues by the modified 
guanidinium-isothiocyanate method (Chomczynski and Sacchi, 1987) using TRIzol 
reagent (Life Technologies, GIBCO BRL, Gaithesburg, MD), with modifications as 
described in the General Methods section. RPA (OBR, P-actin), semi-quantitative RT- 
PCR (SOCS-3, STAT-3, cyclophilin) and Northern (NPY, P-actin) analyses were carried 
out as described in the General Methods section. The intensities of the signals were 
analyzed relative to appropriate internal standard using the Phospholmager (Molecular 
Dynamics, Sunnyvale, CA) and quantified using ImageQuant software.
Protein analysis
Total lysates, nuclear and cytosolic fractions were prepared from hypothalami 
according to the method of Vaisse, et al. (1996) as described in the General Methods 
section. Nuclear STAT-3 protein was immunoprecipitated with anti-STAT-3 antibody
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(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and sequentially immunoblotted with 
anti-phosphotyrosine (pY20), and anti-STAT-3 polyclonal antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA). SOCS-3 and SHPTP-2 proteins were
immunoprecipitated and immunoblotted from the cytosolic fraction using their respective 
antibodies purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA).
Phosphorylation of SHPTP-2 was determined by immunoblotting with anti-
phosphotyrosine (clone 4G10) antibody (Upstate Biotechnology, Lake Placid, NY). 
Electrophoretic mobility shift assay
DNA binding studies were performed using the c-fos 5 /5 -inducible element (m67- 
SIE) which specifically binds STAT-3 protein dimers, as described in the General 
Methods section. Nuclear extracts were incubated with radiolabeled double-stranded 
probe and the products were fractionated on a 5% nondenaturing PAGE. The intensities 
of the bands were analyzed using the Phospholmager (Molecular Dynamics, Sunnyvale, 
CA) and quantified using ImageQuant software.
Serum assays
Plasma corticosterone, insulin and leptin were measured with radioimmunoassay 
(RIA) kits (Linco Research, Inc., St. Charles, MO) based on rat standards according to 
the supplier’s instructions. Nonesterified fatty acids (NEFAs) from serum were quantified 
using a colorimetric in vitro enzymatic assay according to the manufacturer’s 
specifications (Wako Pure Chemical Industries Ltd., Richmond, VA). The blood glucose 
levels were measured with a blood glucose meter (Glucometer Elite, Bayer Corp., 
Elkhart, IN).
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Statistics
Data are presented as means ± SEM. Statistical analysis were performed using the 
Student’s t test, and two-way analysis of variance (ANOVA). Post hoc analysis was 
performed using the Duncan multiple range test method at p < 0.05.
6.3 RESULTS
Adrenalectomy attenuates the development o f obesity and leptin reduces food 
intake and body fat in rodents. To test the hypothesis that adrenalectomy increases the 
sensitivity to leptin, we adrenalectomized and steroid-replaced rats with corticosterone 
pellets and injected them icv with either saline vehicle or 2.5 pg leptin. Figure 6.2 shows 
the effects of adrenalectomy and leptin treatment on food intake. In saline treated rats, 
ADX reduced 24-h food intake by 35% in ADX rats compared to sham-operated rats. 
Leptin treatment of sham-operated rats significantly decreased 24-h food intake by 43% 
compared to saline treated rats. Corticosterone replacement o f saline-treated ADX rats 
returned the food intake to the level equivalent to that of sham-operated rats, indicating 
an inhibition of ADX-induced decrease in food intake. Treatment o f ADX rats with leptin 
significantly decreased food intake by 73% compared to saline treated ADX rats. When 
corticosterone replaced rats were treated with leptin, leptin significantly decreased food 
intake, however corticosterone reduced the sensitivity of leptin-induced decrease in food 
intake by 50% compared with leptin treated ADX rats. Table 6.1 shows the data obtained 
on body and tissue weights, serum hormones, glucose and NEFAs. ADX significantly 
reduced the epididymal fat pad weight compared to sham-operated rats. Leptin treatment 
of ADX rats decreased epididymal fat pad weight by 32% compared to ADX-saline rats, 
however this decrease was not significant.
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Figure 6.2. Effects of adrenalectomy and leptin treatment on the 24-hr food intake. 
Sprague-Dawley rats received an injection o f  2 pL saline vehicle or 2.5 pg leptin in 2 pL 
icv before dark-onset, and food intake was measured after 24-hr. Results are expressed as 
means ± SEM. Significant differences between groups are indicated by the differences in 
letter symbols. ANOVA showed that there is significant differences in food intake (Fs,42  
= 22.92, p =0.0001).
Corticosterone-replacement in ADX rats attenuated leptin- induced fat pad weight loss, 
and permitted weight gain to the level of saline-treated corticosterone-replaced ADX rats. 
As with the slight body weight change, corticosterone-replaced ADX rats had similar 
epididymal fat pad weights regardless of leptin treatment. In sham-operated rats, 
however, leptin treatment significantly reduced the weight of the liver compared to 
saline. Furthermore, leptin treatment consistently caused a decrease in the liver weights in 
all groups, but the decreases were not significant.
To determine the effects o f ADX and leptin treatment on serum hormones, 
changes in serum insulin, corticosterone, leptin, glucose and NEFA levels in ADX,
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Table 6.1. Body weight, liver and epididymal WAT weights and serum hormone levels o f adrenalectomized, adrenalectomized and 
steroid replaced, and sham-operated lean Sprague Dawley rats
ADX ADX+R SHAM
Saline LeDtin Saline Leptin Saline Leptin
Initial Body weight (g) 277.6 ±25,5 316,2±4,4 244.7 ± 11.6 241.1 ± 13.1 289.5 ±18.9 311.2 ± 11,4
Final body weight (g) 275.2 + 24.1 295,1 ±3.4 239.1 ±10.8 225.9 ± 10.3 296.8 ± 18.8 302.7 ± 11.2
Body weight gain (g) -2.5 ± l,6a,b -21,1 ± l,2b,c -5.6 ± l . l b,c -15.2 ± 3,0C 7,4 ± 1.6“ -8.5 ± 0.7b,c
Epididymal WAT (g) 2.42 ± 0 .18a,b 1.64 ± 0.21b 2.03 ±0 .16b 1,73 ± 0 .2 lb 2,96 ± 0,37a 2,25 ± 0.22a,b
Liver (g) 9,95 ± 0.76a,b 8.81 ±0.95b’c 9.56 ± 0.38a,b,c 7.95 ± 0.48c 10.68 ±0.54a 8,57 ± 0.27b,c
Corticosterone (ng/ml) 18.7 ± 18.7d 29,2 ± 19.4c,d 304.4 ± 37.6° 350,3 ± 66.6° 568.2 ± 58.2b 704.3 ± 40.5a
Insulin (ng/ml) 0.56 ± 0.18b 0.63 ± 0,22b 0.95 ±0.17a,b 1.01 ±0.1 la,b 1,82 ± 0.4a 0.93 ± 0.37a,b
Leptin (ng/ml) 0.55 ± 0.18c 1.53 ± 0.8lb>c 0.42 ± 0.1 l c 3.6 ± 1.53a,b 1,27 ± 0,35b’° 4.91 ± l,55a
Glucose (mg/dL) 114 ± 14,8h 130.6 ±5 ,3a’b 129.8 ±3 .3a,b 125.8 ± 3 .8b 139,4 ±2 .4a,b 141,8 ±4 .6a
NEFAs (mmol/L) 0.26 ± 0.04a,b 0,31 ±0.05a'b 0.21 ±0,03b 0 .30±0,03a,b 0,30 ± 0.03a,b 0.38 ±0,04“
Values are means ± SEM, Significant difference between groups is indicated by the differences in letter symbols, with P < 0,05, The 
were 6-8 animals in each experimental group, ANOVA showed significant differences in body weight change (F5i42 = 6,16, p = 0,002), 
epididymal WAT (Fs.^z = 3,84, p = 0.005), liver (Fj>42 = 3.84, p = 0.02), corticosterone (F5i42 = 21.17, p = 0,0001), leptin levels ( F ^  = 
4.03, p = 0,01), and glucose (F5i42 = 2,56, p = 0,01), but not in insulin (Fs,42 = 2.37, p = 0.07), and NEFAs (Fsi42 = 2,37, p = 0,06),
steroid-replaced and sham-operated rats were measured (Table 6.1). In sham-operated 
rats, leptin treatment reduced plasma insulin levels by almost 50% compared to saline 
treated sham-operated rats. ADX significantly reduced plasma insulin levels compared to 
sham-operated rats. However, leptin treatment o f ADX rats had no further effects on 
serum insulin. Corticosterone-replacement showed a tendency to increase plasma insulin 
levels, even though they did not increase to the level o f sham-operated rats. In ADX and 
replaced rats, plasma corticosterone levels were equivalent regardless o f leptin treatment. 
ADX rats had very low corticosterone levels. Sham-operated and ADX-rep laced rats had 
higher levels o f corticosterone, which were also equivalent regardless o f leptin treatment. 
Replacement of ADX rats with corticosterone increased serum corticosterone to levels 
that were approximately 50% of those seen in the sham-operated rats. Plasma leptin 
levels varied not only as a result o f leptin infusion, but also in association with 
corticosterone depletion and replacement. ADX significantly reduced the levels of 
plasma leptin. However, replacement with corticosterone did not elevate plasma leptin 
levels in saline treated rats. Plasma leptin was increased in ADX rats infused with leptin 
and replacement with corticosterone also showed an increase in plasma leptin levels. The 
increment in leptin levels in leptin-treated rats was far greater in sham-operated rats 
compared to ADX rats, with the replaced rats showing intermediate levels.
To determine the effects of ADX and leptin treatment on the hypothalamic leptin 
receptor levels, we used a ribonuclease protection assay to measure mRNA expression 
for the leptin receptor isoforms in ADX, steroid-replaced and sham-operated rats (Figure 
6.3). ADX significantly increased ObR-L mRNA levels compared to sham-operated rats 
(0.104 ± 0.02 vs 0.051 ± 0.009, p < 0.05). Corticosterone replacement of ADX rats did
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not have an effect on the ObR-L mRNA expression compared to ADX rats. Leptin 
treatment had no effect on the levels of ObR-L mRNA in any experimental groups. ADX 
significantly increased ObR-S mRNA levels compared to sham-ADX rats (0.078 ± 0.012 
vs 0.047 ± 0.008, p < 0.05). Corticosterone replacement did not alter these ADX-induced 
increases in ObR-L and ObR-S mRNA levels. In sham-operated rats, leptin treatment did 
not have an effect on the ObR-S mRNA expression compared to saline treated rats (0.048 
± 0.008 vs 0.038 ± 0.003, p > 0.05). Leptin treatment had no effect on the levels of ObR- 
S mRNA in any experimental groups.
To assess the effects of ADX and leptin treatment on hypothalamic STAT-3 
mRNA levels, semi-quantitative RT-PCR was used to measure STAT-3 mRNA 
expression (Figure 6.4). The hypothalamic STAT-3 mRNA levels were increased 
following ADX compared to sham-operated rats (1.30 ± 0.05 vs 0.78 ± 0.10, p < 0.001). 
Glucocorticoid-replacement of ADX-saline treated rats reduced the levels o f  STAT-3 
mRNA (0.99 ± 0.08 vs 1.30 ± 0.05, p< 0.05). Leptin treatment o f ADX rats had no 
further effect on the STAT-3 mRNA expression compared to saline treatment (1.28 ± 
0.05 vs 1.30 ± 0.05). Leptin treatment o f sham-operated rats reduced STAT-3 mRNA 
expression compared to saline treated rats (0.56 ± 0.05 vs 0.78 ± 0.08, p< 0.05).
To assess the effects of ADX and leptin treatment on hypothalamic STAT-3 total 
protein levels, immunoprecipitation and Western blotting was used to measure STAT-3 
protein levels in whole hypothalamic lysates (Figure 6.5). ADX increased the levels o f 
total STAT-3 protein levels compared to sham-operated rats. Leptin treatment o f ADX 
rats increased the levels of STAT-3 compared to saline treated rats. In steroid-replaced 
ADX rats, the levels o f STAT-3 protein were variable, but replacement with
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corticosterone caused a decrease in STAT-3 protein in 75% of the replaced samples. 
Unlike the effects o f leptin on the STAT-3 mRNA levels, leptin treatment had no effect 
on the levels o f  STAT-3 protein in sham-operated rats. This discrepancy may be due to 
differences in the times of sampling for the mRNA and protein, where the rate of 
transcription would have been different between these groups at the time o f sampling.
We then investigated whether the increase in STAT-3 protein levels due to ADX 
was associated with increased STAT-3 activity. Therefore, nuclear protein extracts were 
immunoprecipitated with STAT-3 polyclonal antibody to measure phosphorylation of 
STAT-3 protein (Figure 6.6). Leptin treatment increased STAT-3 protein 
phosphorylation in the hypothalamus of sham-operated rats compared to saline-treated 
rats. ADX induced constitutive STAT-3 protein tyrosine phosphorylation compared to 
sham-operated saline-treated rats. Leptin treatment of ADX rats further increased nuclear 
STAT-3 protein phosphorylation compared to leptin-treated sham operated rats. Steroid 
replacement of adrenalectomized rats returned the levels of STAT-3 protein 
phosphorylation to that o f  sham-operated saline treated rats. However, leptin effects on 
STAT-3 protein phosphorylation were abolished. In order to make sure that equal levels 
o f protein were loaded on the gel and that efficiency of transfer was optimum, 
membranes were stripped and re-blotted with the STAT-3 polyclonal antibody. Western 
blotting with STAT-3 antibody verified that the tyrosine phosphorylated 92-kDa protein 
was STAT-3 and that each lane contained the same amounts of the STAT-3 protein. This, 
therefore, showed that ADX and leptin treatment induced phosphorylation o f STAT-3, 
which is then translocated to the nucleus to affect transcription of STAT-3-dependent 
genes.
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Figure 6.3. Ribonuclease protection assay to determine the effect of ADX and leptin 
treatment on leptin receptor mRNA expression. Total RNA was extracted from individual 
hypothalami o f rats treated icv with either saline vehicle or 2.5 pig leptin. RNA was 
hybridized with 32P-labeled antisense probes for ObR and 3-actin and processed as 
described in the general methods. A) A representative RPA for leptin receptor isoforms, 
and B) histograms showing the quantification of the ObR-L and ObR-S mRNAs, where 
the open-bars are saline-treated and dark-bars are leptin-treated samples. M is century 
RNA molecular markers. Data are presented as means ± SEM. * p < 0.05 compared to 
sham-operated rats.
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Figure 6.4. Effects of ADX and leptin treatment on the hypothalamic STAT-3 mRNA 
expression. Total RNA was extracted from hypothalami of ADX, ADX-steroid replaced 
and sham-operated rats. RNA was reverse transcribed and PCR amplified using STAT-3 
specific primers. PCR products were fractionated in a 1.5% agarose gel for 2 hr. A) A 
representative agarose gel showing the 715-bp STAT-3 PCR product and cyclophilin as 
internal standard, and B) histogram showing the quantification of the STAT-3 mRNA. 
Open-bars are saline-treated and dark-bars are leptin-treated samples. Data are presented 
as means ± SEM for two independent observations. * p < 0.05, ** p < 0.001 and p < 
0.0001 compared between indicated groups.
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Figure 6.5. Effects o f ADX and leptin treatment on hypothalamic STAT-3 protein levels. 
Total STAT-3 protein levels were analyzed by immunoprecipitating STAT-3 from 
hypothalamic lysates o f rats treated with either saline vehicle or 2.5 pg leptin using 
STAT-3 antibody, followed by Western blotting and analysis with STAT-3 antibody. A) 
Immunoblot of STAT-3. B) Densitometric values of the immunoblot. Open-bars are 
saline-treated and dark-bars are leptin-treated samples. Data are presented as means + 
SEM. * p < 0.05 compared to sham-operated rats.
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Figure 6.6. Effects of ADX and leptin treatment on tyrosine phosphorylation o f STAT-3 
protein. Tyrosine phosphorylation o f STAT-3 was analyzed by immunoprecipitating 
STAT-3 from hypothalamic nuclear extracts obtained from ADX, ADX-rep laced and 
sham-operated rats treated with either saline vehicle or 2.5 pg leptin using STAT-3 
antibody, followed by Western blotting and analysis with antiphosphotyrosine (pY20) 
antibody. The membranes were stripped and reprobed with STAT-3 antibody. A) 
Immunoblot o f phosphotyrosine and STAT-3. B) Densitometric values o f the 
immunoblot. Open-bars are saline-treated and dark-bars are leptin-treated samples. Data 
are means ± SEM. * p < 0.05 compared between indicated groups.
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Nuclear extracts were also used to examine the effects o f ADX and leptin 
treatment on STAT-3 DNA binding activity on the sis-inducible element (SIE) from a c- 
fo s  promoter (m67-SIE) by using gel shift assays (Figure 6.7). The DNA-protein 
complex was inhibited by an excess of unlabeled m67-SIE oligonucleotide. Supershift 
analysis showed that the complexes bound to the m67-SIE in response to ADX and leptin 
treatment were composed o f STAT-3. Leptin treatment o f sham operated rats enhanced 
the activation o f STAT-3 compared to saline treated rats. STAT-3 phosphorylation was 
already enhanced in ADX rats compared to sham-operated saline treated rats, which 
suggests constitutive DNA binding activity. This STAT-3 DNA binding activity was not 
further upregulated by leptin treatment, but rather decreased. Corticosterone replacement 
o f ADX rats did not effect DNA binding activity, but again leptin treatment reduced 
DNA binding activity.
SOCS proteins represent a family o f negative regulators of cytokine signaling that 
switch off the cytokine signal by binding to the SH2 domain o f JAK proteins, thereby 
inhibiting the activation of STAT proteins. This family consists of eight known members, 
namely, the cytokine-inducible SH2 proteins (CIS) and the suppressor of cytokine 
signaling 1 to 7 (SOCS-1-7). Recently, peripheral administration o f leptin to ob/ob mice 
was shown to rapidly induce SOCS-3 mRNA in the hypothalamus, but this effect was 
absent in db/db mice (Bjorbaek, et al., 1998; Emilsson, et al., 1999). The effects o f ADX 
and leptin treatment on SOCS-3 mRNA expression (Figure 6.8) and protein levels 
(Figure 6.9) were examined by using semi-quantitative RT-PCR and Western blot 
analysis o f immunoprecipitated SOCS-3, respectively. Leptin treatment o f sham-operated
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Figure 6.7. Effects of ADX and leptin treatment on the DNA binding activity o f STAT-3 
protein. Nuclear extracts were incubated with 32P-labeled m67-SIE and fractionated on a 
5% nondenaturing PAGE. A) A representative EMSA gel, and B) densitometric 
quantification of the STAT-3-DNA complex. Open bars are saline treated and dark bars 
are leptin treated samples. Lane 1 = DNA only, Lane 2 = DNA and unrelated DNA, lane 
3 = competition with 100-fold molar excess of cold m67-SIE, lane 4 and 5 = STAT-3 
antibody competition. Data are presented as means ± SEM. * p < 0.05 and ** p < 0.005 
compared to indicated groups.
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rats had no effect on SOCS-3 mRNA expression, but increased SOCS-3 protein levels. 
ADX decreased the SOCS-3 mRNA expression and protein levels compared to sham- 
operated rats. Glucocorticoid-replacement of ADX rats returned the levels o f SOCS-3 
mRNA and protein to that of sham-operated rats. Leptin treatment o f ADX or ADX- 
replaced rats had no significant effects on SOCS-3 mRNA, but increased protein levels.
Activation o f OBR-L by leptin treatment has recently been shown to induce 
tyrosine phosphorylation o f the SH2-containing phosphotyrosine phosphatase 2 (SH­
PTP-2 or SHP-2) and its recruitment to the cytoplasmic domain o f OBR-L (Carpenter, et 
al., 1998). SHP-2 has also been shown to negatively regulate STAT3-mediated gene 
induction after activation o f OBR-L (Carpenter, et al., 1998). Therefore, the effects of 
ADX and leptin treatment on the protein levels and phosphorylation o f  SHP-2 were 
examined (Figure 6.10). ADX had no effect on the levels and phosphorylation of SHP-2 
protein in all experimental groups. However, leptin treatment showed some increase in 
tyrosine phosphorylation o f SHP-2 protein
NPY, a potent stimulator of food intake that is down-regulated by leptin and 
glucocorticoids, mediates leptin’s action in the CNS (Rohner-Jeanrenaud, et al., 1996). 
The effects o f ADX and leptin treatment on the expression of hypothalamic NPY mRNA 
were determined by using Northern blot analysis (Figure 6.11), adrenalectomy 
significantly reduced NPY mRNA levels and this effect was reversed by corticosterone 
replacement. Leptin treatment of sham-operated and corticosterone replaced 
adrenalectomized rats also significantly reduced NPY mRNA expression compared to 
saline-infused controls. However, no further decrease in NPY mRNA expression was 
observed in ADX rats treated with leptin.
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Figure 6.8. Effects o f ADX and leptin treatment on the hypothalamic SOCS-3 mRNA 
expression. RNA was reverse transcribed and PCR amplified using SOCS-3 specific 
primers. PCR products were fractionated in a 1.5% agarose gel for 2 hr. A) A 
representative agarose gel showing the 450-bp SOCS-3 PCR product and cyclophilin as 
internal standard, and B) histogram showing the quantification of the SOCS-3 mRNA. 
Open-bars are saline-treated and dark-bars are leptin-treated samples. Data are presented 
as means ± SEM for two independent observations. * p < 0.05 and ** p < 0.001 between 
indicated groups.
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Figure 6.9. Effects of ADX and leptin treatment on SOCS-3 protein levels. SOCS-3 
protein levels were analyzed by immunoprecipitating SOCS-3 from hypothalamic cytosol 
extracts obtained from ADX, ADX-replaced and sham-operated rats treated with either 
saline vehicle or 2.5 jig leptin using SOCS-3 antibody (gift o f Dr. Jeffrey Flier, Harvard 
Medical School, Boston, MA), followed by Western blotting and analysis with SOCS-3 
antibody (Santa Cruz Biotechnology, Inc.). A) A representative immunoblot of SOCS-3 
protein, and B) densitometric quantification of the immunoblot. Open-bars are saline- 
treated and dark-bars are leptin-treated samples. Data are presented as mean ± SD. * p < 
0.05 and ** p < 0.005 compared between indicated groups.
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Figure 6.10. Effects of ADX and leptin treatment on SH-PTP2 protein phosphorylation 
and levels. Tyrosine phosphorylation o f SH-PTP2 was analyzed by immunoprecipitating 
SH-PTP2 from hypothalamic cytosol extracts obtained from ADX, ADX-replaced and 
sham-operated rats treated with either saline vehicle or 2.5 pg leptin using SH-PTP2 
antibody, followed by Western blotting and analysis with antiphosphotyrosine (4G10) 
antibody. The membranes were stripped and reprobed with SH-PTP2 antibody. A) 
Representative immunoblots o f phosphotyrosine and SH-PTP2 protein, and B) 
densitometric quantification of the immunoblots. Open-bars are saline-treated and dark- 
bars are leptin-treated samples. Data are presented as mean ± SEM. No statistical 
significance was found between the groups.
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Figure 6.11. Effects o f ADX and leptin treatment on NPY gene expression. A) 
representative Northern blots of NPY and P-actin mRNA. (B) Histogram showing the 
quantification o f NPY mRNA relative to P-actin. Total hypothalamic RNA (20 pg/lane) 
was analyzed by Northern blotting. Relative expression o f NPY mRNA was determined 
by hybridization with 32P-labeled NPY and P-actin cDNAs. Bands were quantified using 
the ImageQuant software. Data are expressed as means ±  SEM. * p < 0.05 compared to 
indicated groups.
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6.4 DISCUSSION
The key findings of this study were: 1) that the feeding response to leptin is 
sensitive to adrenal glucocorticoids, their absence enhancing the anorectic response to 
leptin; 2) that mRNA expression of the leptin receptor isoforms is increased by 
adrenalectomy; 3) that adrenalectomy increased STAT-3 mRNA expression and total 
protein levels; 4) that leptin treatment of sham-operated rats induced phosphorylation of 
STAT-3, and adrenalectomy induced constitutive phosphorylation of STAT-3 protein; 5) 
that adrenalectomy and leptin treatment induced STAT-3 DNA binding activity, but there 
was no synergy between adrenalectomy and leptin treatment; 6) that adrenalectomy 
decreased the expression of SOCS-3 mRNA and protein levels, whereas leptin treatment 
increased SOCS-3 protein levels; and 7) that the increased sensitivity to leptin upon 
adrenalectomy is not due to further changes in NPY mRNA expression.
Our original observations that adrenalectomy increases the expression o f both the 
long-form and short-form leptin receptors in the hypothalamus of obese Zucker rats 
suggested that adrenal glucocorticoids might modulate their effect on leptin response 
through modulation of leptin receptor activity (Madiehe, et al., 1999). Leptin affects food 
intake and body weight by actions on the receptors in the hypothalamus, and 
adrenalectomy has been shown to reduce food intake and stop the development o f 
obesity. Our study is consistent with the published data (Zakrzewska, et al., 1997) which 
showed that adrenalectomized rats have increased sensitivity to leptin treatment. The 
mechanism by which adrenalectomy increases leptin sensitivity was the subject o f this 
study. We hypothesized that glucocorticoids modulate the leptin receptor expression and 
activity in the hypothalamus. To identify the components o f the leptin signal transduction
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pathway modulated by glucocorticoids, we investigated the effects o f adrenalectomy on 
either gene expression, protein phosphorylation, or DNA binding activity o f several 
candidate proteins, which included leptin receptor, STAT-3, SOCS-3, SHP-2 and NPY.
In this dissertation, we show that adrenalectomy caused an increase in the levels 
o f mRNA for the long and short forms of the receptor. This was associated with a 
reduction in circulating leptin levels, which may suggest that the change in receptor 
expression may help to enhance the effects of leptin on food intake when leptin is 
administered directly into the brain. The data could also be interpreted as reflecting that 
leptin can modulate the expression of its own receptors, with receptor gene expression 
increasing when leptin levels decrease. However, if this is the case it appears to be a 
delayed response in the absence of glucocorticoids, since acute treatment o f 
adrenalectomized rats with leptin, did not reduce the levels o f  either ObR-L or ObR-S 
mRNA. The increase in leptin receptor population in the hypothalamus may lead to 
increased receptor activity and thereby cause pronounced effects o f leptin action.
Leptin receptors have been identified in NPY/AGRP- and POMC/CART- 
containing neurons of the ventromedial and ventrolateral ARC, respectively (Elias, et al, 
1998; Hakansson & Meister, 1998), and in MCH- and orexin-containing neurons o f the 
lateral hypothalamus (Elias, et al., 1998; Elmquist, et al., 1997; Elmquist, et al., 1998). 
This suggested that these messengers are mediators o f  the actions of leptin in the 
hypothalamus. Recent functional studies showed that NPY, AGRP, POMC-derived 
peptides, CART, MCH and orexins are all important regulators o f food intake (Sahu, 
1998; Marsh, et al., 1999; Hollopeter, et al., 1998b; Scrocchi, et al., 1997; Goldstone, et
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al., 1997). The exact mechanism by which leptin activates these targets is relatively 
unknown.
Leptin has been shown to control insulin secretion from pancreatic (3-cells 
(Kieffer, et al., 1997; Ookuma, et al., 1998; Poitout, et al., 1998; Pallett, et al., 1997). 
Furthermore, central administration o f leptin inhibits insulin secretion and increases 
insulin sensitivity of peripheral tissues directly (Kamohara, et al., 1997; Cusin, et al., 
1998; Minokoshi, et al., 1999; Haque, et al., 1999). Leptin receptors were identified on 
pancreatic |3-cells (Kieffer, et al., 1996; Islam, et al., 1997; Emilsson, et al., 1997), and it 
was later showed that Ieptin-mediated inhibition of insulin secretion was by activation of 
ATP-sensitive K+ channels (Kieffer, et al., 1997). Seufert and colleagues (1999), showed 
that leptin inhibited transcription of the preproinsulin by altering transcription factor 
binding to sequences upstream from the elements that confer glucose responsivity to the 
rat insulin I gene promoter. Therefore, leptin exerts inhibitory effects on both insulin 
secretion and insulin gene expression in pancreatic (3-cells. In this study, leptin decreased 
insulin levels in sham-operated rats, but not in ADX rats. This may suggest that leptin 
effects on insulin secretion may require circulating glucocorticoids.
Leptin regulates food intake and body weight via interactions with hypothalamic 
neuronal circuits expressing leptin receptors. The long isoform o f  ObR acts through the 
JAK-STAT pathway of signal transduction. Recent evidence suggests that STAT-3 
transcription factor mediates leptin’s action in the hypothalamus (Vaisse, et al., 1996; 
Rosenblum, et al., 1996; Baumann, et al., 1996; McCowen, et al., 1998; Hakansson & 
Meister, 1998). In our study, immunoblotting analysis of hypothalamic nuclear extracts 
with pY20 antibody demonstrated leptin-induced STAT-3 phosphorylation and DNA
131
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
binding activity, consistent with the literature (Vaisse, et al., 1996; McCowen, et al.,
1998). ADX induced a similar, but constitutive phosphorylation o f STAT-3 and DNA 
binding activity. This constitutive phosphorylation of STAT-3, but not the DNA binding 
activity, was increased by leptin treatment. It was rather puzzling that constitutive STAT- 
3 tyrosine phosphorylation after ADX and leptin treatment did not translate into increased 
DNA binding. This finding might be explained if the excess phosphorylated STAT-3 was 
bound by PIAS3, a recently described protein inhibitor of activated STAT-3 (Chung, et 
al., 1997). PIAS3 blocks the DNA binding activity o f STAT-3, thus inhibiting STAT-3 
mediated gene activation. We did not study other ST AT proteins, especially STAT-1, 
because McCowen and colleagues (1998) showed that leptin did not increase the 
phosphorylation o f STAT-l and STAT-5, despite abundant expression o f  these signaling 
molecules in the hypothalamus.
Cytokines are secreted proteins that regulate important cellular responses, with 
well defined key events in cytokine signal transduction. Cytokines induce receptor 
dimerization, leading to activation of members of the JAK family o f cytoplasmic tyrosine 
kinases. In turn, members of the STAT family of transcription factors are recruited and 
phosphorylated, dimerize and increase the transcription of genes with STAT recognition 
sites in their promoters. These cellular responses to cytokines are tightly controlled, but 
little is known about how cytokine signal transduction is switched off. Few molecules 
have now been identified which are able to switch these signals off. The suppressors of 
cytokine signaling (SOCS) proteins are a new family o f negative regulators o f cytokine 
signal transduction. The expression of SOCS proteins is induced by cytokines, including 
leptin (Bjorbaek, et al., 1998). Once expressed, SOCS down-regulate JAK/STAT
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pathways and hence modulate the biological response. The leptin-dependent increase of 
SOCS-3 mRNA was seen in areas of the hypothalamus expressing high levels o f  the long 
form OB-R (Bjorbaek et al., 1998; Emilsson, et al., 1999). Furthermore, SOCS-3 was 
shown to block leptin-induced signal transduction in mammalian cell lines, suggesting 
that SOCS-3 is a leptin-inducible inhibitor of leptin signaling, and suggested SOCS-3 to 
be a potential mediator of leptin resistance in obesity (Bjorbaek, et al., 1998). In our 
study, leptin treatment of sham-operated rats increased SOCS-3 protein levels in the 
hypothalamus, which is consistent with the literature (Bjorbaek, et al., 1998; Emilsson, et 
al., 1999). In contrast, adrenalectomy decreased SOCS-3 mRNA expression and SOCS-3 
protein levels. This decrease in SOCS-3 potentially provides a mechanism by which 
leptin resistance could be alleviated.
In support of this proposal for downregulation of SOCS-3 after adrenalectomy, 
we searched the rat SOCS-3 (GenBank AJ249240) upstream region and identified a 
putative glucocorticoid response element (GRE) with a 393-agaaccaggca-^f03 bases 
sequence. This confirms the possibility that SOCS-3 can be upregulated by 
glucocorticoids. This upstream region also contains two putative STAT-3 binding 
elements that have been characterized (Auernhammer, et al., 1999), and showed to 
regulate SOCS-3 expression induced by LDF. Our studies show that, in the absence of 
glucocorticoids, leptin activation of STAT-3 led to a moderate increase in SOCS-3 
protein levels, whereas sham-operated rats showed a much greater stimulation of SOCS-3 
after leptin treatment. This could suggest that STAT-3 activation and glucocorticoids act 
in a concerted manner to regulate SOCS-3.
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In trying to establish the mechanism of regulation o f  SOCS-3 expression by leptin 
and the mechanism by which SOCS-3 inhibits leptin action, Bjorbaek, et al. (1999) stably 
transfected CHO cells with the long form o f the leptin receptor. In these cells, leptin 
induced transient expression of endogenous SOCS-3 mRNA and protein. Leptin 
signaling was blocked by pretreatment of cells with leptin, which correlated with 
increased SOCS-3 expression. Forced expression of SOCS-3 in OBR-L transfected COS 
cells resulted in inhibition o f leptin-induced tyrosine phosphorylation of JAK2, providing 
further evidence that SOCS-3 is a leptin-regulated inhibitor o f leptin signaling in vivo 
(Bjorbaek, et al., 1999).
Activation o f OBR-L has been reported to induce the tyrosine phosphorylation o f 
the tyrosine phosphatase SH2-containing phosphatase 2 (SH-PTP2 or SHP-2) and that 
SHP-2 binds to OBR. Mutation of Tyr986 to Phe of OBR-L was shown to abrogate SHP- 
2 phosphorylation and binding to the receptor, but this mutation led to dramatically 
increased gene induction mediated by STAT3. Carpenter and colleagues (1998) indicated 
that SHP-2 is a negative regulator of STAT3-mediated gene induction after activation o f  
OBR, raising the possibility that blocking the interaction of SHP-2 with OBR could 
overcome leptin resistance and boost leptin's weight-reducing effects in obese individuals 
(Carpenter, et al., 1998). In our study, adrenalectomy did not have any effect on SHP-2 
protein phosphorylation and levels. This suggests that, upon activation of OBR-L by 
ADX, SHP-2 is inactivated and its interaction with the leptin receptor is reduced. This 
would lead to increased STAT-3 protein activation, consistent with the notion that 
inhibition o f SHP-2 phosphorylation will lead to increased leptin action through STAT-3.
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Li and Friedman (1999) cotransfected OBR-L, JAK2 and SHP-2 into 293T cells 
to study the mechanism by which SHP-2 inhibits leptin induced STAT-3 activation. They 
showed that leptin treatment resulted in direct binding o f SHP-2 to OBR-L and that the 
bound SHP-2 is itself tyrosine phosphorylated after leptin treatment. In the absence of 
SHP-2 phosphorylation, the level o f JAK2 phosphorylation was increased. Tyrosine 
phosphorylation of the OBR-L and STAT3 were not affected by phosphorylation of SHP- 
2, suggesting that activation o f  SHP-2 by the leptin receptor results in a decreased 
phosphorylation of JAK2 and may act to attenuate leptin signal transduction (Li and 
Friedman, 1999). This could explain, at least in part, how ADX induced increased STAT- 
3 phosphorylation compared to sham-operated rats. During adrenalectomy, no increased 
phosphorylation of the SHP-2 was observed, indicating that ADX does not modulate 
tyrosine phosphorylation o f SHP-2. Leptin treatment increased SHP-2 tyrosine 
phosphorylation, and ADX caused the constitutive phosphorylation of STAT-3. The latter 
could be the driving force in the failure o f SHP-2 to attenuate leptin signaling.
Initially, among several mediators o f leptin action within the hypothalamus, NP Y 
was the most compelling (Erickson et al., 1996). Several properties suggested that it 
might be an essential conduit for the leptin signal. Injection of NPY centrally evokes 
virtually all o f the features o f leptin deficiency, including hyperphagia, decreased BAT 
thermogenesis, and hyperinsulinemic insulin resistance. Repetitive injection causes 
obesity. Arcuate nucleus NPY is increased by starvation and is elevated in the ob/ob 
mouse, both o f which are restored to normal by leptin treatment. Recently, leptin 
receptors were found in cells o f  the ARC containing NPY mRNA or POMC mRNA 
(Mercer, et al., 1996; Meister, 2000). Following leptin administration, NPY cells in the
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ARC did not express Fos but expressed SOCS-3 mRNA. In contrast, leptin induced both 
Fos and SOCS-3 expression in POMC neurons, many of which also innervated the LHA. 
These findings suggested that leptin directly and differentially engages NPY and POMC 
neurons that project to the LHA, linking circulating leptin and neurons that regulate 
feeding behavior and body weight homeostasis (Thornton, et al., 1997; Elias, et al.,
1999). Recent studies have shown that a-MSH, produced from POMC precursors, 
decreases food intake (Brown, et al., 1998). In the arcuate nucleus, which also expresses 
NPY, approximately 30% of the POMC neurons express the mRNA for the leptin 
receptor long form, and arcuate POMC mRNA expression is regulated positively by 
leptin (Thornton, et al., 1997; Mercer, et al., 1996). Thus, one can envision a loop in 
which rising leptin drives the increase in arcuate POMC expression, which then projects 
a-M SH containing axons to cell bodies elsewhere in the hypothalamus, causing 
decreased food intake. Both ADX and leptin administration directly into the brain 
decrease NPY gene expression and release. Treatment o f ADX rats, which already have 
low NPY levels, with leptin can further decrease orexigenic neuropeptides (NPY and 
AGRP) and increase anorexigenic ones (POMC and CART) by acting directly on the 
leptin receptors found in these neurons.
Leptin is reported to have effects in peripheral tissues that are independent of its 
central effects on food intake and body weight. ADX causes a decrease in white adipose 
tissue depots and size (Edens, et al., 1999), whereas corticosterone replacement increases 
white adipose tissue weight gain. Leptin treatment, probably through sympathetic 
stimulation of white adipose tissue, causes fat loss which is modulated by the inhibitory 
effect of corticosterone on sympathetic outflow. This increased sympathetic outflow to
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these depots may further be increased by ADX, and therefore have an increased 
sensitivity to leptin in the absence o f glucocorticoids. Furthermore, leptin has been shown 
to decrease lipid synthesis (Edens, et al., 1999). ADX could enhance the adipocyte 
response to leptin on lipid synthesis and fat mobilization. Moreover, Sarmiento and 
colleagues (1997) showed that the peripheral effects o f leptin include increased 
thermogenesis and lipid oxidation in brown fat coupled with increased lipolysis and 
decreased fat synthesis in white and brown fat, which lead to a rapid reduction in  the 
body weight and adiposity o f mice (Sarmiento, et al., 1997). It is, therefore, conceivable 
that the sensitivity to leptin after ADX, could be due to the combined inhibitory effects of 
leptin on WAT leptin production and the disappearance of WAT, as induced by both 
ADX and leptin, but it may also be a consequence of the energy imbalance that is 
induced by leptin in the absence of glucocorticoids.
The induction of SOCS genes, by STAT elements present in the SOCS promoter, 
has so far been restricted to activators o f  the cytokine receptor family, such as LIF, EL-6, 
interferon y, GH and leptin. Although STAT activation is the hallmark o f cytokine action, 
they can be activated by other agents, such as angiotensin n, EGF and PDGF. Recent 
evidence, therefore, indicates that STAT proteins can be activated by a variety o f receptor 
and non-receptor protein-tyrosine kinases (Ihle, 1996). Unlike cytokine-induced 
activation of STATs, where JAKs are known to play a pivotal role in phosphorylating 
STATs, the mechanism for receptor protein-tyrosine kinase-mediated activation of 
STATs remains elusive. Insulin modulates cellular metabolism by modifying the activity 
and intracellular localization of several proteins, and by modulating transcription 
(O’Brien & Granner, 1996). Recently, insulin has been shown to induce tyrosine
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phosphorylation and DNA binding activity o f  STAT-5B in a perfused rat liver (Chen, et 
al., 1997), showing its involvement in the regulation o f transcription by STAT factors.
Moreover, insulin via its receptor with intrinsic tyrosine kinase activity has now 
been shown to specifically induce SOCS-3 mRNA expression and protein translocation 
from the cytoplasm to the cell membrane in 3T3-L1 adipocytes (Emanuelli, et al., 2000). 
This expression o f SOCS-3 was potentiated by STAT-5B activation, but the authors did 
not rule out the possibility that STAT-3 or other transcription factors stimulated by 
insulin might play a role in this mechanism. Caldenhoven and colleagues (1996) showed 
that insulin induced SOCS-3 expression in COS-7 cells that were not transfected with 
STAT-5B, indicating that the induction could result from low levels o f  endogenous 
STAT-3 found in these cells. SOCS proteins generally inhibit cytokine signaling through 
inhibition o f JAK kinase, but insulin receptor kinase has been shown to activate STAT- 
5B independent of JAK (Chen, et al., 1997). Emanuelli and colleagues (2000), therefore, 
proposed that inhibition o f STAT-5B occurs through competition between SOCS-3 and 
STAT-5B for binding to the insulin receptor, and not through inhibition o f  JAK kinase. 
This is quite intriguing for two reasons. First, not only leptin- and CNTF-treatments 
induce SOCS-3, but insulin does as well, and all three of these molecules are recognized 
as satiety factors (Woods, et al., 1998). This insulin effect, however, could provide an 
explanation for the paradox of increased levels o f SOCS-3 in leptin-deficient ob/ob mice, 
which are hyperinsulinemic. It remains to be evaluated how insulin mediates its effects 
on SOCS-3 expression in vivo. Second, leptin and CNTF control feeding behavior and 
inhibit insulin release from pancreatic P-cells (Harvey, et al., 1997; Kieffer, et al., 1997; 
Gloaguen, et al., 1997). Therefore, if insulin induces SOCS-3 expression in vivo, leptin-
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or CNTF-induced inhibition of insulin release should cause a decrease in SOCS-3 
expression. But, this is not the case. On the other hand, insulin stimulates the production 
o f leptin. It is therefore, conceivable that insulin administration in these studies increased 
the endogenous levels o f  leptin, which in turn increased the expression o f SOCS-3. 
Alternatively, one can foresee a situation under hyperinsulinemic conditions, in which 
insulin induces the expression of SOCS-3 which can then negatively regulate the 
cytokine signal transduction of leptin. In order for leptin to overcome the inhibitory 
effects o f SOCS-3, more and more endogenous leptin is released, and this consequently 
leads to leptin resistance.
In studies described in this dissertation, leptin treatment of sham-operated rats 
caused a decrease in serum insulin levels, but an increase in SOCS-3 mRNA expression 
as well as an increase in SOCS-3 protein levels. Furthermore, leptin treatment o f ADX 
rats significantly increased SOCS-3 protein levels despite the low levels o f insulin in 
these animals. Chavez and colleagues (1997) showed that ADX also increased sensitivity 
to central insulin administration, similar to that observed with leptin treatment of ADX 
rats in studies described in this dissertation and those o f Zakrzewska and colleagues 
(1997). Whether the insulin sensitivity of ADX rats is due to increased STAT activation 
remains to be investigated. The three studies suggest that the absence of glucocorticoids 
increases the brain’s sensitivity to leptin and insulin, and that these hormones act to lower 
food intake and body weight through a glucocorticoid-sensitive mechanism, making 
glucocorticoids the more important in the regulation o f  obesity.
Central administration of NPY causes hyperphagia, hyperinsulinemia, and 
obesity, a response that is prevented by prior adrenalectomy in rats (Stanley, et al. 1989).
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NPY-induced food intake was similar in ADX and control rats after acute icv injection of 
NPY. Injection o f NPY caused a significant increase in plasma insulin in control rats, but 
this effect was absent in ADX rats in which basal plasma insulin levels were also lower 
than controls. This suggested that glucocorticoids are necessary for acute NPY-mediated 
insulin release which are absent in ADX rats. Again, it stands to reason that NPY-induced 
insulin release leads to increase in leptin gene expression and secretion which may 
increase the expression of SOCS-3 to inhibit cytokine signaling, but not insulin itself 
inducing the expression of SOCS-3.
In contrast to the work of Emanuelli and colleagues (2000), treatment o f rat 
hepatoma cells with insulin attenuated the IL-6 stimulation o f acute phase protein genes 
(Campos, et al., 1996). This decrease in IL-6 stimulation by insulin was accompanied by 
insulin dose-dependent reduction in STAT-3 gene transcription, mRNA accumulation, 
protein concentration, and IL-6-inducible DNA binding activity. Insulin mediated a 
similar reduction in the mRNA encoding the EL-6 receptor alpha subunit and EL-6 
binding activity. These effects of insulin contribute to the strongly suppressed 
transcriptional induction of the EL-6-responsive acute phase plasma protein genes 
(Campos, et al., 1996).
Using the insulin-like growth factor I receptor (IGF-IR) in vitro and in vivo to 
assess the role of JAKs in the process of STAT activation, Zong and collegues (2000) 
found that STAT-3, but not STAT-5, was activated in response to IGF-I in 293T cells 
cotransfected with IGF-IR and STAT expression vectors. Moreover, tyrosine 
phosphorylation of STAT-3, JAK1, and JAK2 was increased upon IGF-I stimulation of 
endogenous IGF-IR in 293T cells transfected with the respective STAT or JAK
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expression vector. Endogenous STAT-3 was tyrosine-phosphorylated upon IGF-I 
stimulation in the muscle cell line C2C12 as well as in various embryonic and adult 
mouse organs, which supported the observation in 293T cells. They also showed that 
SOCS-1 and SOCS-3 proteins inhibited the IGF-I-induced STAT-3 activation. This 
inhibition o f  STAT-3 activation by SOCS was overcome by overexpression o f native 
JAK1 and JAK2 indicating that IGF-I/IGF-IR mediated activation o f STAT3 in vitro and 
in vivo and that JAKs are essential for the process o f  activation (Zong, et al., 2000).
Kim and colleagues (2000) studied the leptin signal transduction directly in 
insulin-sensitive tissues in vivo to examine the ability of iv leptin to acutely stimulate 
phosphorylation o f STAT-3, STAT-1, and MAPK. Both leptin and insulin stimulated 
tyrosine phosphorylation o f STAT-3 and STAT-1 in adipose tissue, but leptin increased 
STAT-3 phosphorylation in liver and muscle. Both hormones also increased MAPK 
phosphorylation, but leptin was less effective than insulin at stimulating IRS pathways. 
They also showed that leptin stimulated STAT-3 phosphorylation in fat and that these 
effects appear to be direct. Furthermore, leptin activated STAT-3 and MAPK in adipose 
tissue ex vivo and in 3T3-L1 adipocytes. This activation of STAT-3 by leptin is in 
contrast to the effects o f insulin on SOCS-3 expression described by Emanuelli and 
colleagues (2000). It would be interesting to determine whether the activation o f STAT-3 
in 3T3-L1 adipocytes is associated with SOCS-3 expression and whether SOCS-3 affects 
the DNA binding activity o f the activated STAT-3. In their studies, Kim et al., (2000) 
showed that leptin rapidly activates signaling pathways directly at the level o f insulin 
sensitive tissues presumably through the long-form leptin receptor, and this pathway 
overlaps with, but is distinct from, that engaged by insulin.
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Figure 6.12. A proposed model of the effects of ADX and leptin treatment on the leptin receptor signaling system. In a sham-operated 
rat treated with leptin (A), leptin activates OBR-L and JAK, which phosphorylates STAT-3. STAT-3 dimerizes and translocates to the 
nucleus to influence transcription o f STAT-3-dependent genes, like SOCS-3. Glucocorticoids (GC) bind to glucocorticoid receptor 
(GR) and causes translocation of GR, which binds to GRE regions to influence transcription. Leptin activation of STAT-3 in the 
presence of GC, leads to high levels of SOCS-3 gene expression and protein. SOCS-3 then binds to JAK to inhibit leptin-induced 
signaling. In an ADX rat treated with leptin (B), the GR cannot be translocated in the absence of GC, ADX induces constitutive 
activation of STAT-3. Leptin activates OBR-L and JAK, which phosphorylates STAT-3. Activated STAT-3 translocates to the nucleus 
and bind to STAT-3 dependent genes to influence transcription. In the absence o f GC, STAT-3 induces low transcription of SOCS-3 
and protein. SOCS-3 protein cannot inhibit JAK, and this leads to constitutive activation of STAT-3, which may influence expression of 
neuropeptide genes involved in food intake. In ADX rats treated with leptin, decrease in STAT-3 DNA binding could be due to 
inhibition by PIAS-3.
Another interesting observation is one in which leptin activates STAT-3 
signalling mechanism in pancreatic islets and in a rat model of the pancreatic 3-cell, 
RINm5F. Activation o f STAT-3 in RINm5F and isolated rat islets by leptin induced 
DNA binding in a manner consistent with STAT3 activation. Conditions that mimic 
increased metabolic activity resulted in attenuation of leptin-mediated STAT DNA 
binding but had no significant effect on STAT-3 tyrosine phosphorylation in RINm5F 
cells (Morton, et al., 1999).
In conclusion, we have showed that ADX induces increased leptin receptor 
mRNA expression, a constitutive STAT-3 activation, and increases sensitivity to leptin 
by activating the JAK-STAT signaling pathway through activation o f STAT-3 and 
reducing the cytokine inhibitor, SOCS-3. Our studies are consistent with those of Solano 
and Jacobson (1999), who recently showed that ADX-induced sensitivity to leptin is not 
due to further decrease in NPY. Reduced DNA binding o f  phosphorylated STAT-3, 
observed in the stimulation of STAT-3 phosphorylation by leptin treatment o f ADX rats, 
is consistent with the work of Scarpace and colleagues (2000), where leptin treatment of 
old rats increased the levels o f phosphorylated STAT-3 but had no effect on STAT-3 
DNA binding activity compared to young rats. Rothwell et al. (1984) report that ADX of 
older rats produced characteristics similar to those o f  young rats becomes fascinating. It 
will be interesting, therefore, to compare the effects of ADX on the STAT-3 activation 
between young and old rats, for a possible involvement of this pathway in aging. The 
study of the involvement of glucocorticoids in leptin-induced SOCS-3 expression will 
certainly provide useful information for the understanding of the circuitry of various 
signaling networks involved in the development of obesity caused by glucocorticoids.
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CHAPTER SEVEN
DIFFERENTIAL EXPRESSION OF LEPTIN RECEPTOR IN HIGH- AND LOW- 
FAT FED OSBORNE-MENDEL AND S5B/P1 RATS*
7.1 INTRODUCTION
The susceptibility o f  different rat strains to become obese when exposed to dietary 
manipulations has been previously reported (Schemmel, et al., 1970; Shier & Schemmel, 
1975). Osbome-Mendel (OM) rats become obese when fed a high-fat (HF) diet, but the 
S5B/P1 rat is highly resistant to the development of obesity when fed the same diet (Fisler 
& Bray, 1990). These two rat strains show differing preferences for dietary fat when 
given a choice o f macronutrient sources, with OM rats consuming more calories from fat 
than carbohydrate, whereas the opposite is true for S5B/PI rats (Okada, et al., 1992). 
Furthermore, a variety o f  physiological differences have been described in these two rat 
strains. The OM rat is more insulin resistant compared to the S5B/P1 rat (Buchanan, et 
al., 1992) and has an attenuated activity of the fatty acid sensitive K+ channel in their 
taste buds (Gilbertson, et al., 1998). In addition, numerous differences in their response to 
feeding modulators have been reported (Singer, et al., 1997; Nagase, et al., 1996; Arase, 
et al., 1988; Okada, et al., 1992). These have suggested the involvement of hypothalamic 
areas in the sensitivity o f  OM rats for the HF diet induced obesity. Lin, et al., (1996), 
while investigating the feeding response to various orexigenic agents, showed a 
differential feeding response of OM and S5B/P1 rats to galanin, neuropeptide Y (NPY), 
enterostatin and P-casomorphin-(i-7) but a similar inhibitory response to corticotropin 
releasing hormone (CRH). Enterostatin, galanin and P-casomorphin have been implicated
* Published work. Reprinted with permission from Obesity Research.
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in regulation of fat intake (Smith, et al., 1997; Leibowitz, et al., 1998; Lin, et al., 1998). 
Differences in the levels of NPY, NPY Y1 and Y5 receptor mRNAs between OM and 
S5B/P1 rats have also been described (Schaffhauser, et al., 1999) and may be related to 
the susceptibility of OM rats to develop obesity when fed a HF diet.
Leptin is a protein released from adipose tissue that enables the brain to adjust 
energy intake and thermogenesis in relation to the size o f energy reserves (Zhang, et al., 
1994; Tritos & Mantzoros, 1997; Considine & Caro, 1997; Caro, et al., 1996; Collins, et 
al., 1996). The action o f leptin on food intake and weight loss is mediated by interaction 
o f the hormone with its hypothalamic receptor (Chua, et al., 1996). The responsiveness of 
the hypothalamus to the inhibitory effects o f leptin on food intake and body weight is 
influenced by multiple factors, including deficiency of either leptin (Campfield, et al., 
1996) or leptin receptor (OBR) (Baskin, et al., 1998). OBR-L mRNA in the 
hypothalamus is sensitive to genetic and physiological interventions that change 
circulating leptin levels indicating that overexpression of OBR-L in the hypothalamus 
may contribute to increased leptin sensitivity. It has also been shown that rats made obese 
by feeding a high-calorie diet override the normal satiety effects o f leptin (Widdowson, et 
al., 1997). When they are returned to a normal laboratory diet, they reduce their calorie 
intake, possibly as a result o f a restoration of the satiety effects o f endogenous leptin 
(Widdowson, et al., 1997). Also, the hypophagic response to exogenous leptin is 
impaired in these rats, indicative of a resistance to the satiety signal. Other studies 
suggest that HF diet changes the sensitivity to leptin by evoking a sustained increase in 
circulating leptin (Frederich, et al., 1995). Therefore, despite increased leptin levels, 
animals fed a high-fat diet became obese without decreasing their caloric intake
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(Frederick, et al., 1995). Leptin resistance may be caused by a variety o f factors including 
changes in leptin transport into the brain, altered receptor population or sensitivity, 
changes in the JAK-STAT signaling pathway or induction o f a cytokine inhibitory 
protein SOCS-3 (Widdowson, et al., 1997).
The present study provides evidence that OM and S5B/P1 rats differentially 
express leptin receptor mRNA encoding the long form of the receptor and suggest that 
diet-induced hyperleptinemia does not down regulate expression of the receptor gene.
7.2 EXPERIMENTAL PROTOCOLS 
Animals
Osbome-Mendel (OM) and S5B/P1 rats were obtained from the breeding colonies 
at the Pennington Biomedical Research Center. All protocols used in these studies were 
reviewed and approved by the Institutional Animal Care and Use Committee.
Diet
The high-fat (HF) diet contained 56% o f energy from fat and the low-fat (LF) diet 
15%. The specific composition of the diets has been previously described (Okada, et al., 
1992). The protein content of both diets was identical at 24% of total energy.
In  vivo studies
Forty age-matched male, eleven-week old, OM and S5B/P1 rats were used in this 
study. They were housed individually in hanging wire-mesh cages attached to an 
automated watering system in a temperature-controlled room with a 12-hour light/dark 
cycle. All rats consumed nonpurified chow diet (Rodent Chow 5001, Purina Mills, St. 
Louis, MO, USA) until the beginning of the experiment. Food was available ad  libitum 
throughout the experiment. After ten days adaptation to a reversed light/dark cycle, 20
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OM and 20 S5B/PI rats were provided with either the HF or the LF diet for 14 days. Food 
intake and body weight were monitored daily, and diet was replaced daily. Two hours 
before dark onset, rats were killed by decapitation to allow collection o f trunk blood and 
preparation o f serum. Hypothalamic tissue was dissected and frozen in liquid nitrogen 
prior to RNA extraction. Serum samples were stored at -80°C before being used for 
hormone assay.
Ex vivo studies
Isolation o f total RNA. Total RNA was extracted from hypothalamic tissue by 
the modified guanidinium-isothiocyanate method (Chomczynski & Sacchi, 1987) using 
TRIzol Reagent (Gibco BRL, Gaithesburg, MD, USA), as described in the General 
Methods section.
cDNA probes. cDNA riboprobe for the rat leptin receptor was generated from 
the BamHl-linearized pZObR403 plasmid as described in the General Methods section, 
according to Ghilardi, et al. (1996). In vitro transcription was performed with the 
MAXIscript kit (Ambion, Austin, TX, USA) using T3 RNA polymerase and [a-32P]UTP, 
800 Ci/mmol (29.6 TGBq/mmol) (NEN, Boston, MA, USA). As an internal standard, a 
160-bp rat 0-actin riboprobe was synthesized using a cDNA template purchased from 
Ambion (Austin, TX, USA). Transcripts were gel purified in a 5% sequencing gel and 
eluted using the probe elution buffer. The ObR probe is used to detect both the short and 
long forms of the receptor mRNAs by using the principle that RNAse A/Tl will digest all 
single-stranded unprotected fragments. Therefore, the long form mRNA will yield a 403- 
bp protected fragment and the short form mRNA will produce a 270-bp protected 
fragment from the same probe.
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Serum hormone assays. Serum insulin and leptin were measured with double­
antibody radioimmunoassay (RIA) kits (Linco, St. Charles, MO, USA) based on rat 
standards according to the supplier’s instructions. Serum corticosterone was assayed 
using a commercial radioimmunoassay (ICN Pharmaceuticals, Costa Mesa, CA ).
Preparation of total protein lysate. The frozen hypothalamic tissues were 
homogenized in 0.25 ml o f  ice-cold lysis buffer [50 mM Hepes, pH 7.9; 10% glycerol; 1 
mM EDTA; 1 mM sodium pyrophosphate; 1 mM sodium fluoride; 1 mM sodium 
vanadate; 1 mM Phenylmethylsulfonyl fluoride (PMSF); 1 pg/ml each of aprotinin, 
leupeptin, and pepstatin] using the motor-driven Polytron PTA 20S operated at maximum 
speed for 30 s. Nonidet P-40 (NP-40) and Triton X-100 were each added to a final 
concentration of 1%. The homogenates were incubated on ice for 15 min with shaking. 
After centrifugation, the supernatant was carefully removed into a new tube and the 
debris discarded. The protein concentration was determined by the BCA assay (Pierce). 
The protein samples were aliquoted into 100 gg/20pl and were snap-frozen in liquid 
nitrogen and stored at —80°C. The procedure was carried out on ice and dithiothreitol 
(DTT) and sodium vanadate were added in the beginning and at the end o f the 
experiment.
Western blotting. An equal volume of sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) sample buffer was added to the protein samples (100 
|ig/20pL), and the proteins were heated to 100°C for 5 min. Proteins were separated by 
SDS-PAGE and transferred to PVDF membranes (Boehringer Mannheim) with a Trans- 
Blot transfer cell (Bio-Rad Laboratories, Richmond, CA) in TG buffer [48 mM Tris, 39 
mM Glycine] and 20% methanol. Membranes were blocked for 1 h with 5% nonfat dry
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milk in TBS-T [10 mM Tris, pH 8.0 and 150 mM NaCl with 0.05% Tween-20], 
incubated with ObR13 A primary antibody (Alpha Diagnostics, Inc.) in 1% BSA in TBS- 
T for 2 h, washed three times for 15 min with TBS-T, and incubated with secondary 
antibody for 1 h in 1% nonfat dry milk in TBS-T. After washing three times for 20 min 
each time in TBS-T, antibody binding was visualized using an ECL (Renaissance) 
detection system. Before reuse, membranes were stripped, blocked and reprobed 
according to the manufacturer’s instructions. Membranes were reprobed with anti-ObR 
(K-20) antibody (Santa Cruz Biotechnology, Co.).
Statistics
Analyses o f hypothalamic gene expression, plasma corticosterone, leptin and 
insulin data as well as tissue weights were performed using a three-way analysis of 
variance (ANOVA) with the factors o f strain, diet and age. Individual comparisons 
between means were made using Bonferroni’s post-hoc analysis.
7.3 RESULTS
Age-matched OM and S5B/PI rats were maintained either on a HF or LF diet for 
14 days. As is characteristic o f OM rats on a high fat diet, they became significantly 
obese, attaining body weight of 392.2 ± 6.1 g compared to 355.7 ± 9.93 of OM rats on 
the LF diet (Table 7.1). This amounts to 20% increase in body weight from the beginning 
of the study. S5B/P1 rats showed a slight increase in body weight on a high fat diet (285.5 
± 8.64 versus 261.2 ± 9.41 g). Both strains showed only marginal increases in body 
weights on the LF diet. The effect o f dietary fat on serum hormone levels is also shown in 
Table 7.1. OM rats had increased levels o f insulin (2.76 ± 0.40 and 2.04 ± 0.22 ng/ml,
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Table 7.1. The effect of diet on body weight and serum leptin and insulin.
Strain  S5B/P1____________________________ Osborne-Mendel_________
Diet ___________ LF________________ HF________________ LF_______________ HF
Initial Body weight (g) 269.3 ±7,07 261.2 ±9.41 334.418.43H 326.9 ±6.01H
Final Body weight (g) 267.7 + 7,58 285.5 ±8.64* 355,7 ±9,93H 392,2±6.10*H
§  Leptin (ng/ml) 4,84 ±0,82 4.55 ±0.51 6.20 ±0.63 9.43 ± 1.32*H
Insulin (ng/ml) 0.60 ±0,06 0,64 ±0,06 2.04±0.22H 2.76 ± 0,40 H
Animals (10 in each group) were exposed to HF and LF diets for 14 days, This table indicates the final body weights at the 
time of sacrifice. Data are presented as means ± SEM, (n = 10/group) * p < 0,05 compared to LF group, H p < 0.05 compared 
to equivalent S5B/P1 group.
for HF and LF groups respectively) compared to S5B/PI rats on the same diets (0.64 ± 
0.05 and 0.60 ± 0.06 ng/ml respectively). The serum insulin levels in OM rats on HF diet 
were elevated approximately 5-fold over those o f their S5B/PI counterparts. Diet did not 
have any effect on the levels o f  insulin in either OM or S5B/P1 rats.
Serum leptin levels in OM rats fed the HF diet were elevated 2-fold over those of 
their S5B/P1 counterparts. OM and S5B/P1 rats had comparable leptin levels after 
maintenance on the LF diet (6.20 ± 0.63 and 4.81 ± 0.82 ng/ml, respectively). 
Furthermore, OM rats on a HF diet had higher leptin levels than those on a LF diet (9.43 
± 1.32 compared to 6.20 ±  0.63, respectively).
Using a Ribonuclease Protection Assay, we found that neither diet nor strain had 
any significant effect on the expression of either the short form or the long form o f the 
leptin receptor mRNA in the hypothalamus. However, the OM rats on both diets had an 
increase in the long form of the leptin receptor mRNA compared to S5B/P1 rats (Figure 
7.1). Western blots of total protein lysates from the hypothalami are shown in Figure 7.2. 
The levels o f OBR-S were reduced by over 50% in both OM and S5B/P1 rats fed the HF 
diet but there was no intrastrain difference. Likewise, the levels of OBR-L were 
decreased in rats fed the HF diet in both OM and S5B/P1 rats.
7.4 DISCUSSION
The main findings o f this study were; 1) that leptin levels are increased by feeding 
high fat diets; 2) that leptin levels o f OM rats were greater than those of S5B/P1 rats fed 
the same diet; 3) that there were no differences in the levels o f the mRNA for the short 
form of the leptin receptor (OBR-S mRNA) in the hypothalamus between OM and 
S5B/P1 rats or with dietary fat; 4) that the level o f mRNA for the long form o f the
151





































Figure 7.1. A representative RPA autoradiogram of leptin receptor gene expression in OM and S5B/P1 rats fed HF and LF diets. Total 
hypothalamic RNA was hybridized with an antisense riboprobe for leptin receptor as described in the Methods. Arrows indicate the 
positions of the long form protected fragment (403-bp) and the short-form protected fragment (270-bp), Insert: Yeast controls for the 
leptin receptor probe. Lane M is the century marker, lanes 1 and 2 are leptin receptor probe controls in the presence and absence ot 






Figure 7.1 B. Histograms of leptin receptor gene expression in OM and S5B/P1 rats fed 
HF and LF diets. The histogram shows the relative expression of leptin receptor (short 
form and long form) to (3-actin mRNA in OM (filled bars) and S5B/P1 (empty bars) rats 
fed the HF and LF diets. Data are presented as means ± SEM (n = 6-8). * indicates p < 




















Figure 7.2. Comparison of the short isoform leptin receptor protein levels in OM and 
S5B/PI rats fed HF and LF diets. Total hypothalamic protein lysates were prepared as 
described in the general methods section. Samples prepared from individual rat 
hypothalami were analyzed by Western blotting with the short form specific (ObR K-20, 
Santa Cruz Biotechnology Co.) leptin receptor antibodies. M is protein molecular marker. 
The histograms show the relative optical densities of short form leptin receptor to actin 
protein in OM (filled bars) and S5B/P1 (empty bars) rats fed the HF and LF diets. Data 
are means ± SEM. * p < 0.05 compared to LF diet.
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Figure 7.3. Comparison o f the long isoform leptin receptor protein levels in OM and 
S5B/P1 rats fed HF and LF diets. Total hypothalamic protein lysates were prepared as 
described in the general methods section. Samples prepared from individual rat 
hypothalami were analyzed by Western blotting with the long form specific (ObR13A, 
Alpha Diagnostics, Inc.) leptin receptor antibodies. M is protein molecular marker. The 
histograms show the relative optical densities of long form leptin receptor to actin 
protein in OM (filled bars) and S5B/P1 (empty bars) rats fed the HF and LF diets. Data 
are means ± SEM. * p < 0.05 compared to LF diet.
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receptor (OBR-L) was increased in the hypothalamus of OM rats compared to S5B/PI 
rats, but was not affected by dietary fat; 5) that the protein levels o f  OBR-L and OBR-S 
were decreased in rats fed HF diets.
While obesity in mutant rodents has been associated with decreased leptin 
production (ob/ob mouse) (Zhang, et al., 1994) or absence of a functional receptor (db/db 
mouse and fa /fa  rat) (Considine & Caro, 1997; Chua, et al., 1996), these abnormalities 
are rare in humans (Clement, et al., 1996). Like human obesity, nonmutant obese animals 
typically show elevated plasma leptin levels and increased expression o f leptin mRNA in 
the adipose tissue (Lin, et al., 1998; Guerre-Millo, 1997) suggesting leptin resistance. By 
manipulating nutritional variables in different inbred strains, several animal models of 
diet-induced obesity have been developed (Schemmel, et al., 1970). In our model of 
dietary obesity, Osbome-Mendel (OM) and S5B/P1 rats differ in their sensitivity to 
develop obesity when fed a high fat (HF) diet, OM rats become obese, whereas S5B/P1 
rats remain thin (Bray, et al., 1990a; Bray, et al., 1990b). Such models provide the 
opportunity to evaluate the interaction of diet and genetic background on the 
development o f obesity.
The discovery o f leptin has elucidated a feedback loop in the hormonal control of 
energy balance and body fat. Murine mutations that lack an intact ob gene or its 
receptors become obese (Zhang, et al., 1994; Considine & Caro, 1997; Chua, et al., 
1996). In this study, the role of leptin and its receptor in high fat diet-induced obesity was 
investigated. We confirmed our previous result showing hyperleptinemia in OM rats in 
response to HF feeding for two weeks. However, we did not observe any increase in 
serum leptin levels in S5B/P1 rats fed the HF diet in this study. Previously (Lin, et al.,
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1998) we reported that S5B/P1 rats responded to the introduction o f a HF diet by an 
increase in leptin gene transcription and serum leptin levels after 2 days, but the 
magnitude of the responses was greatly decreased at 7 days and serum leptin levels were 
not affected by diet after 5 weeks. Thus the absence of a HF diet induced increase in 
serum leptin reported in this study may reflect the length of exposure (14 days) to the 
diet. Previous studies reporting the hyperleptinemia in obese humans and other animals 
seem to contradict the ability of leptin to increase energy expenditure and reduce food 
intake (Bray & York, 1997). Further, the differential leptin response to a high fat diet that 
we observed here in OM and S5B/P1 rats suggests that sensitivity to a HF diet, rather than 
resistance, is associated with an increase in leptin secretion. This contrasts to studies in 
mice in which dietary fat-induced obesity was associated with an attenuated increase in 
plasma leptin (Ahren, et al., 1997). Ob gene expression and leptin production by the 
adipose cells are under the control of various hormonal and metabolic factors. High-fat 
feeding increases ob gene and plasma leptin, and induces a state of leptin resistance (Lin, 
et al., 1998; Ahren, et al., 1997; Van Heek, et al., 1997). Two hormones, insulin and 
corticosterone, increase leptin production in rodent and human adipose cells (Barr, et al., 
1997; Slieker, et al., 1996; Dagogo-Jack, et al., 1996; MacDougald, et al., 1995; 
Malmstrom, et al., 1996). In contrast, the activity of the sympathetic nervous system 
exerts an opposite effect, mainly through activation of the adipose ph-adrenergic 
receptors (Guerre-Millo, 1997; Lu, et al., 1998). Insulin has been postulated to be 
necessary stimulus for leptin release, and our data suggest that this is the case. 
Hyperleptinemia developed in HF-fed OM rats in parallel with their increase in insulin 
secretion, whereas S5B/P1 rats, which did not have increased leptin levels, did not
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increase insulin levels when fed the HF diet. Devaskar, et al (1997), have shown that 
leptin mRNA and peptide levels are higher during consumption of a high fat milk diet. 
They suggested that high levels of leptin with increasing food intake and body weight 
gain signify hypothalamic leptin receptor resistance during the immediate postnatal 
period. Our laboratory has previously shown that a high fat diet significantly increased 
leptin mRNA and serum leptin levels (Lin, et al., 1998). However, when leptin was 
administered centrally, a similar dose-dependent reduction in energy intake was observed 
in response to leptin in both OM and S5B/PI rats. These responses were independent of 
the diet. These studies suggested that the acute susceptibility of OM rats to HF diet- 
induced obesity was not related to either a loss of central sensitivity to leptin or a failure 
to enhance leptin production (Lin, et al., 1998). Similar conclusions were made from a 
study of HF induced obesity mice (Van Heek, et al., 1997) in which obesity was induced 
in two strains o f mice, C57BL/6 and AKR, by exposure to HF diet. Serum leptin 
increased in proportion to body weight. C57BL/6 mice on the HF diet developed leptin 
resistance, whereas those on LF diet retained their leptin sensitivity. Intriguingly, both 
groups became resistant to peripherally administered leptin after long term exposure, but 
retained sensitivity to centrally administered leptin (Van Heek, et al., 1997).
To date there is little information on the regulation o f the leptin receptor. Both 
nutritional status and estradiol (E2) treatments affect OBR mRNA expression (Bennett, et 
al., 1998). Food deprivation increased the abundance o f OBR-L transcripts in the 
thalamus despite a decrease in total OBR and OBR-S in this area. Fasting has also been 
shown to up-regulate ObR mRNA expression in the Arcuate nucleus of C57 BL/6 lean 
(+/+) but not obese (ob/ob) mice (Lin & Huang, 1997). Obese Zucker rats also show
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different expression to lean rats with an increased expression of OBR-L transcripts in all 
brain areas analyzed and a decrease in total OBR gene expression.
Changes in the balance between OBR-L and OBR-S forms of the receptor, 
observed in these studies could alter tissue sensitivity to leptin. In the current study, we 
did not identify any changes in the total hypothalamic levels o f mRNA for either OBR-S 
or OBR-L with dietary fat, but there was a significantly elevated level of OBR-L mRNA 
in hypothalamus o f OM compared to S5B/P1 rats. In contrast, OBR-S mRNA levels were 
similar in both strains. The increase in OBR-L mRNA in hypothalamus of OM rats was 
evident despite the increase in circulating leptin and insulin in this strain. However, 
Western blot analyses showed that mRNA expression levels were not an index o f 
receptor protein levels. Indeed, OBR-L protein levels were reduced in rats fed HF diets 
suggesting that posttranscriptional events are important for the control of receptor 
activity. This result is somewhat surprising since we have previously shown that there is 
no difference in the dose-response curve to central leptin in OM and S5B/P1 rats fed a HF 
diet. The possible explanation for this may be that these receptor protein changes are not 
uniformly spread across all hypothalamic sites and that the changes in the nuclei that 
regulate feeding behavior are less dramatic. In situ hybridization and 
immunohistochemical approaches will be needed to investigate this possibility.
The uptake of leptin in the choroid plexus appears to be saturable (Banks, et al., 
1996; Karonen, et al., 1998). The possibility exists that the high fat feeding may influence 
the transport and, in so doing, the availability of leptin, to the centers important in 
regulation of food intake and energy expenditure. Leptin may gain access to the brain via 
receptor-mediated transport through the blood-brain barrier (BBB), and the BBB leptin
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receptor (OBR) may regulate the availability o f circulating leptin to brain cells. Boado et 
al (1998) showed that the OBR-S is the principal leptin receptor expressed at the BBB 
and that this BBB OBR isoform is up-regulated by a high fat diet. We were unable to 
confirm this in the current study in which we assayed total hypothalamic OBR-S mRNA 
levels. Further, we showed that OBR-S protein levels were significantly reduced by HF 
feeding in both rat strains suggesting that leptin transport across the BBB would be 
reduced by HF feeding. This is consistent with a recent report that leptin transport is 
decreased in mice that become fat (Banks, et al., 1999). Again the differential responses 
of mRNA and protein levels for OBR-S suggest regulation at a posttranscriptional level. 
However, despite this reduction in OBR-S, S5B/P1 rats fed a HF diet do not become 
obese suggesting that mechanisms other than leptin transport and leptin receptor numbers 
may be important to their response.
Insulin and leptin are thought to regulate feeding behavior through their abilities 
to regulate transcription of several neuropeptide genes including neuropeptide Y (Baskin, 
et al., 1999). We have recently shown that OM rats fed a high fat diet have elevated 
hypothalamic NPY mRNA levels (Schaffhauser, et a., 1999), suggestive o f both leptin 
and insulin resistance since both these hormones normally decrease neuropeptide Y. As 
NPY activity in the PVN promotes hyperinsulinemia and hypercorticism (Rohner- 
Jeanrenaud & Jeanrenaud, 1997), the elevated levels o f insulin and glucocorticoids would 
in turn enhance leptin synthesis and secretion (Barr, et al., 1997). The majority of 
genetically obese rodents have similar endocrine profiles in which the hyperleptinemia is 
associated with hyperinsulinemia and hypercorticosteronemia (Bray, et al., 1990a; Bray, 
et al., 1990b; Rohner-Jeanrenaud & Jeanrenaud, 1997). Our data is, therefore, consistent
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with the hypothesis, that insulin promotes the observed hyperleptinemia observed in OM 
rats compared to S5B/P1 rats and the increase in leptin associated with feeding a high fat 
diet. The apparent resistance to endogenous leptin in OM rats is reflected in the 
increased hypothalamic NPY levels (Schaffhauser, et al., 1999). Likewise, the anorectic 
response to intra-cerebroventricular insulin is lost when rats are fed a HF diet implying a 
fat-induced central insulin resistance (Arase, et al., 1988).
The results of this current study confirm that obesity associated with consumption 
of a high fat diet is characterized by hyperleptinemia. Despite the high levels o f the long- 
form o f the leptin receptor mRNA in the hypothalamus of obese OM rats and the normal 
levels o f the short form receptor mRNA, changes in the protein levels o f  both receptors 
would lead to impaired leptin transport across the BBB and impaired leptin signaling. 
These protein changes would be expected to promote obesity and contribute to the leptin 
resistance that is seen in HF fed rats.
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CHAPTER EIGHT 
SUMMARY AND RESEARCH DIRECTIONS
Adrenal glucocorticoids play a significant role in the control o f substrate supply to 
tissues. They protect the body fat stores by counter-regulating the effects o f lipolytic 
agents (Remesar, et al., 1997), and also enhance the induction of lipogenic enzymes by 
insulin (Wurdeman, et al., 1978). The obese often show enhanced sensitivity to 
glucocorticoids (Tokuyama & Himms-Hagen, 1989. Humans and rodents maintain high 
circulating levels of cortisol and corticosterone, respectively, due to alterations in the 
activity o f the HPA axis (Rosmond & Bjorntorp, 2000). The effects o f circulating 
glucocorticoids are mediated through the adipose tissue, the main target for lipid storage 
induced by insulin (Wurdeman, et al., 1978). Glucocorticoids also regulate the expression 
and production of leptin from the white adipose tissue, therefore regulating the 
expression o f  its counter-regulatory hormone. Adrenalectomy prevents fat accretion of 
the already obese rat and stops weight gain and obesity development in all forms of 
obesity (Bray, et al., 1990a; Bray, et al., 1990b). After adrenalectomy, a situation exists in 
which all the counter-regulatory mechanisms that depend on glucocorticoids are 
removed. For example, the integrity of fat stores is no longer protected, because ADX 
affects energy balance.
Leptin, whose expression and production are controlled by glucocorticoids, 
modulates food intake (Weigle, et al., 1995; Rentsch, et al., 1995; Campfield, et al., 
1995), body weight (Halaas, et al., 1995; Pelleymounter, et al., 1995; De Vos, et al., 
1995) and energy expenditure (Mistry, et al., 1997; Haynes, et al., 1997; Scarpace, et al., 
1997; Himms-Hagen, 1997) through its action in the hypothalamus. It also modulates
162
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
insulin release and function (Cohen, et al., 1996; Walder, et al., 1997) and thermogenesis 
(Hwa, et al., 1996). Some of these effects o f leptin are analogous to those produced by 
adrenalectomy. For example, leptin treatment and ADX both increase BAT 
thermogenesis, decrease food intake and body weight, increase energy expenditure, and 
lower circulating levels o f insulin. Furthermore, Jeanrenaud’s group showed that 
adrenalectomy increases sensitivity to leptin (Zakrzewska, et al., 1997). Therefore, the 
present studies investigated the molecular bases o f this sensitivity to leptin by studying 
the effects of adrenalectomy and leptin treatment on the leptin signal transduction 
pathway, to determine whether glucocorticoids are implicated in the reduced response to 
leptin in obesity.
In this research project, we studied leptin receptor expression and activity in the 
hypothalamus and liver after adrenalectomy. To confirm that ADX increases sensitivity 
to leptin when given icv, we measured food intake, serum hormones, gene expression and 
protein levels and activities of candidates in the leptin receptor signaling pathway in the 
hypothalamus. Since inhibition of food intake by leptin is thought to be caused, in part at 
least, by inhibition o f NPY, its mRNA expression in the hypothalamus was also 
measured. The results demonstrate that leptin treatment o f adrenalectomized rats caused a 
large decrease in food intake and body weight, consistent with data o f Zakrzewska and 
colleagues (1997). The possibility existed that the reduced food intake and body weight 
in leptin-treated ADX rats may be due to activation or inhibition o f central food intake 
related genes or neurotransmitters. We hypothesized, that removal o f adrenal 
glucocorticoids may potentiate leptin effects by modulating the leptin receptor signaling 
pathway, with positive effects on genes that are negatively regulated by glucocorticoids,
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and vice versa. The results from experiments described in this dissertation show that 
ADX increased ObR mRNA expression, constitutively enhanced STAT-3 
phosphorylation and DNA binding, decreased the cytokine inhibitory SOCS-3 mRNA 
and protein levels. Leptin treatment of ADX produced superior effects on food intake and 
body weight because leptin effects could not be counteracted by glucocorticoids. The 
deregulating effects o f leptin treatment in ADX rats were more evident in the lowering of 
insulin levels, and central administration of leptin has been shown to inhibit insulin 
secretion and increase insulin sensitivity of peripheral tissues directly (Kamohara, et al., 
1997; Cusin, et al., 1998; Minokoshi, et al., 1999; Haque, et al., 1999). The results 
presented here strongly support the hypothesis that glucocorticoids play a key role in the 
modulation o f leptin-induced imbalance of energy intake and expenditure. The 
mobilization o f fat reserves, elicited by leptin treatment, is probably hampered by 
glucocorticoids.
Furthermore, leptin receptors are expressed in the arcuate POMC neurons 
(Cheung, et al., 1997), and the anorectic effects of leptin can be blocked by central MC4- 
R antagonist (Satoh, et al., 1998). The neuropeptides, NPY, 3-endorphin, AGRP, orexin, 
galanin and melanin concentrating hormone, all increase food intake and reduce 
sympathetic activity. In contrast, peptides including CCK, CRH, enterostatin, leptin, 
CART and a-M SH reduce food intake and increase sympathetic activity. The 
melanocortin receptor system may be particularly important in modulating food intake, 
because a transgenic mouse which does not express melanocortin-4 receptors is 
massively overweight (Marsh, et al., 1999). Adrenal glucocorticoids are important in 
obesity since ADX prevents the development of all forms o f obesity. It will therefore be
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interesting to study, by immunohistochemistry, the effects of leptin and ADX on the 
expression o f some of these central neuropeptides. The increased sensitivity to leptin on 
food intake, fat stores and energy expenditure may be related to changes in these 
neuropeptides, but, NPY was recently showed not to be influenced by a combination of 
leptin and ADX (Solano & Jacobson, 1999). AGRP was recently shown to be suppressed 
by leptin, but was not regulated by ADX (Li, et al., 2000).
The reciprocal relationship between food intake and sympathetic activity is 
robust, and suggests that 3 -receptors in the periphery and brain may be involved in the 
control o f feeding (Bray, 2000). Haque and colleagues (1999) examined the interaction of 
the effects of hypothalamic leptin and insulin administered peripherally. They reported 
that leptin in the hypothalamus enhances glucose uptake in certain peripheral tissues 
through mediation of a P-adrenergic mechanism for the sympathetic nerves innervating 
the tissues and that central leptin and peripheral insulin have a synergistic role in 
augmenting tissue glucose uptake (Haque, et al., 1999). Furthermore, exercise was shown 
to decrease leptin mRNA expression, an action attributed to activation o f the P3- 
adrenergic receptor, because this decrease was blocked by pretreatment with P3- 
adrenergic receptor antagonist, SR.-59230A (Bramlett, et al., 1999). Whether the 
activation o f 3 3 -adrenergic receptors (receptor numbers) or the increase in its gene 
expression account for the increased sympathetic activity remains to be determined. 
Therefore, P3-receptor stimulation, like ADX, down-regulates adipose tissue leptin 
mRNA in vivo and increase sympathetic activity. It will be interesting to see whether the 
combination o f a chronic 3 3 -receptor stimulation with CL316,243 agonist and icv leptin 
could show a similar response to that shown in this dissertation.
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We have also showed that peripheral leptin resistance was induced in OM rats fed 
HF diet (Lin, et al., 1998), and also that HF diet down-regulates the hypothalamic leptin 
receptor protein in OM and S5B/P1 rats (Madiehe, et al., 2000). Recently, Bjorbaek and 
colleagues (1998) showed that leptin resistance was accompanied by increase in SOCS-3, 
which was named a potential marker for leptin resistance. Because leptin induce SOCS-3 
mRNA and protein expression, it is imperative to expand this study to determine whether 
HF feeding induced-leptin receptor down-regulation was associated with SOCS-3 
expression. It will also be interesting to determine the potential differences in the leptin 
receptor signaling between OM and S5B/P1 rats due to their distinct differences in 
sensitivity to HF diet-induced obesity.
The identification of other genes that could be involved in the induction of leptin 
resistance remains a lucrative endeavor, because it offers endless opportunities toward 
understanding how diet-induced obesity is manifested and how certain genes within diet- 
sensitive and diet-resistant individual may be influenced by a conducive environment. 
This study reveals a need in future research to identify potential molecules that could 
alleviate the decrease in leptin receptor protein, or those that could influence other genes 
that are regulated by leptin to reduce adiposity. Our data shows consistency with the 
literature, and further suggests a need to address key issues associated with leptin 
resistance, as these will be useful in developing drugs toward the treatment of human 
obesity. The identity o f  neuropeptides and pathways required for development of obesity 
need to be mapped out and various interactions be resolved. An understanding of the 
participants and their functions will expand the knowledge that could potentially be used 
in treatment of obesity and/or diabetes.
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Future research should continue to focus on the interaction o f glucocorticoids, leptin and 
insulin, the major players in obesity thus far, to offer a clear connection between 
glucocorticoids, leptin and insulin in the development of obesity. A variety o f questions 
to guide and focus future research arise from this study: 1) In what ways could we 
activate the leptin receptor or inhibit SOCS-3 expression under conditions of high 
corticosterone levels? Glucocorticoid receptor antagonists have been shown to decrease 
body weight. 2) Can GR antagonists activate leptin receptor activity or down-regulate 
cytokine signaling inhibitors (e.g. SOCS-3)? The analysis o f SOCS knockout mice 
showed that SOCS proteins have physiological role in regulating responsiveness because 
the SOCS knockout mice die before weaning due to liver degeneration and lymphoid 
deficiency (Starr, et al., 1998). Alternatively, mutations that may lead to the loss of SOCS 
activity could give rise to increased cytokine responsiveness, which may contribute to the 
development o f diabetes. Therefore, small molecule effectors which modify SOCS 
function may potentially be useful therapeutic agents for the treatment of certain diseases, 
including obesity. (Starr & Hilton, 1998). 3) Are there any other unknown potentially 
novel systems involved in the development of obesity that are regulated by high 
glucocorticoid levels, and what interactions do they have with other known systems? In 
searching for answers to these questions, we can both develop a better understanding of 
how obesity is manifested and also take the necessary steps toward treatment of obesity.
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